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 CHAPTER 1 
 
General introduction 
  
 
 
 
 
 
 
 
 
 
 
 
 RHEUMATOID ARTHRITIS 
 
Rheumatoid arthritis (RA) is a systemic auto-immune disease, which is characterized by 
chronic inflammation of multiple joints. About 1% of the people in western countries 
have RA, and each year in 5 – 50 per 100.000 persons the diagnose of RA is made. The 
prevalence of RA varies geographically.1 In the Netherlands the prevalence of RA in 
2007, based of primary care registries, was 0.7% (95% confidence interval (CI): 0.48% - 
1.03%) for men and 1.1% (95% CI: 0.76% - 1.60%) for women. The mean annual 
incidence in the Netherlands in 2007 was respectively 75 and 120 per 100.000  for men 
and women. Disease onset is most often between 40 and 60 years of age. The mortality 
rate for men and women with RA in 2010 was respectively 0.3 and 0.9 per 100.000.2  
Clinical and radiographic outcomes have improved enormously in the last two 
decades, due to major paradigm changes in the management of RA.3-4 Evolvement of 
clinical trial methodology, emergement of new therapeutic options – in particular 
biologicals – and reevaluating treatment strategies caused these major paradigm 
changes. These paradigm changes are:  
• Early detection of the disease; 
• Early initiation of ‘intensive’ therapy; 
• A treat-to-target approach 
The 2010 ACR/EULAR classification criteria for RA and formulation of the EULAR 
recommendations for the management of RA were developed, so rheumatologists 
could apply these changes in daily practice.3-4 The 2010 EULAR recommendations 
advocate, in patients with newly diagnosed RA, that: (1) the initial treatment strategy 
encompasses at least methotrexate (MTX) with or without glucocorticoids (GCs), (2) 
treatment is targeted to achieve remission, or low disease activity, preferably within 3 
months, and (3) treatment should be adjusted, every 1-3 months, until the target is 
reached.4 Complying with these recommendations result in better functional and 
radiological outcomes.1, 5  
Despite of the new classification criteria and treatment recommendations, 
important unresolved questions for daily practice remain. Therefore, the focus of this 
thesis will be on the management of early RA. In the next section I will elaborate on the 
argumentation for each paradigm change and accentuate the unresolved questions, 
which need to be solved for daily practice. 
 
Early detection of the disease 
Various studies suggest the existence of a ‘window of opportunity’, which encompasses 
the first 12 weeks after symptom onset. Early initiation of Disease Modifying Anti-
Rheumatic Drugs (DMARDs) during this 12 week period improved clinical outcome and 
delayed or even prevented radiographic damage.6-11 Distinguishing RA from other 
arthritic disorders is rather difficult, especially in the very early stages of the disease. 
Until 2010 only the 1987 classification criteria for RA, made by the American College of 
 Rheumatology (ACR), were available (table 1).12 The 1987 criteria for RA are not sensitive 
enough to detect RA in the earlier stages of the disease. Therefore, different algorithms 
for recognizing RA in a very early phase were developed. Examples of algorithms are the 
models made by van der Helm et al13 and Visser et al.14 At the time of writing the 
protocol of our clinical trial ‘treatment in the Rotterdam Early Arthritis Cohort’ (tREACH), 
the foundation of  this thesis, we chose to use the Visser model since this model had 
proven to detect more patients within an earlier phase of the disease compared with 
the 1987 ACR criteria.14  
 
Table 1: The 1987 ACR classification criteria for RA 
To make the diagnosis of RA, four of the following criteria must be present. Criteria 1- 4 
must have been present for at least six weeks 
1. Morning stiffness ≥1 hour 
2. Synovitis or hydrops in ≥ 3 joints, including proximal interphalangeal joints (PIP), 
metacarpophalangeal (MCP) joints, wrists, elbows, ankles and 
metatarsophalangeal (MTP) joints 
3. Synovitis or hydrops in MCP joints, PIP joints and/or wrists 
4. Symmetrical distribution 
5. Rheumatoid nodules 
6. Rheumatoid factor positivity 
7. Radiographic changes typical for RA 
 
 
Visser et al14 developed a prediction model which could discriminate between 
self-limiting and persistent (erosive) arthritis at the first visit. The Visser model consisted 
of 7 variables. Odds ratios of each variable were simplified to weighted scores. Added 
scores range from 0 to 13 points. One point corresponds with a 10% probability of 
developing persistent arthritis and 13 points with a 99% probability (table 2).14  
 
Table 2: (A) Diagnostic criteria of the Visser model and (B) total scores and 
predictive values for persistent arthritis 
A. Criteria Score B. Total  Probability of  
 Symptom duration   score persistence 
 • ≥6 weeks but <6 months 
• ≥6 months 
2 
3 
 0 
1 
0.10 
0.15 
 Morning stiffness ≥1 hour 1  2 0.23 
 Arthritis in ≥3 joint groups* 1  3 0.34 
 Bilateral compression pain in MTPs 1  4 0.46 
 RF positivity 2  5 0.59 
 ACPA positivity 3  6 0.71 
 Erosions on radiograph 2  7 0.80 
*joint groups are: sternoclavicular, shoulder, elbow, wrist, knee, ankle, 
MTP, MCP, PIP and DIP on left and right side (22 groups in total). The 
MTP, MCP, PIP and DIP were counted as 1 joint. Abbreviations: ACPA, 
anti-citrullinated protein antibody; DIP, distal interphalangeal; MCP, 
metacarpophalangeal; MTP, Metatarsophalangeal; PIP, proximal 
interphalangeal and RF, rheumatoid factor. 
8 0.87 
9 0.92 
10 0.95 
11 0.97 
12 
13 
0.98 
0.99 
 In our trial eligible patients were stratified into three groups according to their 
likelihood of progressing to persistent arthritis based of the Visser model. The three 
strata (low (grey), intermediate (white), and high (black), table 2) correspond with 
probability tertiles of developing persistent arthritis.14  
In 2010 new classification criteria for RA were developed (table 3).3 Although in 
the rheumatic field classification criteria are often used as diagnostic criteria, they are 
not the same. In the meanwhile studies have shown that for RA the 2010 ACR/EULAR 
classification criteria can be used as diagnostic criteria, since the performance has been 
investigated in several studies, including the REACH study.15 A recent review 
summarized the results of these studies and showed that the 2010 criteria for RA had an 
overall sensitivity of 82% and specificity of 61% to identify persistent arthritis.16 The 
difference in sensitivity and specificity between the 2010 and 1987 criteria for RA was 
respectively +11% and -4%. In others words, the 2010 criteria detect an additional 11 
out of 100 patients with persistent arthritis and misclassify 4 out of 100 patients without 
persistent arthritis, as having persistent arthritis in comparison with the 1987 criteria for 
RA. Consequently, 11 patients will start treatment earlier in the disease course and 
subsequently 4 patients might be overtreated.16 The beneficial effect of starting 
treatment in a earlier phase will probably outweigh the negative effect of 
overtreatment. Interestingly, the Visser algorithm and 2010 criteria for RA have similar 
discriminative abilities to identify patients at risk of persistent arthritis at 1 year.15 
Since its publication, the 2010 ACR/EULAR classification criteria for RA are more 
and more incorporated in daily practice of rheumatologists.  All current guidelines for 
the management of RA, however, are based upon data from studies in patients fulfilling 
1987 criteria for RA. Thus trials in the early phase of RA, like our tREACH trial, are needed 
for validation of those guidelines and to solve this unresolved question.  
Furthermore, there are still some pitfalls for managing early RA. For example, feet 
are frequently affected in the early stages of the disease, while for assessing disease 
activity, rheumatologists often use disease activity indices (DAIs), which exclude the 
feet, because of their user-friendliness.17 Thus, measuring disease activity with 
mentioned DAIs in early RA needs to be improved. Another challenge is the valid 
interpretation of DAIs. Although all DAIs have been developed in cohorts comprising 
patients with RA according to the 1987 criteria12, DAIs already have been used in 
undifferentiated arthritis18-20, since validation is lacking in this early population.  
 
 
Early initiation of ‘intensive’ therapy 
Several studies showed that early initiation of ‘intensive’ DMARD therapy improved 
clinical efficacy and may even prevent radiographic damage.8, 11, 21-22 Aletaha et al23, as 
one of the first, demonstrated that high disease activity during the first 3 months of 
treatment is significantly related to high disease activity at 1 year, which subsequently 
led to more destructive and disabling disease. Since the time span for the optimal effect 
of DMARDs is at least 6–12 weeks, the right choice of the initial treatment regimen has 
an important role in improving clinical efficacy.24  
 Table 3: The 2010 ACR/EULAR classification criteria for RA 
 Score 
Target population (Who should be tested?):  
1. Patient with at least 1 joint with definite clinical synovitis (swelling)* 
2. Synovitis is not better explained by another disease 
Classification criteria for RA (score-based algorithm: add score of categories A-D; 
A score of ≥6/10 is needed for classification of a patient as having definite RA) 
A. Joint involvement§ 
• 1 large joint¶  
• 2−10 large joints  
• 1−3 small joints (with or without involvement of large joints)**  
• 4−10 small joints (with or without involvement of large joints)  
• >10 joints (at least 1 small joint) 
 
0 
1 
2 
3 
5 
B. Serology (at least 1 test result is needed for classiScation)‡‡ 
• Negative RF and negative ACPA  
• Low-positive RF or low-positive ACPA  
• High-positive RF or high-positive ACPA  
 
0 
2 
3 
C. Acute-phase reactants (at least 1 test result is needed for classification) 
• Normal CRP and normal ESR  
• Abnormal CRP or abnormal ESR 
 
0 
1 
D. Duration of symptoms¶¶ 
• <6 weeks  
• ≥6 weeks  
 
0 
1 
*The criteria are aimed at classification of newly presenting patients.  
§ Joint involvement refers to any swollen or tender joint on examination, which may be confirmed by 
imaging. Categories of joint distribution are classified according to the location and number of involved 
joints, with placement into the highest category possible based on the pattern of joint involvement. 
¶ Large joints refers to shoulders, elbows, hips, knees and ankles. 
**’Small joints refers to the metacarpophalangeal joints, proximal interphalangeal joints, second to fifth 
metatarsophalangeal joints, thumb interphalangeal joints and wrists. 
‡‡ NEG refers to IU values ≤upper limit of normal (ULN) for the laboratory and assay; low-positive refers to 
IU values >ULN but ≤3x ULN; high-positive refers to IU values >3x the ULN. When RF information is only 
available as POS or NEG, a POS should be scored as low-positive for RF. 
¶¶ Duration of symptoms refers to patient self-report of the duration of signs of synovitis. 
Abbreviations: ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate; IU, International Unit; and RF, Rheumatoid Factor. 
 Therefore, the aim of many clinical trials, in the past 20 years, was to compare 
different treatment strategies. Besides comparing different treatment strategies, also 
optimal dosing and route of administration of different DMARDs were reevaluated. 
However, still no consensus has been reached about what the most appriorate initial 
‘intensive’ treatment regimen should be. Most important unresolved question herein is 
that of initital monotherapy versus a combination of DMARDs and the role of 
glucocorticoids (GCs). 
Several clinical trials concluded that initial combination therapy had superior 
clinical efficacy over initial monotherapy, however, most rheumatologists have not 
implemented this in daily practice.8, 21, 25-26 Moreover, the 2010 EULAR guideline 
recommends MTX monotherapy rather than a combination of DMARDs as initial 
treatment regimen, in patients with newly diagnosed RA.4 Most important reason to 
disregard the outcomes of mentioned trials, is the fact that all these trials were biased 
 by GCs.27 Moreover, other trials invalidate this supposed superior efficacy. 28-29 Trials 
comparing triple DMARD therapy versus MTX monotherapy in DMARD naïve patients 
are, however, sparse. Other reasons not to implement combination therapy in daily 
practice is due to safety concern issues and practical feasibility.29 These safety concerns 
consist primarily of the fact that multiple drug usage, due to (1) synergistic effects and 
(2) higher prior chance, leads to more adverse events.  
GCs are often used as bridging therapy for active disease in the period between 
initiation of DMARD treatment and onset of their therapeutic effect.30 GCs have disease-
modifying traits with long-lasting benefits even after withdrawal.30 Gorter et al31 
reviewed the literature for the 2010 EULAR recommendations, looking at the efficacy of 
GCs in RA. They concluded that GCs relieved symptoms and inhibited radiographic 
progression. However, research is needed to optimise GC bridging therapy with 
DMARDs, especially determination of optimal dosage and tapering schemes.  
For the above mentioned unresolved questions about initial treatment 
strategies, we compared, within the tREACH trial,  the clinical efficacy of (1) initial triple 
DMARD therapy versus MTX monotherapy, and (2) different GC bridging therapies: oral 
versus a single intramuscular injection. 
Ideally, a tailor-made treatment approach is used in this very early phase, 
especially since about 60% will respond sufficiently to the initial treatment. Moreover, 
problems as over-treatment and accompanying (serious) adverse events are 
circumvented by this tailor-made treatment approach. In view of aforementioned 
problems, we think it would be helpful if treatment response to the initial DMARD 
treatment could be adequately measured and, ideally, predicted as soon as possible 
after initiation. This would be a major improvement in the management of early RA, 
because it could ultimately lead to a ‘tailor made’ treatment approach. 
 
Treat-to-target 
Grigor et al32 introduced the treat-to-target approach in their TICORA trial, in which 
intensive outpatient management of patients with RA was compared with routine care. 
Intensive management led to improvement of disease activity and functional ability and 
less radiographic progression without additional costs. The CAMERA trial confirmed 
improvement of clinical efficacy using intensive management, in this case making use 
of a strict protocol and a computerized decision program.33 The BeSt study was the first 
trial to compare different initial treatment strategies with a treat-to-target approach in 
their follow-up.25 
In a treat-to-target approach rheumatologists strive to reach a predefined 
therapeutic goal as soon as possible. The 2010 EULAR recommendations recommend to 
strive for remission within 3 months.34 To achieve this goal mentioned guideline 
recommends that patients should be monitored strictly (‘tight control’), every 1-3 
months, with a DAI and if the target is not reached, treatment should be intensified.34 
Consequently, intensifying treatment will be more expensive since most international 
guidelines recommend starting expensive biologicals after failing on 2 conventional 
 DMARDs in an optimal dosage.4, 35 On the other hand tightly controlled intensive 
treatment also had an increased remission rate compared with routine care.27-28 
Therefore, DAI usage might expand to giving guidance in tapering treatment in case of 
sustained remission.5 
For health economic reasons efficient use of expensive drugs is needed to be 
able to continue optimal rheumatic care in the future. In order to manage the 
exponentially increasing health care costs health insurance companies and 
governments will judge the compensation of  prescribed drugs by evidence based data 
on cost-effectiveness.33,36 Previous cost analyses showed that a strategic approach with 
rapid treatment intensification to biological agents is cost-effective. 36-37 However, it is 
still unclear which initial treatment regimen has the best cost-effectiveness ratio. 
Furthermore, all previous cost-effectiveness analysis were performed in patients 
fulfilling 1987 classification criteria for RA.12 Until now no data on cost-effectiveness in 
patients fulfilling 2010 criteria for RA were available.3 Trials in the early phase of RA, like 
our tREACH trial, are needed to evaluate if aforementioned approach is also cost-
effective in very early RA. 
 
Table 4: Formulas and thresholds for disease activity indices (DAIs). 
DAI Formula Thresholds1 
DAS 0.53938√(RAI) + 0.06465(SJC44) + 0.33ln(ESR) + 0.00722(GH)   <1.6/<2.4/<3.7 
DAS (3var) 0.53938√(RAI) + 0.06465(SJC44) + 0.33ln(ESR) + 0.224    
DAS (CRP) 0.53938√(RAI) + 0.06465(SJC44) + 0.17ln(CRP+1) + 0.00722(GH) + 0.45   
DAS (CRP/3var) 0.53938√(RAI) + 0.06465(SJC44) + 0.17ln(CRP+1) + 0.65    
DAS28 0.56√(TJC28) + 0.28√(SJC28) + 0.70ln (ESR) + 0.014(GH) <2.6/<3.2/<5.1 
DAS28 (3var) (0.56√(TJC28) + 0.28√(SJC28) + 0.70ln (ESR))1.08 + 0.16  
DAS28 (CRP) 0.56√(TJC28) + 0.28√(SJC28) + 0.36ln (CRP+1) + 0.014(GH) + 0.96  
DAS28 (CRP/3var) (0.56√(TJC28) + 0.28√(SJC28) + 0.36ln (CRP+1))*1.10 + 1.15  
SDAI SJC28 + TJC28 + PGA + EGA + CRP ≤3.3/≤11/≤26 
CDAI SJC28 + TJC28 + PGA + EGA ≤2.8/≤10/≤22 
1Thresholds for respectively remission / low disease activity / moderate disease activity 
Abbreviations: CDAI, Clinical Disease Activity Index; CRP, C-reactive protein (DAS  mg/l & SDAI  mg/dl); 
DAS, Disease Activity Score; DAS(3var), DAS without GH; DAS(CRP), DAS with CRP instead of ESR; 
DAS(CRP/3var), DAS with CRP and without GH; DAS28, DAS using a 28 joint count; EGA, Evaluator Global 
Assessment of disease activity (VAS of 10cm); ESR, Erythrocyte Sedimentation Rate; GH, General Health 
(VAS of 100mm); PGA, Patient Global Assessment of disease activity (VAS of 10cm); RAI, Ritchie Articular 
Index (53 joints in 26 units, graded for tenderness); SDAI, Simplified Disease Activity Index; SJC, Swollen 
Joint Count; TJC, Tender Joint Count. 
 
There are various DAIs available (table 4) for monitoring disease activity in RA.38-41 
A DAI is a pooled index that involves the incorporation of various parameters into a 
formula to obtain a numerical indicator of disease activity. The following core set 
parameters were identified: tender and swollen joint counts, acute-phase reactants and 
general evaluator’s and patient’s global assessment of disease activity.42 All DAIs have 
their own thresholds for remission, low, moderate and high disease activity (table 4).41 
However, there is no consensus about which DAI should be used, because direct 
comparison of all DAIs is not yet investigated. Moreover, mentioned DAIs need to be 
validated in patients with RA according to 2010 criteria, since all DAIs were developed in 
cohorts comprising patients fulfilling 1987 criteria for RA. 
 In the tREACH we used a treat-to-target approach, aiming for low disease 
activity, defined as a DAS<2.4.38,43 Patients were examined every three months and 
treatment was adjusted, if the target was not reached. Although current guidelines 
recommend to target treatment at achieving remission, no trials comparing different 
predefined treatment goals have been conducted.4-5  
 
 
OUTLINE OF THE THESIS 
 
Early detection of the disease is one of the paradigm changes in the management of RA. 
Because the Visser algorithm and 2010 criteria for RA have similar discriminative abilities 
to identify persistent arthritis at 1 year, the results of the tREACH trial may be used to 
validate current guidelines for patients within an earlier phase of the disease. 
Early initiation of ‘intensive’ therapy is another important paradigm change. 
However, still no consensus has been reached about what the most appropriate initial 
‘intensive’ treatment regimen should be. Most important discussion herein is that of 
initial MTX monotherapy versus a combination of DMARDs. Therefore, in chapter 2 and 
3, the efficacy of initial triple DMARD therapy is compared with MTX monotherapy, 
unbiased for GCs, using respectively the 3 months and 1 year data of the tREACH trial.  
For health economic reasons efficient use of expensive drugs is needed to be 
able to continue optimal rheumatic care in the future. Therefore, we investigated, in 
chapter 4, which initial treatment regimen had the best cost-effectiveness ratio. 
A treat-to-target approach is advocated in order to obtain better functional and 
radiological outcomes in RA. To achieve the predefined treatment goals patients should 
be monitored strictly with a DAI. There are various DAIs available for monitoring RA. In 
chapter 5 we investigate how inconsistencies between DAIs influence therapeutic 
decisions and accompanying costs in early RA.  
Although the management of RA has underwent major paradigm changes, there 
is still room for improvement, particularly in the areas of efficiency. Ideally a ‘tailor 
made’ treatment approach is used to circumvent problems as over-treatment and 
accompanying (serious) adverse events. However, until now no clinical applicable 
predictors for early treatment response were available. In chapter 6 we link the early 
effect of GCs to the initial DMARD response. 
Incorporation of the 2010 criteria for RA in daily practice leads to changing 
disease characteristics of a ‘typical’ RA patient. Feet are frequently affected in the early 
stages of the disease, while rheumatologists often use DAIs, which exclude feet, 
because of their user-friendliness. Thus, measuring disease activity with mentioned DAIs 
needs to be improved when used in early RA. Therefore, in chapter 7, we analyzed 
whether disease activity assessments could be improved, for patients with early RA, by 
adding the squeeze test of forefeet. 
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 Background  
To determine the most effective induction disease-modifying antirheumatic drug 
(DMARD) strategy in early rheumatoid arthritis (RA), second to compare one single dose 
of intramuscular glucocorticoids (GCs) with daily oral GCs during the induction phase. 
 
Methods 
The 3-month data of a single-blinded clinical trial in patients with recent-onset arthritis 
(tREACH) were used. Patients were included who had a high probability (> 70%) of 
progressing to persistent arthritis, based on the prediction model of Visser. Patients 
were randomised into three induction therapy strategies: (A) Combination therapy 
(methotrexate (MTX) + sulfasalazine + hydroxychloroquine) with GCs intramuscularly, 
(B) Combination therapy with an oral GC tapering scheme, and (C) MTX with oral GCs 
similar to B. A total of 281 patients were randomly assigned to (A) (n=91), (B) (n=93) or 
(C) (n=97).   
 
Findings 
The Disease Acitivity Score (DAS) after 3 months was lower in patients with initial 
combination therapy than in those receiving MTX monotherapy (0.39 (0.67 to 0.11, 95% 
confidence interval)). DAS did not differ between the different GC bridging therapies. 
After 3 months 50% fewer biologicals were prescribed in the combination therapy 
groups. Although the proportion of patients with medication adjustments due to 
adverse events differed significantly between the treatment arms, no differences were 
seen in these adjustments after stratification for drug. 
 
Interpretation 
Triple DMARD induction therapy is better than MTX monotherapy in early RA. 
Furthermore no differences were seen in medication adjustments due to adverse events 
after stratification for drug. Intramuscular and oral GCs are equally effective as bridging 
therapy and can both be used. 
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induction therapy 
 
 
 
 
 
 
 
 
 
 INTRODUCTION 
 
The EULAR recommendations suggest use of methotrexate (MTX) with or without 
glucocorticoids (GCs) as adequate induction therapy for patients with newly diagnosed 
rheumatoid arthritis (RA).1 Furthermore, rheumatologist should strive for remission 
within 3 months in order to obtain better functional and radiological outcomes.1-3 
However, some points of these recommendations should be discussed.  
 First, although several clinical trials concluded that combination therapy had 
better clinical efficacy than monotherapy, current guidelines recommend MTX 
monotherapy. This is mainly because in all these trials the results were biased by GCs.4  
Another reason to recommend MTX monotherapy is due to safety concerns.5 
 Second, GCs are often used as bridging therapy for active disease in the period 
between induction of disease-modifying antirheumatic drug (DMARD) therapy and 
onset of their therapeutic effect.6 However, the extend and rapidity of clinical 
effectiveness may differ between the different GC bridging therapies. 
 Finally, new ACR/EULAR criteria for RA7 have been published and 
rheumatologists will increasingly begin to use these criteria in their daily practice. The 
EULAR recommendations for treatment1, however, were all based upon data from 
studies performed in patients fulfilling 1987 ACR classification criteria.8 Therefore, 
rheumatologists need data to make a valid choice of induction DMARD therapy in the 
early phase of RA. 
 To obtain answers to all these objectives we studied within the tREACH trial the 
clinical efficacy of (1) induction combination DMARD therapy versus MTX monotherapy 
and (2) different GC bridging therapies: oral tapering versus a single injection. All 
objectives were carried out in patients with a high probability of developing persistent 
arthritis and two subgroups comprising patients with RA according to 1987 and 2010 
criteria.7, 8 
 
 
PATIENTS AND METHODS 
 
Patients 
For this study data were used of a clinical trial (ISRCTN26791028), namely Treatment in 
the Rotterdam Early Arthritis Cohort (tREACH).9 tREACH, a multicenter, stratified single-
blinded trial, is performed in eight rheumatology centres in the southwestern part of 
the Netherlands. The medical ethics committee at each participating centre approved 
the study protocol, and all patients gave written informed consent before inclusion.  
 An extended description of the tREACH has already been published.9 Inclusion 
criteria for the tREACH are: Age ≥18 years, arthritis in one or more joints and symptom 
duration <1 year.  Patients were excluded if (1) they were diagnosed with a crystal 
arthropathy, (post)infectious arthritis, or autoimmune disorder other than RA; (2) were 
receiving DMARD therapy or GCs; or (3) had contraindications for the initial study 
 medication (chronic liver disease; excessive alcohol and drug use; pregnancy (wish) ; or 
laboratory abnormalities: leucopenia (< 3.0 × 109/l), thrombocytopenia (< 150 × 109/l), 
aspartate aminotransferase/ alanine aminotransferase > 2x upper normal value and 
creatinine level > 150 μmol/l).  
Eligible patients were stratified into three groups according to their likelihood of 
progressing to persistent arthritis based of the prediction model of Visser.10 The three 
strata (low, intermediate and high) correspond to probability tertiles of developing 
persistent arthritis according to the Visser model. For this analysis we only included the 
high probability group since for the other strata recruitment is still continuing. 
 
Randomisation and masking 
Patients were randomised, using variable block randomisation stratified for centre, by 
an independent call-centre during working hours. Trained research nurses were blinded 
for the allocated treatment arm throughout the study. Research nurses examined the 
patients and calculated the Disease Activity Score (DAS), on which treatment decisions 
are based.  
Design 
Patients were randomised into one of following induction therapy arms: 
A. Combination therapy (MTX, Sulfasalazine (SASP) and hydroxychloroquine (HCQ)) 
with GCs intramuscularly) 
B. Combination therapy with an oral GC tapering scheme 
C. MTX with an oral GC tapering scheme  
Concurrent therapy with non-steroidal anti-inflammatory drugs and intra-articular GC 
injections (max. two per 3 months) was allowed during the study.  
 DMARD dosages were: MTX 25 mg/week orally (dosage reached after 3 weeks), 
SASP 2 g/day and HCQ 400 mg/day. GCs were either given intramuscularly 
(methylprednisolone 120mg or triamcinolone 80mg) or in an oral tapering scheme 
(weeks 1-4: 15 mg/day, weeks 5-6: 10 mg/day, weeks 7-8: 5 mg/day, and weeks 9-10: 2.5 
mg/day). All patients received folic acid (10 mg/week) during MTX prescription. 
Osteoporosis prophylaxis (risedronate 35 mg/week and calcium/vitamin D combination 
500/400 mg/IU/day) was given to patients allocated to treatment arms B and C, during 
the first 3 months.  
 Treatment strategies were ‘tightly controlled’, with patients being examined 
every 3 months and treatment decisions are based upon the original DAS thresholds for 
low disease activity.9, 11 When treatment failed, defined as DAS≥2.4, medication is 
intensified to MTX with etanercept (50 mg/week). Treatment intensifications were the 
same in each stratum for each treatment arm.9 
 
 Assessment of clinical efficacy 
For assessment of clinical efficacy the primary outcomes were (1) disease activity (state), 
and (2) functional ability. Disease activity is measured with the original DAS and its 
corresponding thresholds were used for the disease state categorizations.11 Functional 
ability was measured with the Dutch version of the Health Assessment Questionnaire 
(HAQ).12 Higher HAQ scores indicate poorer function. Secondary endpoints were: EULAR 
response criteria13 and self assessed disease activity, measured with the Rheumatoid 
Arthritis Disease Activity Index questionnaire (RADAI).14 EULAR response criteria are 
based on attained level and change in DAS. They classify patients as good, moderate or 
none-responder (see supplementary figure S1). Higher RADAI scores correspond with 
more active disease. 
 
Safety monitoring and toxicity 
Safety monitoring was carried out according to Dutch guidelines15, 16 and included 
laboratory tests at fixed intervals. The study drug was either stopped or dosage lowered 
in accordance with the protocol if (serious) adverse events,9 using WHO’s adverse 
reaction terminology,17 were seen by the attending rheumatologist. MTX could be given 
subcutaneously if patients had gastrointestinal complaints. If MTX needed to be 
stopped for safety reasons, leflunomide (20 mg/day) was substituted.9  
 
Statistical Analyses 
Sample-size calculation was based upon the area under the curve (AUC) of the HAQ, 
using data from the BeSt study18, where mean AUC HAQ of combination therapy and 
monotherapy respectively was 7.7 (SD 5.5) and 10.5 (SD 7.4). A target sample size of 270 
patients per probability stratum (90 patients per arm) was needed to detect mentioned 
difference in AUC HAQ with a power of 80% and a two-sided α=0.05. This number of 
patients is sufficient to detect a difference of 6.1 AUC DAS (α = 0.05; power 80%). 
 Clinical efficacy was calculated in an intention-to-treat, using all available data, 
and per-protocol analysis. Statistical comparison between baseline characteristics and 
outcome measures of the treatment allocations were made by the Student t test, χ2 test, 
or the Wilcoxon rank-sum test, when appropriate. Multivariate analyses for the primary 
outcomes were performed, if imbalances in baseline characteristics between treatment 
groups existed. 
 All analyses were performed for patients in the high-probability stratum and for 
two subgroups consisting of patients with RA according to 1987 and 2010 classification 
criteria.7, 8 All statistical analyses were carried out using STATA version 11.1. A p value 
<0.05 was considered statistically significant.   
 
  
Figure 1: Trial profile. 
*Other reasons to drop out were: incorrect randomisation and problems with communication. 
Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate and 
SASP, sulfasalazine. 
 RESULTS 
 
Patients 
Up to now, a total of 693 patients have been assessed for eligibility and of those, 515 
patients were included in the tREACH (figure 1). A total of 281 patients were included in 
the high-probability stratum and randomly assigned to (A) (n=91), (B) (n=93) or (C) 
(n=97). Four patients (1%) had protocol violations because of non-compliance 
(respectively 1, 2, and 1 patient in arm A, B, and C), but these patients were not lost to 
follow-up. All patients, who were assessed at 3 months, were included in our intention-
to-treat (ITT) analysis (n=264). For the per protocol analysis we excluded only the four 
patients with non-compliance, because medication adjustments due to adverse events 
(AEs) are taken up in the medication protocol.  
Table 1 shows the baseline characteristics per treatment arm. The symptom 
duration, occurrence of erosions and proportion of patients who fulfilled the 1987 
criteria for RA differed significantly between treatment arms (table 1).  Therefore, we 
also performed multivariate analyses for the primary outcomes. 
 
Clinical outcomes 
The DAS after 3 months, was 0.39 (0.11 to 0.67, 95% confidence interval (CI)) lower in 
patients with initial combination therapy than those receiving MTX monotherapy. The 
difference in DAS between the different GC bridging therapies was 0.03 (-0.24 to 0.31, 
95% CI) (table 2). About 78% of the patients, using combination therapy, had a DAS<2.4, 
compared with 60% of the patients using MTX monotherapy (table 2). Consequently, 
induction therapy failed for about 22% and 40% of the patients treated with 
respectively combination therapy and MTX monotherapy and, therefore, treatment was 
intensified to MTX with etanercept (table 2). Baseline DAS was the only factor associated 
with active disease (DAS≥2.4) after 3 months in all treatment arms. Odds ratios (95% CI) 
were respectively 2.27 (1.12 – 4.62), 4.36 (2.15 – 8.19) and 2.50 (1.47 – 4.26) in treatment 
arm A, B and C. 
 Functional improvement was seen in all patients. The difference in functional 
ability between the treatment arms was not significant and only a trend could be 
observed (table 2). Secondary endpoints  - namely, EULAR response criteria and RADAI - 
are shown in table 2.  
In the multivariate analyses we corrected for following factors: gender, 
rheumatoid factor, anti-citrullinated protein/peptide antibodies, presence of erosions, 
complaint duration and baseline DAS. A significant difference in disease activity (state) 
at 3 months persisted between MTX monotherapy versus combination therapy, but 
now also functional ability differed significantly between both groups (table 3). Again 
disease activity (state) and HAQ did not differ significantly between both GC bridging 
therapies (table 3). 
 Table 1: Baseline characteristics of patients with a high probability of developing persistent arthritis, stratified for induction 
therapy. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ  C. MTX + oral GCs 
 + im GCs (n=91) + oral GCs (n=93) (n=97) 
Age (yrs), mean (sd) 53 (15) 54 (14) 54 (14) 
Sex, female, no(%) 55 (60) 67 (72) 68 (72) 
Symptom duration (days), mean (sd)* 162 (97) 184 (92) 154 (83) 
RF positivity, no(%) 55 (60) 51 (55) 51 (53) 
ACPA positivity, no(%) 59 (65) 50 (54) 56 (58) 
Erosion, no(%)† 24 (26) 12 (13) 12 (12) 
Fullfillment RA criteria, no(%)    
• 1987‡ 69 (76) 57 (61) 63 (65) 
• 2010 83 (91) 80 (86) 83 (86) 
DAS, mean (sd) 3.28 (1.06) 3.39 (1.07) 3.38 (0.97) 
DAS28, mean (sd) 4.81 (1.12) 4.83 (1.28) 4.78 (1.27) 
TJC44, median (IQR) 8 (4 - 14) 9 (5 - 15) 10 (4 - 14) 
SJC44, median (IQR) 8 (5 -12) 7 (4 - 12) 7 (4 - 12) 
VAS global (0 -100mm), median (IQR) 52 (34 - 70) 55 (29 – 69) 53 (38 – 70) 
ESR in mm/hr, median (IQR) 27 (14 - 40) 22 (13 – 40) 24 (14 – 42) 
CRP in mg/L, median (IQR) 8 (3.5 - 23) 6.5 (4 -19) 11 (5 - 26) 
HAQ, mean (sd) 0.98 (0.67) (n=84) 0.96 (0.64) (n=84) 1.06 (0.68) (n=92) 
RADAI (0-10), mean (sd) 3.97 (1.83) (n=81) 3.94 (1.63) (n=80) 4.21 (1.82) (n=87) 
Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
*p=0.018 for B vs C. 
†p=0.021 and p=0.015 for respectively A vs B and A vs C. 
‡p=0.034 for A vs B. 
Abbreviations:  ACPA, anti-citrullinated protein/peptide antibodies; CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte 
sedimentation rate; GCs, glucocorticoids; HAQ, Health Assessment Questionnaire; HCQ, hydroxychloroquine; IQR, interquartile range; MTX, 
methotrexate; RADAI, Rheumatoid Arthritis Disease Activity Index questionnaire; RF, rheumatoid factor; SASP, sulfasalazine; sd, standard deviation; 
SJC44, swollen joint count (44 joints); TJC44, tender joint count (44 joints); VAS, visual analogue scale.
 Table 2: Clinical response after 3 months for each induction therapy group, intention-to-treat analysis. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
 + im GCs (n=85) + oral GCs (n=89) (n=90) 
DAS, mean (sd)† 1.86 (0.96) 1.82 (0.86) 2.21 (1.04) 
ΔDAS (T3 - T0), mean (sd)‡ -1.39 (1.00) -1.54 (0.98) -1.19 (1.02) 
Disease state according to DAS, no (%)    
• moderate to high disease activity (DAS≥2.4)§* 20 (24) 19 (21) 36 (40) 
• low disease activity (1.6≥DAS<2.4) 28 (33) 32 (36) 26 (29) 
• remission(DAS<1.6) 37 (44) 38 (43) 28 (31) 
EULAR response criteria, no(%)    
• good 45 (53) 43 (48) 39 (43) 
• moderate 23 (27) 30 (34) 23 (26) 
• None¶ 17 (20) 16 (18) 28 (31) 
TJC44, median (IQR)# 1 (0 - 4) 1 (0 - 5) 3 (0 – 7) 
SJC44, median (IQR) 1 (0 - 3) 1 (0 - 3) 1 (0 – 4) 
VAS global (0 -100mm), median (IQR)** 24 (13 - 36) 26 (15 - 48) 39.5 (21 - 54) 
ESR in mm/hr, median (IQR) 14 (6 – 27) 10 (5 – 21) 12.5 (7 - 22.5) 
CRP in mg/L, median (IQR)†† 4.4 (1.2 - 8) 3.2 (1 - 5.6) 5 (2 - 9) 
HAQ, mean (sd) 0.53 (0.54) (n=73) 0.52 (0.55) (n=83) 0.69 (0.64) (n=79) 
ΔHAQ (T3 - T0), mean (sd) -0.41 (0.50) (n=69) -0.40 (0.53) (n=78) -0.37 (0.57) (n=78) 
RADAI (0 - 10), mean (sd)‡‡ 1.99 (1.78) (n=71) 1.93 (1.81) (n=79) 2.57 (2.02) (n=76) 
ΔRADAI (T3 - T0), mean (sd) -1.95 (1.73) (n=67) -1.96 (1.92) (n=71) -1.54 (1.75) (n=73) 
Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
Abbreviations: CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; GCs, glucocorticoids; HAQ, Health Assessment 
Questionnaire; HCQ, hydroxychloroquine; IQR, interquartile range; MTX, methotrexate; RADAI, Rheumatoid Arthritis Disease Activity Index 
questionnaire; SASP, sulfasalazine; sd, standard deviation; SJC44, swollen joint count (44 joints); TJC44, tender joint count (44 joints); VAS, visual 
analogue scale. 
*Starting biological agent. 
†p=0.021 and p=0.007 for respectively A vs C and B vs C.  ‡p=0.020 for B vs C.  ¶p=0.04 for B vs C.  #p=0.018 for A vs C 
§p=0.020 and p=0.007 for respectively A vs C and B vs C.  **p=0.0009 for A vs C.  ††p=0.035 for B vs C.  ‡‡p=0.038 for B vs C
 Table 3: Multivariate analyses for primary outcomes for monotherapy versus combination therapy and both GC bridging 
therapies: oral tapering versus a single injection, intention-to-treat analysis. 
  Monotherapy (C) (ref.) vs. Bridging: oral tapering (B) (ref.) 
  Combination therapy (B) vs. 1x im. injection (A) 
Linear regression, beta (95% CI)   
Diff. in DAS at 3 months -0.39 (-0.65 to -0.14)† 0.15 (-0.11 to 0.41) 
Diff. in HAQ at 3 months -0.19 (-0.34 to -0.03)‡ 0.08 (-0.07 to 0.24) 
   
Logistic regression, OR (95% CI)   
Disease state according to DAS   
• moderate to high disease activity* 0.31 (0.15 - 0.68)§ 1.89 (0.82 – 4.35) 
• low disease activity 1.31 (0.69 - 2.49) 0.83 (0.43 - 1.59) 
• remission 1.90 (0.95 - 3.81) 0.89 (0.45 - 1.76) 
Primary outcomes were corrected for gender, rheumatoid factor positivity, anti-citrullinated protein/peptide antibodies positivity, 
presence of erosions, complaint duration and baseline DAS. The first mentioned treatment strategy in each column is used as 
reference group. 
*Starting biological agent. 
†p=0.002 for B vs. C 
‡p=0.017 for B vs. C 
§p=0.003 for B vs. C 
Abbreviations: CI, confidence interval; DAS, Disease Activity Score; GCs, glucocorticoids; HAQ, Health Assessment Questionnaire; im, intramuscular; OR, 
odds ratio and ref, reference.
 Table 4: Number (%) of patients with (serious) adverse events and treatment alterations due to side-effects for each induction 
therapy group. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
 + im GCs (n=85) + oral GCs (n=89) (n=90) 
Serious AE(s) 1 (1) 4 (4) 6 (7) 
Patients with ≥1 AE(s)* 61 (72) 67 (75) 50 (56) 
no.of AEs per patient, median(IQR) 1 (0 - 2) 2 (1 - 2) 1 (0 - 2) 
Medication changes due to AE(s)    
• Patients with medication changes 19 (22) 18 (20) 14 (16) 
• lowering MTX dosage <20 mg/wk 8 (9) 6 (7) 9 (10) 
• STOP MTX 5 (6) 6 (7) 5 (6) 
• STOP SASP 9 (11) 7 (8) NA 
• STOP HCQ 2 (2) 2 (2) NA 
Results are shown as number (%) unless stated otherwise. 
*p=0.026 and p=0.006 for respectively A vs C and B vs C. 
Serious AEs per treatment arm are respectively: [A] 1× hospitalisation (pneumonia); [B] 4× hospitalisation (for respectively severe obstipation, transient 
ischaemic attack, gastroenteritis and unexplained chest pain); [C] 1× myocardial infarction, 1× colon carcinoma, 4× hospitalisation (for respectively 
pneumonia, blood transfusion, syncope and exacerbation of rheumatoid arthritis).  
Abbreviations: AE, adverse event; GCs, glucocortoids; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate; SASP, sulfasalazine.  
 All mentioned analyses were based upon ITT. We also performed a per-protocol 
analysis for all primary and secondary outcomes, which showed similar results to those 
of the ITT analysis (data not shown). We also performed all the abovementioned analysis 
for both subgroups – namely, RA according to the 1987 and 2010 classification criteria, 
which produced similar results (see supplementary tables S1 to S4). 
 
Adverse events (AEs) 
Table 4 shows the number (%) of patients with (serious) adverse events and treatment 
alterations due to adverse events for each treatment arm. The proportion of patients 
with medication adjustments differed significantly between the treatment arms. 
However, no differences were seen in medication adjustments due to AEs, after 
stratification for drug. 
The reasons for lowering the MTX dosage were (1) gastrointestinal complaints 
n=6, n=2 and n=4; (2) raised liver enzymes n=1, n=2 and n=4; (3) distorted kidney 
function n=0, n=2 and n=1 and (4) bone marrow depression n=1, n=0 and n=0 in 
treatment arms A, B and C, respectively. MTX was switched to subcutaneous injections 
in 4 (5%), 14 (16%) and 5 (6%) patients in arms A, B and C, respectively. MTX was 
stopped in 5 patients (6%) in arm A, because of gastrointestinal complaints (n=4) and 
skin rash (n=1). In arm B MTX was stopped in 6 patients (7%), because of gastrointestinal 
complaints (n=5) and raised liver enzymes (n=1). Gastrointestinal complaints (n=2), 
elevated liver enzymes (n=1), bone marrow depression (n=1) and hair loss (n=1) were 
the reasons for stopping MTX in 5 patients in arm C.   
SASP was stopped in 9 (11%), and 7 (8%) patients in arm A and B, respectively. 
Reasons for stopping SASP were (1) gastrointestinal complaints, n=7 and n=6, and (2) 
skin rashes, n=2 and n=1, in arms A and B, respectively. The HCQ discontinuation rate 
was 2% in both arms (A + B). In both arms, the reasons for stopping HCQ were 
gastrointestinal complaints (n=1) and skin rashes (n=1). Gastrointestinal complaints and 
fatigue were the most commonly reported  AEs (table 5). 
 
 
DISCUSSION 
 
In this study, unbiased for GCs, induction therapy consisting of a combination of 
DMARDs is better than MTX monotherapy in early RA. The combination therapy groups 
achieved more often a DAS<2.4 wihin 3 months, which led to 50% less frequent 
treatment intensifications to biological agents compared with MTX monotherapy. A 
difference in functional ability was seen, which became significant after correction for 
baseline imbalances. Bridging therapy consisting of one single dose of intramuscular 
GCs is as effective as a 10-week intermediate dose of oral GCs. Although the proportion 
of patients with medication adjustments due to AEs differed significantly between the 
treatment arms, no differences were seen in medication adjustments, after stratification 
for drug. 
 Table 5: Number(%) of patients reporting adverse events per treatment arm. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
 + im GCs (n=84) + oral GCs (n=89) (n=90) 
Malaise 11 (13) 8 (10) 9 (11) 
Fatigue 18 (21) 20 (24) 18 (21) 
Gastrointestinal complaints 43 (51) 46 (55) 25 (30) 
Hypertension 1 (1) 2 (2) 0 (0) 
Oedema 2 (2) 1 (1) 4 (5) 
Infection 3 (4) 4 (5) 9 (11) 
Skin rashes 8 (10) 8 (10) 7 (8) 
Hair loss 3 (4) 2 (2) 6 (7) 
Muscle weakness 0 (0) 1 (1) 3 (4) 
Headache 8 (10) 10 (12) 8 (10) 
Visual impaiment 1 (1) 9 (11) 2 (2) 
Feeling ‘sad’ 2 (2) 9 (11) 8 (10) 
Sleepdisorder 2 (2) 6 (7) 2 (2) 
Dizziness 1 (1) 7 (8) 1 (1) 
Palpitations 2 (2) 2 (2) 1 (1) 
Bone marrow depression 13 (15) 4 (5) 4 (5) 
High Creatinine 0 (0) 6 (7) 3 (4) 
Elevated liver enzymes 4 (5) 7 (7) 9 (11) 
Hyperglycemia 0 (0) 1 (1) 0 (0) 
Results are shown as number (%).  
Bone marrow depression is defined as an anaemia, thrombocytopenia or leucopenia with respectively  a 
haemoglobin level, platelet and white blood cells count below the lower limit of the normal range. High 
creatinine, raised liver enzymes and hyperglycaemia are defined as having respectively a creatinine, liver 
transaminases and glucose level above the upper limit of the normal range. 
Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate; 
SASP, sulfasalazine.  
 
 This study was designed to start DMARD treatment in the early phase of RA. At 
the time of writing the protocol no international accepted criteria for classifying the 
early phase of RA were defined. Therefore, we based our design on the Visser model 
reflecting patients in a early phase of persisting arthritis.10 Interestingly, the Visser 
algorithm and 2010 criteria for RA have similar discriminative abilities to identify 
patients at risk of persistent arthritis at 1 year.19 Moreover, subgroup analyses in patients 
with RA according to the 2010 and/or 1987 classification criteria7, 8 were performed and 
produced similar results.    
 In this study  we analysed the effect of MTX monotherapy in comparison with  
combination DMARD therapy without making any concessions on GC bridging therapy. 
Our findings are in contrast to the present EULAR recommendations on RA1 and favour 
induction therapy with a combination of DMARDs rather than MTX monotherapy. 
Current recommendations are based upon a systemic review5, which concluded that in 
DMARD-naïve patients the efficacy/toxicity ratio favours MTX monotherapy over 
combination therapy. However, in that review triple DMARD therapy versus MTX 
monotherapy in DMARD-naïve patients was not compared. Furthermore, trials 
favouring triple DMARD therapy (BeSt, FIN-RACo and COBRA trial) were excluded from 
that review18, 20, 21, because a MTX monotherapy control arm (without GCs) was missing. 
 A recent systemic review, made by Graudal and Jürgens22, supports the results found in 
our study. 
 The second strength of our study is the higher proportion of patients reaching 
lower disease activity states than previous trials. A DAS<2.4 was reached in 80% of our 
patients compared with 60% in the BeSt trial18. Remission (DAS<1.6) rates were 
respectively 40% in tREACH versus 20% in BeSt. This difference is probably due to: (1) 
the choice of induction therapy and (2) a lower baseline DAS. Important differences in 
initial combination therapy between our trial and the BeSt were higher MTX dosage 
(respectively 25 mg/week vs. 7.5 mg/week), and addition of hydroxychloroquine. Our 
baseline DAS was lower than in the BeSt trial (3.4 vs. 4.5), but this is probably correlated 
with the phase of the disease.  
This study underlines current perspective of treating patients in an earlier phase 
of RA, for which the 2010 ACR/EULAR classification criteria are developed. Furthermore, 
induction combination therapy contributes to achieving the desired remission within 3 
months, recommended by the current recommendations, in order to obtain better 
functional and radiological outcomes.1-3 A tailor-made treatment approach might be 
preferable in this very early phase of RA, because 60% of the patients respond well to 
MTX monotherapy. However, clinical applicable predictors for early treatment response 
are still missing. 
 GC bridging therapy is used to treat active disease in the period between 
induction of DMARD therapy and onset of their therapeutic effect.6 We find that 
intramuscular and oral GCs are equally effective as bridging therapy, but one single 
dose of GCs intramuscularly might be more feasible. GCs have disease-modifying traits 
with longlasting benefits even after withdrawal.6 Therefore, the oral GC tapering 
scheme might be superior in the long-term. Furthermore, the duration and dosage of 
our GC tapering scheme was short (10 weeks) and at a low level (initial dosage 15mg) in 
comparison with, for example, the original COBRA regimen (respectively 28 weeks, 
initial dosage 60mg).20 For current EULAR recommendations Gorter et al23 reviewed the 
literature, looking at the efficacy of GCs in RA. They concluded that GCs relieve 
symptoms and inhibit radiographic progression. However, future research is needed to 
optimise GC bridging therapy with DMARDs, especially determination of optimal 
dosage and tapering schemes.23 
 Our study had certain limitations. First, despite randomisation, an important 
difference in prognostic factors was present at baseline. However, these imbalances 
were in favour of MTX monotherapy. Moreover, correcting for these imbalances by 
multivariate analyses led to a significant difference in functional ability at 3 months 
(favouring combination therapy).  
Second, in our study only the research nurses, who performed the disease 
activity assessments on which treatment decisions are based, were blinded. This design 
was chosen, because we wanted to conduct a trial which closely represents daily 
practice of rheumatologists. Single blinding, however, might be a potential source of 
bias -  namely, an information bias.   
 Third, MTX was in some cases given subcutaneously because of gastrointestinal 
complaints. The distribution of parenteral MTX is imbalanced over the treatment arms. 
The bioavailability of parenteral MTX is higher than with MTX given orally, which is 
associated with an increased efficacy.24 However, similar results were found if patients 
with parenteral MTX were omitted.   
 Several studies have demonstrated that the choice of induction therapy 
influences the initial clinical response and indirectly the amount of joint destruction and 
treatment changes needed to achieve low disease activity, with cost possibly increasing 
over many years.18, 20, 21 The current RA treatment recommendation, however, is cost-
effective when a strategic approach with rapid treatment intensification to biological 
agents is used, when the response is inadequate.25 In tREACH 20% of patients need 
biological agents after 3 months, compared with 40% in the BeSt study, which suggest a 
50% reduction in biological usage.18 However, we included patients in an earlier phase 
of RA, representing a larger population than the BeSt study, which might lead to higher 
costs. On the other hand if patients are in sustained remission medication can be 
tapered swiftly.26 The results of the long-term follow-up of the tREACH trial, including 
analyses of joint destruction and cost-effectiveness, should clarify aforementioned 
issues for patients with early RA. 
 In conclusion, we recommend induction therapy consisting of a combination of 
DMARDs (MTX + SASP + HCQ) as first choice in patients with newly diagnosed RA, 
because combination therapy reduced disease activity more rapidly after 3 months than 
MTX monotherapy. Consequently, 50% fewer biological agents were prescribed in the 
combination therapy groups. Although the proportion of patients with medication 
adjustments due to AEs differed significantly between the treatment arms, no 
differences were seen in medication adjustments after stratification for the drug. One 
single intramuscular GC injection or an oral GC tapering scheme can be used, because 
they are equally effective as bridging therapy. 
  
 
 Supplement figure 1: EULAR response criteria  
 
 
        Improvement in DAS from baseline 
DAS at endpoint >1.2 >0.6 and ≤1.2 ≤0.6 
≤2.4 Good   
>2.4 and ≤3.7  Moderate  
>3.7   None 
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Table 1: Baseline characteristics of patients with RA according to 2010 ACR/EULAR criteria, stratified for induction therapy. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
 + im GCs (n=83) + oral GCs (n=80) (n=83) 
Age (yrs), mean (sd) 52 (15) 54 (14) 53 (14) 
Sex, female, no(%) 50 (60) 59 (74) 60 (72) 
Symptom duration (days), mean (sd) 160 (96) 179 (92) 154 (80) 
RF pos., no(%) 55 (66) 50 (63) 51 (61) 
ACPA pos., no(%) 58 (70) 49 (61) 56 (67) 
Erosion, no(%)* 24 (29) 12 (15) 12 (14) 
DAS, mean (sd) 3.35 (0.79) 3.52 (1.09) 3.51 (0.96) 
DAS28, mean (sd) 4.86 (1.10) 5.02 (1.25) 4.91 (1.26) 
TJC44, median (IQR) 9 (5 - 14) 10.5 (5 – 17.5) 11 (5 – 15) 
SJC44, median (IQR) 8 (5 - 12) 8 (4 – 12) 8 (4 – 13) 
VAS global (0 -100mm), median (IQR) 53 (34 - 70) 56 (29 – 70.5) 55 (38 – 70) 
ESR in mm/hr, median (IQR) 25 (13 – 39) 22 (13 – 45.5) 24 (14 – 44) 
CRP in mg/L, median (IQR) 8 (4 -23) 6.4 (3.75 - 19) 11 (5 – 26) 
HAQ, mean (sd) 0.97 (0.68) (n=77) 1.03 (0.63) (n=74) 1.09 (0.70) (n=81) 
RADAI (0-10), mean (sd) 4.01 (1.87) (n=75) 4.01 (1.62) (n=70) 4.30 (1.84) (n=77) 
Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
*p=0.032 and p=0.024 for resp. A vs. B and A vs.C 
Abbreviations:  ACPA, anti-citrullinated protein/peptide antibodies; CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; GCs, 
glucocorticoids; HAQ, Health Assessment Questionnaire; HCQ, hydroxychloroquine; im, intramuscular;  IQR, interquartile range; MTX, methotrexate; RADAI, 
Rheumatoid Arthritis Disease Activity Index questionnaire; RF, rheumatoid factor; SASP, sulfasalazine; sd, standard deviation; SJC44, swollen joint count (44 joints); 
TJC44, tender joint count (44 joints); VAS, visual analogue scale. 
 Table 2: Clinical response after 3 months for each induction therapy group in the subgroup of patients with RA according to 2010 
criteria, intention-to-treat analysis. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
 + im GCs (n=78) + oral GCs (n=78) (n=77) 
DAS, mean (sd)† 1.86 (0.99) 1.91 (0.85) 2.34 (0.99) 
ΔDAS (T3 - T0), mean (sd)‡ -1.46 (1.00) -1.56 (0.98) -1.19 (1.06) 
Disease state according to DAS, no(%)    
• moderate to high disease activity (DAS≥2.4)§* 20 (26) 19 (24) 34 (44) 
• low disease activity (1.6≥DAS<2.4) 23 (29) 29 (37) 24 (31) 
• remission(DAS<1.6)¶ 35 (45) 30 (38) 19 (25) 
EULAR response criteria, no(%)    
• good 43 (55) 38 (49) 32 (42) 
• moderate 22 (28) 27 (35) 20 (26) 
• None# 13 (17) 13 (17) 25 (32) 
TJC44, median (IQR)** 1 (0 - 5) 2 (0 – 6) 4 (0 – 9) 
SJC44, median (IQR) 1 (0 - 4) 1 (0 - 3) 2 (0 - 5) 
VAS global (0 -100mm), median (IQR)†† 22 (12 - 36) 28 (15 - 49) 40 (22 – 55) 
ESR in mm/hr, median (IQR) 14 (6 – 27) 10.5 (5 – 22) 13 (8 – 24) 
CRP in mg/L, median (IQR)‡‡ 4 (1.2 – 8) 3.35 (1 – 5.1) 5 (2 – 9) 
HAQ, mean (sd)§§ 0.49 (0.55) (n=69) 0.55 (0.56) (n=74) 0.72 (0.65) (n=71) 
ΔHAQ (T3 - T0), mean (sd) -0.42 (0.51) (n=66) -0.42 (0.54) (n=70) -0.38 (0.58) (n=71) 
RADAI (0 - 10), mean (sd)¶¶ 1.95 (1.80) (n=68) 2.01 (1.87) (n=70) 2.69 (1.94) (n=68) 
ΔRADAI (T3 - T0), mean (sd) -1.95 (1.74) (n=65) -1.98 (1.95) (n=63) -1.56 (1.80) (n=66) 
Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
Abbreviations: CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; GCs, glucocorticoids; HAQ, Health Assessment 
Questionnaire; HCQ, hydroxychloroquine; im, intramuscular; IQR, interquartile range; MTX, methotrexate; RADAI, Rheumatoid Arthritis Disease Activity Index 
questionnaire; SASP, sulfasalazine; sd, standard deviation; SJC44, swollen joint count (44 joints); TJC44, tender joint count (44 joints); VAS, visual analogue scale. 
*Starting biological agent. 
†p=0.003 and p=0.004 for resp. A vs. C and B vs. C   **p=0.008 for A vs. C 
‡p=0.025 for B vs. C      ††p=0.0001 and p=0.033 for resp. A vs. C and B vs. C 
§p=0.016 and p=0.009 for resp. A vs. C and B vs. C   ‡‡p=0.034 for B vs. C  
¶p=0.008 for A vs. C      §§p=0.024 for A vs. C   
#p=0.022 and p=0.022 for resp. A vs. C and B   ¶¶p=0.023 and p=0.04 for resp. A vs. C & B vs.
 Supplement 3: Subgroup analyses for patients with RA according to 1987 ACR criteria  
 
Table 3: Baseline characteristics of patients with RA according to 1987 ACR/EULAR criteria, stratified for induction therapy. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
 + im GCs (n=69) + oral GCs (n=57) (n=63) 
Age (yrs), mean (sd) 54 (16) 55 (14) 55 (14) 
Sex, female, no(%) 41 (59) 39 (68) 43 (68) 
Symptom duration (days), mean (sd) 161 (94) 174 (87) 146 (73) 
RF pos., no(%) 43 (62) 37 (65) 35 (56) 
ACPA pos., no(%) 44 (64) 30 (53) 36 (57) 
Erosion, no(%)* 23 (33) 11 (19) 9 (14) 
DAS, mean (sd) 3.43 (0.76) 3.59 (1.06) 3.57 (0.99) 
DAS28, mean (sd) 5.04 (0.99) 5.13 (1.24) 5.03 (1.22) 
TJC44, median (IQR) 9 (6 - 14) 10 (5 - 15) 10 (5 - 15) 
SJC44, median (IQR) 9 (6 - 12) 11 (6 - 12) 9 (6 - 13) 
VAS global (0 -100mm), median (IQR) 55 (37 - 69) 58 (31 - 71) 55 (35 - 70) 
ESR in mm/hr, median (IQR) 28 (15 - 44) 24 (16 - 51) 25 (20 - 44) 
CRP in mg/L, median (IQR) 9 (4 - 24) 8 (4 - 24) 13 (5.6 - 31) 
HAQ, mean (sd) 1.05 (0.67) (n=64) 0.98 (0.64) (n=52) 1.10 (0.68) (n=60) 
RADAI (0-10), mean (sd) 4.16 (1.86) (n=63) 4.14 (1.55) (n=50) 4.31 (1.98) (n=57) 
Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
*p=0.011 for A vs C 
Abbreviations:  ACPA, anti-citrullinated protein/peptide antibodies; CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; GCs, 
glucocorticoids; HAQ, Health Assessment Questionnaire; HCQ, hydroxychloroquine; im, intramuscular;  IQR, interquartile range; MTX, methotrexate; RADAI, 
Rheumatoid Arthritis Disease Activity Index questionnaire; RF, rheumatoid factor; SASP, sulfasalazine; sd, standard deviation; SJC44, swollen joint count (44 joints); 
TJC44, tender joint count (44 joints); VAS, visual analogue scale. 
 
 
 Table 4: Clinical response after 3 months for each induction therapy group in the subgroup of patients with RA according to 1987 
criteria, intention-to-treat analysis. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
 + im GCs (n=65) + oral GCs (n=55) (n=59) 
DAS, mean (sd)† 1.83 (0.77) 1.83 (0.84) 2.18 (1.07) 
ΔDAS (T3 - T0), mean (sd) -1.55 (0.90) -1.77 (1.04) -1.41 (1.00) 
Disease state according to DAS, no(%)    
• moderate to high disease activity (DAS≥2.4)‡* 15 (23) 12 (22) 23 (39) 
• low disease activity (1.6≥DAS<2.4) 22 (34) 19 (35) 17 (29) 
• remission(DAS<1.6) 28 (43) 24 (44) 19 (32) 
EULAR response criteria, no(%)    
• good 38 (58) 32 (58) 30 (51) 
• moderate 18 (28) 15 (27) 15 (25) 
• none 9 (14) 8 (15) 14 (24) 
TJC44, median (IQR) 1 (0 - 4) 1 (0 - 5) 3 (0 - 7) 
SJC44, median (IQR) 2 (0 - 4) 1 (0 - 3) 2 (0 - 5) 
VAS global (0 -100mm), median (IQR)§ 22 (13 - 34) 21 (14 - 52) 35 (18 - 55) 
ESR in mm/hr, median (IQR) 15 (7 - 27) 11 (5 - 24) 13 (7 - 24) 
CRP in mg/L, median (IQR) 4.4 (1.6 – 9) 4 (1 - 7) 5 (2 - 12) 
HAQ, mean (sd) 0.50 (0.51) (n=57) 0.48 (0.53) (n=50) 0.67 (0.70) (n=53) 
ΔHAQ (T3 - T0), mean (sd) -0.47 (0.54) (n=54) -0.47 (0.55) (n=47) -0.42 (0.52) (n=52) 
RADAI (0 - 10), mean (sd)¶ 1.93 (1.61) (n=56) 1.62 (1.56) (n=46) 2.70 (2.07) (n=52) 
ΔRADAI (T3 - T0), mean (sd)# -2.09 (1.58) (n=54) -2.53 (1.74) (n=41) -1.46 (1.77) (n=51) 
Not everyone fi lled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
Abbreviations: CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; GCs, glucocorticoids; HAQ, Health Assessment 
Questionnaire; HCQ, hydroxychloroquine; im, intramuscular; IQR, interquartile range; MTX, methotrexate; RADAI, Rheumatoid Arthritis Disease Activity Index 
questionnaire; SASP, sulfasalazine; sd, standard deviation; SJC44, swollen joint count (44 joints); TJC44, tender joint count (44 joints); VAS, visual analogue scale. 
*Starting biological agent. 
†p=0.04 for A vs. C  
‡p=0.047 for B vs. C  
§p=0.011 for A vs. C  
¶p=0.033 and p=0.005 for resp. A vs. C and B vs. C 
#p=0.005 for B vs. C 
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 CHAPTER 3 
 
Initial triple DMARD therapy is more efficient  
than methotrexate monotherapy in  recent onset 
rheumatoid arthritis; 1-year data of a randomized 
clinical trial (tREACH) 
 
de Jong PH, Hazes JM, Han HK,, Huisman M, van Zeben D,  
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 Importance:  There is still debate on the most appropriate initial treatment regimen in 
patients with newly diagnosed rheumatoid arthritis (RA). Most important discussion 
herein is that of methotrexate monotherapy versus a combination of DMARDs. 
 
Objectives: To compare 1-year clinical efficacy of (1) initial triple DMARD therapy (iTDT) 
versus initial methotrexate (MTX) monotherapy (iMM) unbiased for glucocorticoids 
(GCs) (arm B versus C), and (2) different GC bridging therapies: oral versus a single 
intramuscular injection (arm A versus B) in very early RA. 
 
Design, Setting:  The tREACH trial, a multicenter, stratified single-blinded trial, is 
performed in eight rheumatology centres in the Netherlands. Outpatients aged 20 to 85 
years were evaluated every 3 months for 1 year, from 2007 through 2012. 
 
Participants: Patients with a high probability (> 70%) according to their likelihood of 
progressing to persistent arthritis, based of the prediction model of Visser, were 
included. The Visser algorithm and 2010 criteria for RA have similar discriminative 
abilities to identify patients at risk of persistent arthritis at 1 year. 
 
Intervention: Random assignment to one of following initial treatment strategies: (A) 
iTDT (MTX + sulfasalazine + hydroxychloroquine) with GCs intramuscular (n=91), (B) 
iTDT with an oral GC tapering scheme (n=93), and (C) MTX with oral GCs similar to B 
(n=97). 
 
Main outcomes and measures: Disease activity, functional ability, radiological 
damage, and adverse events were assessed. 
 
Results: Over time disease activity and functional ability, measured with the area under 
the curve, were respectively  -2.39 (-4.77 to -0.00, 95% confidence interval) and  
-1.67 (-3.35 to 0.02, 95% confidence interval)  lower in patients with iTDT compared with 
iMM. After 3 months, less treatment failure occurred in the iTDT, resulting in the 
prescription of 40% fewer biologicals. This difference remained over time. No 
differences were seen between both GC bridging therapies. Respectively 19%, 23%, and 
21% of patients in arm A, B, and C had radiographic progression after 1 year. No 
differences in serious adverse events were seen. 
 
Conclusion: We recommend iTDT over iMM as first choice in newly diagnosed RA 
patients, because treatment goals are attained faster and maintained with less 
biologicals. Furthermore intramuscular and oral GCs are equally effective as bridging 
therapy and can both be used. 
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 INTRODUCTION 
 
In last two decades major paradigm changes in the management of rheumatoid 
arthritis (RA) have occurred. These changes are: (1) early detection of the disease, hence 
development of 2010 criteria for RA1, (2) early initiation of intensive therapy, and (3) 
treat-to-target, which is included in all current guidelines.2-3 Functional and radiological 
outcomes improve if current guidelines are uphold.4-5 Nevertheless, some major debate 
points still exist.  
First, 2010 criteria for RA1 are more and more incorporated in daily practice. All 
current guidelines, however, were formulated using data from studies in patients 
fulfilling 1987 RA criteria.2-3, 6 Thus trials comparing initial treatment strategies in the 
early phase of RA are needed for validation.  
Second, several clinical trials concluded that initial combination therapy had 
superior clinical efficacy over monotherapy, however, most rheumatologists have not 
implemented this in daily practice.7-11 Moreover, current guidelines do not recommend 
combination therapy for all newly diagnosed RA patients.2-3 Principal motive of 
disregarding combination therapy was the fact that (1) trials were biased by 
glucocorticoids (GCs), (2) patients were not DMARD naïve and (3) there are safety 
concern issues.12-13 
Third, GCs have a rapid anti-inflammatory effect, and are therefore used as 
bridging therapy to treat active disease in between initiation of DMARD(s) and onset of 
their therapeutic effect.14 However, trials specifically comparing GC bridging therapies 
are sparse. More trials are, therefore, needed to investigate optimal dosage and 
tapering schemes.  
Finally, for health economic reasons efficient use of expensive drugs is needed to 
be able to continue optimal rheumatic care in the future.15  
Therefore, our aim is to compare in patients with very early RA the 1-year clinical 
efficacy of (1) initial triple DMARD therapy (iTDT) versus methotrexate (MTX) 
monotherapy, unbiased for GCs, and (2) different GC bridging therapies: oral versus a 
single intramuscular injection.  
 
 
PATIENTS AND METHODS 
 
Patients 
For this study data were used of a clinical trial (ISRCTN26791028), namely treatment in 
the Rotterdam Early Arthritis Cohort (tREACH).16 tREACH, a multicenter, stratified single-
blinded trial, is performed in eight rheumatology centres in the Netherlands. Medical 
ethics committees at each participating centre approved the study protocol, and all 
patients gave written informed consent before inclusion. Inclusion criteria for the 
tREACH are: Age ≥18 years, arthritis in ≥1 joint(s), and symptom duration  <1 year. 
Exclusion criteria for the tREACH are given in appendix 1. 
 Eligible patients were stratified into three groups according to their likelihood of 
progressing to persistent arthritis based of the Visser model.17 The three strata (low, 
intermediate, and high) correspond with probability tertiles of developing persistent 
arthritis. For this analysis we included the high probability stratum. 
 
Randomisation and blinding 
Patients were randomised, using variable block randomization stratified for centre, by 
an independent call-centre. Trained research nurses, blinded for allocated treatment 
arm throughout the study, examined patients and calculated the disease activity score 
(DAS).  
 
Design 
Patients were randomised into one of following initial treatment strategies: 
A. iTDT (MTX, sulfasalazine, and hydroxychloroquine with GCs intramuscular) 
B. iTDT with an oral GC tapering scheme 
C. initial MTX monotherapy (iMM) with oral GCs similar to B  
Concurrent therapy with non-steroidal anti-inflammatory drugs and intra-articular GC 
injections (maximum of two per three months) were allowed during the study. 
DMARD dosages were: MTX 25 mg/week orally (dosage reached after three 
weeks), sulfasalazine 2 grams/day and hydroxychloroquine  400 mg/day, reduced to 
200mg/day after 3 months. GCs were either given intramuscular (methylprednisolone 
120mg or triamcinolone 80mg) or in an oral tapering scheme (weeks 1-4: 15 mg/day, 
weeks 5-6: 10 mg/day, weeks 7-8: 5 mg/day, and weeks 9-10: 2.5 mg/day). All patients 
received folic acid (10 mg/week) during MTX prescription. Osteoporosis prophylaxis 
(risedronate 35 mg/week and calcium/vitamin D combination 500/400 mg/IU/day) is 
given to patients in treatment arms B and C, during the first three months.  
A treat-to-target approach was used, aiming for a DAS < 2.4.18 If DAS≥2.4 
medication is intensified. Intensification steps were subsequently (1) MTX + etanercept 
(50mg/week, subcutaneous), (2) MTX + adalimunab (40mg/ 2 weeks, subcutaneous), 
and (3) MTX + abatacept (500 – 1000 mg/ 4 weeks, intravenous, depending on weight). 
Treatment intensifications were the same for each treatment arm.  
If DAS<1.6 at two consecutive visits, medication was tapered. Hierarchically 
ordered tapering steps are: (1) biological, (2) sulfasalazine, (3) MTX, and (4) 
hydroxychoroquine. Biological(s), MTX and sulfasalazine were gradually discontinued, 
whereas hydroxychloroquine was stopped immediately. A flare during tapering, defined 
as DAS ≥2.4, results in restarting full therapy, according to the stage in the protocol.  
 
 Outcomes and assessments 
Patients were examined every 3 months for all outcomes, except for hand/foot 
radiographs, which were done at baseline and half-yearly. 
Primary outcomes were (1) disease activity (state), (2) functional ability, and (3) 
radiographic progression. DAS and its thresholds are used for disease state 
categorizations.18 Functional ability was measured with the Health Assessment 
Questionnaire (HAQ).19 Higher HAQ scores indicate poorer function. Radiographic 
progression was measured with the modified Sharp-van der Heijde score (SHS).20 
Radiographs were read chronologically by 2 out of 5 qualified assessors, who were 
blinded for patient’s identity and treatment allocation.21 Mean SHS are reported.22 
Weighted kappa between assessors was 0.36 with 98% agreement. Proportion of 
patients with radiographic progression, defined as SHS change  >0.5 and  >1.2 (smallest 
detectable change ) per year, were also calculated.22  
Secondary endpoints were: EULAR response criteria23, Boolean-defined remission 
criteria24, self-assessed disease activity, and medication usage. EULAR response criteria 
are based on attained level and change in DAS (appendix 2).23 Boolean remission criteria 
are defined as having a tender joint count, swollen joint count, C-reactive protein (in 
mg/dl), and patient global assessment (0 -10 scale) of ≤1.24 Self-assessed disease activity 
is measured with the Rheumatoid Arthritis Disease Activity Index questionnaire 
(RADAI).25 Higher RADAI scores correspond with more active disease. 
 
Safety monitoring and toxicity 
Safety monitoring occurred according to Dutch guidelines26-27, which included 
laboratory tests at fixed intervals. Study medication was either stopped or dosage 
lowered in accordance with the protocol if (serious) adverse events16 were observed by 
the attending rheumatologist. MTX could be given subcutaneously if patients had 
gastro-intestinal complaints. If MTX needed to be stopped for safety reasons, it was 
substituted with leflunomide (20 mg/day).16 
 
Statistical Analysis 
Sample-size calculation was based upon the area under the curve (AUC) of the HAQ, 
using data from the BeSt study8, where mean AUC HAQ of combination therapy and 
monotherapy respectively were 7.7 (SD 5.5) and 10.5 (SD 7.4). A target sample size of 
270 patients per probability stratum,and thus 90 patients per arm, was needed to detect 
mentioned difference with a power of 80% and two-sided α=0.05. This size is sufficient 
to detect a difference of 6.1 AUC DAS and 20% difference in radiographic progression.16 
Clinical efficacy was calculated in an intention-to-treat and per-protocol analysis. 
Statistical comparison of the baseline characteristics and outcomes (after 12 months) 
between iTDT and iMM (arm B versus C) and both GC bridging therapies (arm A versus 
B)  were made by student t test, χ2 test,  or Wilcoxon rank-sum test, when appropriate.  
  
 
 
 
 
 
 
 
 
  A. MTX + SASP + HCQ B. MTX + SASP + HCQ  C. MTX + oral GCs 
   + im GCs (n=91) + oral GCs (n=93) (n=97) 
Protocol violations    
Skipped ≥1 time point(s) 16 (18) 12 (13) 14 (14) 
Postponing/withholding biological 7 (8) 11 (12) 11 (11) 
illicit treatment intensifications 1 (1) 1 (1) 1 (1) 
no tapering of treatment 6 (7) 11 (12) 5 (5) 
other1 2 (2) 2 (2) 1 (1) 
total 32 (35) 37 (40) 32 (33) 
Figure 1: Trial profile and protocol violations.  
Results shown are a number (%). 
1Other reasons are: 3x No compliance, 1x pregnancy wish and 1x continuation of SASP after switch to 
etanercept.  
The figure shows the flowchart of the tREACH trial, whereas the table shows the protocol violations within 
the tREACH trial during the first year of follow-up. Other reasons for dropping out, in the flowchart, were 
incorrect randomization and problems with communication.  
Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate; 
SASP, sulfasalazine. 
 
We used the AUC to compare DAS, and HAQ over time between treatment arms, in 
which missing values at each time-point were substituted with mean value of the 
corresponding treatment arm. Radiographic progression was extra- or interpolated if 
SHS was missing after 12 months. Analyses were corrected for baseline imbalances. 
All analyses were performed for patients in the high probability stratum and two 
subgroups consisting of patients with RA according to 1987 and 2010 criteria.1, 6 All 
statistical analyses were carried out using STATA version 12.0. A p value <0.05 was 
considered statistically significant.   
 
 
RESULTS 
 
Patients 
A total of 797 patients have been assessed for eligibility and of those, 568 patients were 
included. In the high probability stratum 281 patients were randomly assigned to 
treatment arm A (n=91), B (n=93), or C (n=97) (figure 1). Besides an intention-to-treat 
(ITT) analysis, we also performed a per-protocol analysis. We excluded, from our per-
protocol analysis, respectively 32 (35%), 37 (40%), and 32 (33%) patients randomised to 
arm A, B, and C (figure 1).  
At baseline, the symptom duration and patients fulfilling 1987 criteria for RA 
differed significantly between arms (table 1). Our primary outcomes were corrected for 
these baseline imbalances and baseline HAQ, DAS or SHS, when appropriate, by making 
use of multivariate analyses. 
 
 Table 1: Baseline characteristics and clinical response after 12 months for each induction 
therapy group, according to intention-to-treat. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
   + im GCs (n=91) + oral GCs (n=93) (n=97) 
Demographic    
Age (yrs), mean (sd) 53 (15) 54 (14) 54 (14) 
Sex, female, no(%) 55 (60) 67 (72) 68 (72) 
Disease characteristics    
Symptom duration (days), mean (sd)* 162 (97) 184 (92) 154 (83) 
RF pos., no(%) 55 (60) 51 (55) 51 (53) 
ACPA pos., no(%) 59 (65) 50 (54) 56 (58) 
Fulfillment RA criteria, no(%)    
1987† 69 (76) 57 (61) 63 (65) 
2010 87 (96) 88 (95) 95 (98) 
Disease activity    
• Baseline    
DAS, mean (sd) 3.28 (1.06) 3.40 (1.07) 3.38 (0.97) 
• After 12 months    
DAS, mean (sd)  1.40 (0.68) 1.61 (0.87) 1.68 (0.89) 
ΔDAS (T12 - T0), mean (sd) -1.83 (-1.03) -1.75 (-1.14) -1.69 (-1.27) 
Disease state according to DAS, no(%)    
moderate to high disease activity (DAS≥2.4) 8/77 (10) 15/84 (18) 19/87 (22) 
low disease activity (1.6≥DAS<2.4) 22/77 (29) 24/84 (29) 24/87 (28) 
remission (DAS<1.6) 47/77 (61) 45/84 (54) 44/87 (51) 
Boolean remission criteria, no(%)1 17/77 (22) 13/84 (16) 14/87 (16) 
EULAR response criteria (T12 - T0), no(%)2    
good 54/77 (70) 52/84 (62) 57/87 (66) 
Moderate 13/77 (17) 19/84 (23) 9/87 (10) 
none 10/77 (13) 13/84 (15) 21/87 (24) 
Radiographs (hand/foot)    
• Baseline    
Total SHS (0 - 488 ), median (IQR) 0.5 (0 – 2) 0.5 (0 – 2) 1 (0 – 2.5) 
Erosion score (0 - 280), median (IQR) 0 (0 – 1) 0 (0 – 1) 0.5 (0 – 1) 
JSN score (0 - 168), median (IQR) 0 (0 – 1) 0 (0 - 1) 0 (0 – 1.5) 
Erosion, no(%)3 18/91 (20) 18/93 (19) 20/95 (21) 
• After 12 months    
Total SHS (0 - 488 ), median (IQR) 1 (0 – 3) 1 (0 – 3) 1 (0 – 3.5) 
Erosion score (0 - 280), median (IQR) 0.5 (0 – 1.25) 0.5 (0 – 1.5) 0.5 (0 – 1.5) 
JSN score (0 - 168), median (IQR) 0.5 (0 - 1.5) 0 (0 – 1.5) 0.5 (0 – 1.5) 
ΔTotal SHS (T12 - T0), median (IQR) 0.13 (0 – 1) 0 (0 – 1) 0 (0 - 1) 
Patients with progression >0.5, no (%) 25/76 (33) 24/82 (29) 28/84 (33) 
Patients with progression >1.2, no (%) 16/76 (21) 20/82 (24) 19/84 (23) 
Questionnaires4    
• Baseline    
HAQ, mean (sd) 0.98 (0.67) (n=84) 0.96 (0.64) (n=84) 1.06 (0.68) (n=92) 
RADAI (0-10), mean (sd) 3.97 (1.83) (n=81) 3.94 (1.63) (n=80) 4.21 (1.82) (n=87) 
• After 12 months    
HAQ, mean (sd)  0.38 (0.46) (n=69) 0.51 (0.55) (n=78) 0.63 (0.57) (n=82) 
ΔHAQ (T12 - T0), mean (sd) -0.48 (-0.63) (n=65) -0.42 (-0.59) (n=74) -0.47 (-0.53) (n=80) 
RADAI (0 - 10), mean (sd) 1.43 (1.24) (n=68) 1.78 (1.51) (n=75) 2.15 (1.81) (n=79) 
ΔRADAI (T12 - T0), mean (sd) -2.22 (-1.68) (n=63) -2.06 (-1.87) (n=69) -2.11 (-1.91) (n=74) 
1Boolean remission criteria are defined as having a TJC44≤1, SJC44≤1, VAS global≤10mm and CRP≤10 mg/L 
2EULAR response criteria are based on attained level and change in DAS 
3Erosive disease is defined as having a erosion score >1.2 (=smallest detectable change) 
4Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
*p=0.018 for B vs C.   
†p=0.034 for A vs B. 
 
 
 Clinical outcome 
After 12 months DAS was 0.08 (-0.34 to 0.19, 95% confidence interval (CI)) lower in 
patients with iTDT than in those with iMM (arm B vs. C). Difference in DAS between the 
different GC bridging therapies was -0.20 (-0.45 to 0.04, 95% CI) (arm A vs. B). Similar 
results were found in our multivariate analyses (data not shown). No differences in 
disease activity states are found after 12 months between iTDT and iMM, or both GC 
bridging therapies (table 1). Difference in AUC DAS between iTDT and iMM was  -2.39  
(-4.77 to -0.00, 95%CI, p=0.05), and  -0.91 (-3.17 to 1.34, 95% CI, p=0.42) between both 
GC bridging therapies.  Adjusted differences were respectively -2.67 (-4.61 to -0.74, 
95%CI, p=0.007) and -0.07 (-2.04 to 1.90, 95% CI, p=0.95). The largest difference in 
disease activity (states) between treatment arms is seen after 3 months, whereupon it 
gradually diminished (figure 2).  
There was no significant difference in SHS after 12 months of therapy (table 1). 
Respectively 19%, 23%, and 21% of patients in arm A, B, and C had radiographic 
progression. The cumulative probability plot for the 3 treatment arms were 
superimposable (appendix 3). 
Functional improvement was seen in all patients. No significant difference in 
functional ability was seen after 12 months (table 2). Difference in AUC HAQ between 
iTDT and iMM was -1.67 (-3.35 to 0.02, 95%CI, p=0.05), and -0.46 (-2.04 to 1.12, 95% CI, 
p=0.57) between both GC bridging therapies (figure 2). Adjusted differences were 
respectively -1.35 (-2.51 to -0.19, 95% CI, p=0.02) and 0.36 (-0.83 to 1.54, 95% CI, p=0.55). 
Secondary end points are shown in table 1 and figure 2.  
All mentioned analyses were based upon ITT. We also performed a per-protocol 
analysis, which showed similar results (data not shown). Above mentioned analyses 
were also performed in both subgroups, namely RA according to 1987 and 2010 criteria, 
which produced similar results (appendix  4 and 5).  
 
Medication 
After 3 months 40% fewer biologicals were prescribed in the iTDT group compared with 
the iMM group (arm B vs. C). This difference remained over time (figure 3). After 12 
months respectively 27% and 43% of patients, with iTDT and iMM, were using a 
biological (arm B vs. C, p=0.03) . Moreover, more patients with iMM failed on their first 
biological (16% vs. 6%, p=0.031) (figure 3).  In 117/281 (42%) of patients treatment could 
be tapered, of those 14/117 (12%) flared. Treatment could be tapered more often in 
patients with iTDT compared with iMM, respectively 28% vs. 23%, without occurrence of 
more flares (6% vs. 7%) (figure 3).  Biological usage did not differ between both GC 
bridging therapies (arm A vs. B) (figure 3). Aforementioned analysis were also performed 
in both subgroups and showed similar results (appendix  4 and 5). 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: (Self-assessed) disease activity, functional ability and radiographic joint 
damage over time, stratified for induction therapy. 
Error bars indicate respectively 95% confidence intervals and interquartile range for given means and 
median. 
 
  
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ   C. MTX + oral GCs 
   + im GCs (n=91) + oral GCs (n=93) (n=97) 
Medication after 12 months    
MTX 73 (80) 72 (77) 82 (85) 
MTX dosage, median (IQR) 15 (7.5 - 25) 15 (7.5 - 25) 20 (7.5 - 25) 
SASP 27 (30) 27 (29) 2 (2) 
HCQ 51 (56) 59 (63) 8 (8) 
Biological use* 26 (29) 24 (26) 42 (43) 
Etanercept 18 (20) 12 (13) 22 (23) 
Adalimumab† 4 (4) 6 (6) 16 (16) 
Abatacept 3 (3) 5 (5) 4 (4) 
Other1 1 (1) 1 (1) 0 (0) 
Tapered treatment2    
Taperings‡ 88/238 (37) 71/256 (28) 60/260 (23) 
at 1 time-point 16 (18) 19 (20) 16 (16) 
at 2 time-points 12 (13) 11 (8) 10 (10) 
at 3 time-points 15 (16) 10 (11) 8 (8) 
Flare after tapering3 6/88 (7) 4/71 (6) 4/60 (7) 
Figure 3: Withdrawal, flares and medication usage over time and after 12 months, stratified for induction therapy.  
Results shown are a number (%) unless stated otherwise. 
1Other biologicals are: Infliximab (A) and Rituximab (B) 
2Treatment could be tapered after 6 months. Therefore the total amount of possible taperings is the sum of all assessments at the last three visits per treatment arm. 
3A flare is defined as a DAS≥2.4. The proportion is calculated by dividing the number of flares by the total amount of taperings 
*p=0.011  for B vs C.   
†p=0.031 for B vs C   
‡p=0.028 for A vs B 
Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; IQR, interquartile range; MTX, methotrexate; SASP, sulfasalazine. 
 Adverse events (AEs) 
No differences in serious AEs were seen between treatment arms (table 2). However, the 
proportion of patients with medications adjustments due to AEs differed significantly 
between iTDT and iMM (60/93 (65%) and 44/97 (45%), p=0.008).  Besides switching to 
MTX subcutaneously, aforementioned differences vanished after stratification for drug 
(table 2). No differences were seen between both GC bridging therapies. Most treatment 
adjustments occurred in the first 3 months (51/159, 32%). Gastrointestinal complaints 
and fatigue were most commonly reported AEs, respectively 56% and 36% (table 2). 
 
 
DISCUSSION 
 
In this study, unbiased for GCs, iTDT had a better clinical efficacy and efficiency than 
iMM in early RA. The burden of disease over time, reflected by the AUC, was less in the 
iTDT group compared with iMM. Treatment goals were attained faster and maintained 
with 40% fewer biologicals in the iTDT group. Moreover, more patients with iMM failed 
on their first biological, reducing therapeutic options. Radiographic progression did not 
differ between groups. No differences in serious AEs were seen. Treatment could also be 
tapered more often with iTDT, without the occurrence of more flares. On contrary, no 
differences were seen between both GC bridging therapies.  
We based our design on the Visser model, because we wanted to initiate DMARD 
therapy in a very early phase of the disease and at the time of writing the protocol the 
2010 criteria for RA still had to be developed.17 Interestingly, the Visser algorithm and 
2010 criteria for RA have similar discriminative abilities to identify patients at risk of 
persistent arthritis.28 Our trial is, therefore, one of the first studies conducted in RA 
patients fulfilling 2010 criteria. 
Because of early initiation of DMARD therapy more patients achieve their 
treatment goal in comparison with previous trials.8-10 After 12 months 80% had a 
DAS<2.4 compared with 65% in the BeSt trial.8 Adjacent to this less erosive disease and 
radiographic progression were seen in our trial.8-10 Our intensive treatment strategy also 
contributed to aforementioned differences. Important differences in iTDT between 
tREACH and BeSt were MTX dosage (respectively 25 versus 7.5 mg/week), and addition 
of hydroxychloroquine. This underlines the importance of initiating DMARD therapy in 
an earlier phase.  
We were able to analyse difference in efficacy between iTDT and iMM, unbiased 
for GCs and in DMARD naïve patients. Our findings do not support current guidelines2-3 
and favour iTDT over iMM, but reconfirm the findings found in previous studies.7-12, 29 
Although the TEAR trial concluded otherwise, similar results are found in their trial as in 
the tREACH trial. Like the TEAR trial, clinical outcomes did not differ after 12 months, 
which is obviously due to our treat-to-target approach (intensifying treatment until the 
target is reached). Therefore, not the endpoint, but what happens along the way is what 
matters most.  
 Table 2: Number (%) of patients with (serious) adverse events, and treatment 
alterations due to side effects for each induction therapy group. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ  C. MTX + oral GCs 
   + im GCs (n=91) + oral GCs (n=93) (n=97) 
Adverse events (AE)    
Serious AE(s)1 5 (5) 10 (11) 10 (10) 
Patients with ≥1 AE(s) 76 (84) 82 (88) 77 (79) 
no. of AEs per patient, median (IQR) 2 (1 - 3) 2 (1 - 4) 2 (1 - 4) 
    Medication changes due to AE(s)    
Switch to MTX sc* 12 (13) 21 (23) 11 (11) 
lowering MTX dosage <20mg/wk† 17 (19) 10 (11) 22 (23) 
STOP MTX 11 (12) 14 (15) 7 (7) 
STOP SASP 11 (12) 8 (9) NA 
STOP HCQ 4 (4) 5 (5) NA 
STOP Biological 0 (0) 2 (2) 4 (4) 
   Observed AEs2    
Malaise 20 (22) 19 (20) 15 (15) 
Fatigue 23 (25) 34 (37) 40 (41) 
Dizziness 2 (2) 10 (11) 7 (7) 
Headache 10 (11) 13 (14) 13 (13) 
Muscle weakness 2 (2) 8 (9) 7 (7) 
Hypertension 2 (2) 4 (4) 0 (0) 
Palpitations 0 (0) 4 (4) 7 (7) 
Edema 3 (3) 3 (3) 6 (6) 
Dyspnea 0 (0) 4 (4) 7 (7) 
Gastrointestinal complaints 57 (63) 59 (63) 41 (42) 
Infection 12 (13) 21 (23) 22 (23) 
Skin problems 20 (22) 25 (27) 27 (28) 
Hair loss 8 (8) 7 (8) 14 (14) 
Hearing loss 1 (1) 0 (0) 0 (0) 
Visual impairment 7 (8) 17 (18) 7 (7) 
Hyperglycemia 0 (0) 1 (1) 0 (0) 
Feeling "sad" 7 (8) 13 (14) 12 (12) 
Sleep disorder 4 (4) 13 (14) 8 (8) 
Bone marrow depression 17 (19) 8 (9) 7 (7) 
High Creatinine 2 (2) 6 (6) 4 (4) 
Elevated liver enzymes 12 (13) 15 (16) 18 (19) 
Results shown are a number (%) unless stated otherwise. 
1Serious AEs per treatment are respectively: [A] 4x Hospitalisation (2x pneumonia, kidney stones and inguinal 
hernia surgery), 1x lung carcinoma; [B] 5x Hospitalisation (MTX pneumonitis, Severe constipation, Transient 
Ischemic Attack, Gastroenteritis and Observation chest pain), 1x Deceased, 1x Myocardial infarction and 2x 
Carcinoma (lung and mamma); [C] 6x Hospitalisation (Pneumonia, Blood transfusion, Syncope, 
Cholecystectomie, Inguinal Hernia Surgery and active RA), 1x Myocardial infarction, 2x Colon carcinoma and 1x 
Maculopathy.  
2Bone marrow depression is defined as an anemia, thrombocytopenia or leucopenia with respectively a 
hemoglobin level, platelet count and white blood cells count below the lower limit of the normal range. High 
creatinine, raised liver enzymes and hyperglycemia are defined as having respectively a creatinine, liver 
transaminases and glucose level above the upper limit of the normal range. 
*p=0.039 for B vs C   
†p=0.028 for B vs C 
Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; IQR, interquartile range; MTX, 
methotrexate; SASP, sulfasalazine; sc, subcutaneous. 
 Aletaha et al30 already demonstrated that the initial clinical response is related to 
disease activity in the long-term, and indirectly the amount of joint destruction and 
treatment changes needed to achieve the predefined treatment goals, which 
corresponds with our results. The TEAR trial showed that the predefined treatment goal 
is 1.5x more often reached with iTDT compared with iMM  (respectively 42% versus 
28%), which matched our results.11 Moreover, the difference in mean DAS between iTDT 
and iMM nullified after 36 weeks (favouring iTDT).11 However, in our trial (and TEAR trial) 
no difference in joint destruction was seen, which was probably due to early initiation of 
intensive therapy, causing less joint destruction and thus less radiological progression. 
In our trial switching to biologicals was already possible after three months, if the 
target was not reached. In the iMM group one could argue if triple DMARD therapy 
instead of biologicals should be the first step-up, especially since striking evidence of 
superior clinical efficacy of step-up therapy to biological over triple DMARD therapy is 
lacking.11, 31-32 There again, current guidelines recommend switching to biologicals, after 
3 months, in patients with active disease and poor prognostic factors (i.e. auto-antibody 
positivity and erosive disease).2-3 In our trial 29/36 (81%) of iMM failures, after three 
months, had ≥2 aforementioned factors. Therefore, we think intensification to 
biologicals after failing on iMM was a valid choice.  
For health economic reasons efficient use of biologicals is needed to be able to 
continue optimal rheumatic care in the future.33 With iTDT treatment goals are attained 
faster and maintained with 40% fewer biologicals, which cuts down expenses 
enormously, also, because treatment can be tapered more often. Besides lowering 
medication costs, better disease control improves worker productivity and, therefore, 
reduces the costs due to loss of productivity.34-35 However, the cost-utility analysis of the 
tREACH trial still has to re-confirm aforementioned statement. 
Patients and/or rheumatologist, however, may have some aversion for iTDT, 
mainly because of the large amount of drugs that have to be taken. Medication 
adherence in RA is strongly influenced by patient’s belief about the needfulness of the 
drugs.36 These beliefs are moulded by rheumatologists through the information given 
about the disease and treatment approach.36 A tailor-made treatment approach would 
be ideally in this very early phase, especially since 60% respond well to iMM. 
Determination of early GC response after treatment initiation is a promising predictor, 
possibly leading to a more tailor-made treatment approach.37 Therefore, we think that 
the emphasis of future treatment trials should be more on efficiency rather than 
efficacy. 
In 42% of patients treatment could be tapered, of those 12% flared. Therefore, 
we think tapering DMARDs and/or biologicals in case of sustained remission is justified. 
However, patients should still be monitored strictly during tapering. Data on tapering 
medication are sparse, especially in early RA.3, 38 Future research is needed to determine 
(1) when to commence tapering, (2) how to taper and (3) what the optimal interval is 
between taperings. 
 We find that intramuscular and oral GCs are equally effective as bridging therapy, 
but one single injection might be more feasible. However, duration and dosage of our 
GC tapering scheme was short (10 weeks) and low (initial dosage 15mg) in comparison 
with, for example, the COBRA regimen (respectively 28 weeks and  60mg).10 Because 
GCs have disease-modifying traits with long-lasting benefits even after withdrawal, a 
different GC oral tapering scheme might be superior.14 Therefore, future research is 
needed for optimizing GC bridging therapies.  
Our study had certain limitations. Foremost, baseline imbalances occurred, 
despite randomisation, which were in favour of iMM; after adjustment even AUC HAQ 
differed significantly (favouring iTDT). Additionally, only research nurses, who assessed 
the DAS, were blinded for allocated treatment arm. This design was chosen, since we 
wanted to mimic daily practice as well as possible. Single blinding, however, could be a 
potential source of bias, in our case possibly favouring iMM, because of the aversion for 
iTDT by  rheumatologists and/or patients. Moreover, due to various reasons 101 (36%) 
patients were excluded from our per-protocol analysis, which was more than expected. 
Our exclusion percentage, however, was comparable with other trials.10-11, 31  
In conclusion, we recommend iTDT over iMM as first choice in newly diagnosed 
RA patients, because treatment goals are attained faster and maintained with 40% 
fewer biologicals. No differences were seen in dosage adjustments due to AEs, after 
stratification for drug. One single intramuscular GC injection as well as an oral GC 
tapering scheme would suffice as bridging therapy. 
 
 
 
 Appendix 1: Exclusion criteria for the tREACH trial 
 
The tREACH exclusion criteria are:  
1. Diagnosed with 
a. a crystal arthropathy, 
b. a (post-)infectious arthritis, or 
c. an autoimmune disorder other than RA 
2. Previous DMARD therapy or glucocorticoid usage 
3. Contra-indications for initial study medication, namely: 
a. chronic liver disease 
b. excessive alcohol and drug use 
c. pregnancy (wish) 
d. leucopenia <3.0 × 109/l 
e. thrombocytopenia <150 × 109/l 
f. aspartate aminotransferase/ alanine aminotransferase more than two 
times the upper normal value  
g. creatinine level >150 μmol/l.  
 
 
Appendix 2: EULAR response criteria  
        Improvement in DAS from baseline 
DAS at endpoint >1.2 >0.6 and ≤1.2 ≤0.6 
≤2.4 Good   
>2.4 and ≤3.7  Moderate  
>3.7   None 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix  3: Cumulative probability plot for radiological progression 
stratified for induction therapy. 
Each point on the plot represents the radiographical progression in an individual patient (score after 1 
year minus score at baseline). Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, 
intramuscular; MTX, methotrexate; SASP, sulfasalazine; SHS, modified Sharp/Van der Heijde score. 
 Appendix 4: Subgroup analyses for patients with RA according to 2010 
ACR/EULAR criteria 
 
Table 1: Number of participants, with RA according to 2010 ACR/EULAR criteria,  at 
each time-point, stratified for induction therapy. 
 T0 T3 T6 T9 T12 
A. MTX + SASP + HCQ + im GCs 87 82 78 77 74 
B. MTX + SASP + HCQ + oral GCs 88 84 81 81 80 
C. MTX + oral GCs 95 88 86 84 85 
 
 
Table 2: Baseline characteristics of patients with RA according to 2010 ACR/EULAR 
criteria, stratified for induction therapy. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
   + im GCs (n=87) + oral GCs (n=88) (n=95) 
Demographic    
Age (yrs), mean (sd) 53 (15) 54 (14) 54 (14) 
Sex, female, no(%) 52 (60) 63 (72) 67 (71) 
    
Disease characteristics    
Symptom duration (days), mean (sd)* 160 (95) 183 (93) 151 (81) 
RF pos., no(%) 68 (78) 64 (72) 65 (68) 
ACPA pos., no(%) 72 (83) 66 (75) 75 (79) 
    
Disease activity    
DAS, mean (sd) 3.34 (0.78) 3.44 (1.08) 3.40 (0.98) 
DAS28, mean (sd) 4.86 (1.09) 4.88 (1.29) 4.79 (1.28) 
TJC44, median (IQR) 8 (4 - 14) 9.5 (5 – 16) 10 (4 – 14) 
SJC44, median (IQR) 8 (5 - 12) 8 (4 – 12) 7 (4 – 12) 
VAS global (0 -100mm), median (IQR) 53 (37 - 70) 55 (29 – 69) 53 (37 – 70) 
ESR in mm/hr, median (IQR) 27 (14 – 40) 22 (13 – 39.5) 24 (14 – 43) 
CRP in mg/L, median (IQR) 8.5 (4 -23) 6.4 (3.75 - 19) 11 (5 – 26) 
    
Radiographs (hand/foot)    
Total SHS (0 - 488 ), median (IQR) 0.5 (0 – 2) 0.5 (0 – 2) 1 (0 - 2.5) 
Erosion score (0 - 280), median (IQR) 0 (0 – 1) 0 (0 – 1) 0.5 (0 – 1) 
JSN score (0 - 168), median (IQR) 0 (0 – 1) 0 (0 – 1) 0 (0 - 1.5) 
Erosion, no(%)1 17/87 (20) 18/88 (20) 20/93 (22) 
    
Questionnaires2    
HAQ, mean (sd) 0.98 (0.69) (n=80) 0.99 (0.63) (n=82) 1.06 (0.68) (n=90) 
RADAI (0-10), mean (sd) 4.01 (1.85) (n=78) 4.02 (1.59) (n=78) 4.18 (1.83) (n=85) 
1Erosive disease is defined as having a erosion score >1.2 (=smallest detectable difference) 
2Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
*p=0.016 for B vs C. 
 
 
 Table 3: Clinical response after 12 months for each induction therapy group in the 
subgroup of patients with RA according to 2010 criteria, intention-to-treat 
analysis. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
 + im GCs (n=74) + oral GCs (n=80) (n=85) 
Disease activity    
DAS, mean (sd) 1.40 (0.69) 1.62 (0.88) 1.67 (0.88) 
ΔDAS (T12 - T0), mean (sd) -1.89 (-1.00) -1.77 (-1.16) -1.72 (-1.28) 
Disease state according to DAS, no(%)    
moderate to high disease activity (DAS≥2.4) 8 (11) 15 (19) 18 (21) 
low disease activity (1.6≥DAS<2.4) 20 (27) 23 (29) 24 (28) 
remission (DAS<1.6) 46 (62) 42 (53) 43 (51) 
Boolean remission criteria, no(%)1 17 (23) 12(15) 14(17) 
EULAR response criteria (T12 - T0), no(%)2    
good 54 (73) 50 (63) 56 (66) 
Moderate 13 (18) 18 (23) 9 (11) 
none 7 (9) 12 (15) 20 (24) 
TJC44, median (IQR) 0 (0 - 2) 0 (0 - 4) 1 (0 - 4) 
SJC44, median (IQR)* 0 (0 - 2) 0 (0 - 1) 0 (0 - 2) 
VAS global (0 -100mm), median (IQR) 18 (8 - 32) 22.5 (9.5 - 37.5) 23 (10 - 40) 
ESR in mm/hr, median (IQR) 11 (5 - 18) 10.5 (6.5 - 20.5) 12 (6 - 21) 
CRP in mg/L, median (IQR) 3 (1 - 5.2) 4 (1 - 7) 3 (1.9 - 5) 
    
Radiographs (hand/foot)    
Total SHS (0 - 488 ), median (IQR) 1.25 (0 – 3) 1 (0 – 3) 1.5 (0 - 3.5) 
Erosion score (0 - 280), median (IQR) 0.5 (0 - 1.25) 0.5 (0 - 1.5) 0.5 (0 - 1.5) 
JSN score (0 - 168), median (IQR) 0.5 (0 - 1.5) 0 (0 - 1.5) 0.5 (0 – 2) 
ΔTotal SHS (T12 - T0), median (IQR) 0.38 (0 – 1) 0 (0 – 1) 0 (0 – 1) 
Patients with progression >0.5, no (%) 25/73 (34) 24/78 (31) 28/82 (34) 
Patients with progression >1.2, no (%) 16/73 (22) 20/78 (26) 19/82 (23) 
    
Questionnaires3    
HAQ, mean (sd) 0.38 (0.46) (n=66) 0.52 (0.56) (n=74) 0.63 (0.57) (n=82) 
ΔHAQ (T12 - T0), mean (sd) -0.47 (-0.64) (n=62) -0.43 (-0.59) (n=71) -0.47 (-0.53) (n=80) 
RADAI (0 - 10), mean (sd) 1.45 (1.24) (n=65) 1.83 (1.54) (n=71) 2.15 (1.82) (n=78) 
ΔRADAI (T12 - T0), mean (sd) -2.23 (-1.70) (n=61) -2.07 (-1.89) (n=66) -2.12 (-1.92) (n=73) 
1Boolean remission criteria are defined as having a TJC44≤1, SJC44≤1, VAS global≤10mm and CRP≤10 mg/L 
2EULAR response criteria are based on attained level and change in DAS 
3Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
*p=0.044 for B vs C. 
Abbreviations: CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; GCs, 
glucocorticoids; HAQ, Health Assessment Questionnaire; HCQ, hydroxychloroquine; im, intramuscular; IQR, 
interquartile range; JSN, joint space narrowing; MTX, methotrexate; RADAI, Rheumatoid Arthritis Disease Activity 
Index questionnaire; SASP,sulfasalazine; sd, standard deviation; SHS, modified Sharp/Van der Heijde score; SJC44, 
swollen joint count (44 joints); TJC44, tender joint count (44 joints); VAS, visual analogue scale. 
 Table 4: Medication usage after 12 months and treatment alteration over time for 
each induction therapy group in the subgroup of patients with RA according to 
2010 criteria. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ   C. MTX + oral GCs 
   + im GCs (n=87) + oral GCs (n=88) (n=95) 
Medication after 12 months    
MTX 69 (79) 68 (77) 80 (84) 
MTX dosage, median (IQR) 15 (7.5 - 25) 15 (7.5 - 25) 20 (7.5 - 25) 
SASP 25 (29) 25 (28) 2 (2) 
HCQ 49 (56) 54 (61) 8 (8) 
Biological use* 26 (30) 23 (26) 41 (43) 
Etanercept 18 (21) 12 (14) 22 (23) 
Adalimumab† 4 (5) 5 (6) 16 (17) 
Abatacept 3 (3) 5 (6) 3 (3) 
Other1 1 (1) 1 (1) 0 (0) 
Tapered treatment2    
Taperings‡ 84/229 (37) 65/242 (27) 59/255 (23) 
at 1 time-point 15 (18) 18 (20) 15 (16) 
at 2 time-points 12 (13) 10 (8) 10 (10) 
at 3 time-points 15 (16) 9 (11) 8 (8) 
Flare after tapering3 6/84 (7) 3/65 (5) 4/59 (7) 
Results shown are a number (%) unless stated otherwise. 
1Other biologicals are: Infliximab (A) and Rituximab (B) 
2Treatment could be tapered after 6 months. Therefore the total amount of possible taperings is the sum 
of all assessments at the last three visits, per treatment arm. 
3A flare is defined as a DAS≥2.4. The proportion is calculated by dividing the number of flares by the total 
amount of taperings 
*p=0.016  for B vs C. 
†p=0.018 for B vs C 
‡p=0.022 for A vs B 
Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; IQR, interquartile range; 
MTX, methotrexate; SASP, sulfasalazine. 
  
Figure 1: Medication usage over time, stratified for induction therapy in the 
subgroup of patients with RA according to 2010 criteria. 
Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate; 
SASP, sulfasalazine. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: (Self-assessed) disease activity, functional ability and radiographic joint 
damage over time, stratified for induction therapy in the subgroup of patients 
with RA according to 2010 criteria. 
Error bars indicate respectively 95% confidence intervals and interquartile range for given means and median. 
 
Results shown are mean(SD)  
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ   C. MTX + oral GCs 
   + im GCs  + oral GCs  
AUC    
DAS 22.4 (7.3) (n=87) 23.5 (8.4) (n=88)  25.6 (8.4) (n=95) 
HAQ 6.4 (5.0) (n=80) 7.0 (5.5) (n=82) 8.5 (5.9) (n=90) 
 Appendix 5: Subgroup analyses for patients with RA according to 1987 
ACR criteria  
 
Table 1: Number of participants, with RA according to 1987 ACR criteria,  at each 
time-point, stratified for induction therapy. 
 T0 T3 T6 T9 T12 
A. MTX + SASP + HCQ + im GCs 69 65 63 60 58 
B. MTX + SASP + HCQ + oral GCs 57 55 52 53 52 
C. MTX + oral GCs 63 59 57 55 56 
 
Table 2: Baseline characteristics of patients with RA according to 1987 ACR 
criteria, stratified for induction therapy. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
  + im GCs (n=69) + oral GCs (n=57) (n=63) 
Demographic    
Age (yrs), mean (sd) 54 (16) 55 (14) 55 (14) 
Sex, female, no(%) 41 (59) 39 (68) 43 (68) 
   
Disease characteristics    
Symptom duration (days), mean (sd) 160 (94) 174 (87) 146 (73) 
RF pos., no(%) 55 (80) 47 (82) 45 (71) 
ACPA pos., no(%) 56 (81) 40 (70) 49 (78) 
    
Disease activity    
DAS, mean (sd) 3.43 (0.76) 3.56 (1.06) 3.57 (0.99) 
DAS28, mean (sd) 5.04 (0.99) 5.13 (1.24) 5.03 (1.22) 
TJC44, median (IQR) 9 (6 - 14) 10 (5 – 15) 10 (5 – 15) 
SJC44, median (IQR) 9 (6 - 12) 11 (6 – 12) 9 (6 – 11) 
VAS global (0 -100mm), median (IQR) 55 (37 - 69) 58 (31 – 71) 55 (35 – 70) 
ESR in mm/hr, median (IQR) 28 (15 – 44) 24 (16 – 51) 25 (20 – 44) 
CRP in mg/L, median (IQR) 9 (4 -24) 8 (4 - 24) 13 (5.6 – 31) 
    
Radiographs (hand/foot)    
Total SHS (0 - 488 ), median (IQR) 1 (0 – 2.5) 1 (0 – 2.5) 1 (0 – 3) 
Erosion score (0 - 280), median (IQR) 0.5 (0 – 1) 0.5 (0 – 1.5) 0.5 (0 – 1) 
JSN score (0 - 168), median (IQR) 0 (0 - 1.5) 0 (0 - 1.5) 0.5 (0 - 1.5) 
Erosion, no(%)1 15/69 (22) 15/57 (26) 14/62 (23) 
    
Questionnaires2    
HAQ, mean (sd) 1.05 (0.67) (n=64) 0.99 (0.64) (n=53) 1.10 (0.68) (n=60) 
RADAI (0-10), mean (sd) 4.16 (1.86) (n=63) 4.13 (1.53) (n=51) 4.31 (1.98) (n=57) 
1Erosive disease is defined as having a erosion score >1.2 (=smallest detectable difference) 
2Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
Abbreviations:  ACPA, anti-citrullinated protein/peptide antibodies; CRP, C-reactive protein; DAS, Disease 
Activity Score; ESR, erythrocyte sedimentation rate; GCs, glucocorticoids; HAQ,Health Assessment 
Questionnaire; HCQ, hydroxychloroquine; im, intramuscular; IQR, interquartile range; JSN, joint space 
narrowing; MTX, methotrexate; RADAI, Rheumatoid Arthritis Disease Activity Index questionnaire; RF, 
rheumatoid factor; SASP,sulfasalazine; sd, standard deviation; SHS, modified Sharp/Van der Heijde score; 
SJC44, swollen joint count (44 joints); TJC44, tender joint count (44 joints); VAS, visual analogue scale. 
 
 Table 3: Clinical response after 12 months for each induction therapy group in the 
subgroup of patients with RA according to 1987 criteria, intention-to-treat 
analysis. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
  + im GCs (n=58) + oral GCs (n=52) (n=56) 
Disease activity    
DAS, mean (sd) 1.41 (0.68) 1.64 (0.93) 1.64 (0.94) 
ΔDAS (T12 - T0), mean (sd) -1.97 (-1.00) -1.93 (-1.22) -1.92 (-1.26) 
Disease state according to DAS, no(%)    
moderate to high disease activity (DAS≥2.4) 6 (10) 9 (17) 12 (21) 
low disease activity (1.6≥DAS<2.4) 17 (29) 15 (29) 16 (29) 
remission (DAS<1.6) 35 (60) 28 (54) 28 (50) 
Boolean remission criteria, no(%)1 16 (28) 10 (20) 12 (21) 
EULAR response criteria (T12 - T0), no(%)2    
Good 43 (74) 33 (63) 40 (71) 
Moderate 11 (19) 13 (25) 6 (11) 
None 4 (7) 6 (12) 10 (18) 
TJC44, median (IQR) 0 (0 - 2) 0 (0 - 4) 0 (0 - 4) 
SJC44, median (IQR) 0 (0 - 2) 0 (0 - 2) 0 (0 - 2) 
VAS global (0 -100mm), median (IQR) 14 (7 - 30) 24.5 (9 - 38) 23 (8.5 - 42.5) 
ESR in mm/hr, median (IQR) 12 (5 - 20) 13 (7 - 20.5) 14.5 (5 - 22) 
CRP in mg/L, median (IQR) 3.1 (1 - 6) 3.1 (1 - 7) 3 (1.85 - 5.5) 
    
Radiographs (hand/foot)    
Total SHS (0 - 488 ), median (IQR) 1.5 (0.5 - 3.75) 1.5 (0.5 - 5.5) 2 (0 - 4) 
Erosion score (0 - 280), median (IQR) 0.5 (0 - 1.5) 1 (0 - 3) 0.5 (0 - 2) 
JSN score (0 - 168), median (IQR) 0.5 (0 - 1.75) 0 (0 - 1.5) 0.63 (0 - 2.25) 
ΔTotal SHS (T12 - T0), median (IQR) 0.38 (0 – 1) 0.5 (0 – 2) 0 (0 – 1.5) 
Patients with progression >0.5, no (%) 20/57 (35) 20/51 (39) 21/54 (39) 
Patients with progression >1.2, no (%) 14/57 (25) 18/51 (35) 16/54 (30) 
    
Questionnaires3    
HAQ, mean (sd) 0.39 (0.49) (n=53) 0.56 (0.59) (n=49) 0.61 (0.61) (n=55) 
ΔHAQ (T12 - T0), mean (sd) -0.55 (-0.63) (n=50) -0.44 (-0.65) (n=47) -0.51 (-0.49) (n=54) 
RADAI (0 - 10), mean (sd) 1.40 (1.20) (n=52) 1.89 (1.61) (n=48) 2.14 (1.96) (n=51) 
ΔRADAI (T12 - T0), mean (sd) -2.36 (-1.62) (n=49) -2.12 (-2.01) (n=44) -2.24 (-1.91) (n=49) 
1Boolean remission criteria are defined as having a TJC44≤1, SJC44≤1, VAS global≤10mm and CRP≤10 mg/L 
2EULAR response criteria are based on attained level and change in DAS 
3Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
Abbreviations: CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; GCs, 
glucocorticoids; HAQ,Health Assessment Questionnaire; HCQ, hydroxychloroquine; im, intramuscular; IQR, 
interquartile range; JSN, joint space narrowing; MTX, methotrexate; RADAI, Rheumatoid Arthritis Disease 
Activity Index questionnaire; SASP,sulfasalazine; sd, standard deviation; SHS, modified Sharp/Van der Heijde 
score; SJC44, swollen joint count (44 joints); TJC44, tender joint count (44 joints); VAS, visual analogue scale. 
 
  
Table 4: Medication usage after 12 months and treatment alteration over time for 
each induction therapy group in the subgroup of patients with RA according to 
1987 criteria 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
  + im GCs (n=69) + oral GCs (n=57) (n=63) 
Medication after 12 months    
MTX 56 (81) 48 (84) 53 (84) 
MTX dosage, median (IQR) 15 (7.5 - 25) 20 (7.5 - 25) 20 (10 - 25) 
SASP 22 (32) 17 (30) 2 (3) 
HCQ 41 (59) 37 (65) 5 (8) 
Biological use* 20 (29) 13 (23) 25 (40) 
Etanercept 14 (20) 8 (14) 13 (21) 
Adalimumab† 3 (4) 2 (4) 10 (16) 
Abatacept 2 (3) 3 (6) 2 (3) 
Other1 1 (1) 0 (0) 0 (0) 
Tapered treatment2    
Taperings 64/181 (35) 49/157 (31) 46/168 (27) 
at 1 time-point 10 (18) 11 (20) 14 (16) 
at 2 time-points 9 (13) 7 (8) 7 (10) 
at 3 time-points 12 (16) 8 (11) 6 (8) 
Flare after tapering3 2/64 (3) 3/49 (6) 4/46 (9) 
Results shown are a number(%) unless stated otherwise. 
1Other biologicals are: Infliximab (A) and Rituximab (B) 
2Treatment could be tapered after 6 months. Therefore the total amount of possible taperings is the sum 
of all assessments at the last three visits, per treatment arm. 
3A flare is defined as a DAS≥2.4. The proportion is calculated by dividing the number of flares by the total 
amount of taperings 
*p=0.047  for B vs C. 
†p=0.024 for B vs C 
Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; IQR, interquartile range; 
MTX, methotrexate; SASP, sulfasalazine. 
  
Figure 1: Medication usage over time, stratified for induction therapy in the 
subgroup of patients with RA according to 1987 criteria. 
Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate; 
SASP, sulfasalazine. 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: (Self-assessed) disease activity, functional ability and radiographic joint 
damage over time, stratified for induction therapy in the subgroup of patients 
with RA according to 1987 criteria. 
Error bars indicate respectively 95% confidence intervals and interquartile range for given means and median.  
 
Results shown are mean(SD). 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ   C. MTX + oral GCs 
   + im GCs  + oral GCs  
AUC    
DAS 22.3 (6.3) (n=69) 23.3 (8.3) (n=57)  25.3 (8.8) (n=63) 
HAQ 6.8 (5.2) (n=64) 6.8 (5.3) (n=53) 8.4 (6.4) (n=60) 
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Best cost-effectiveness and worker productivity with 
initial triple DMARD therapy compared with MTX 
monotherapy in early rheumatoid arthritis;  
Cost-utility analysis of the tREACH trial. 
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van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB,  
Grillet BA, Rutten-van Mölken MP, Weel AE 
 
 
 
 
 Objective:  
To evaluate direct and indirect costs per Quality Adjusted Life Year (QALY) for different 
initial treatment strategies in very early rheumatoid arthritis.  
 
Methods:  
The 1-year data of the tREACH trial were used. Patients with a high probability (>70%) 
according to their likelihood of progressing to persistent arthritis, based on the 
prediction model of Visser, were randomized into one of following initial treatment 
strategies: (A) initial triple DMARD therapy (iTDT) with glucocorticoids (GCs) 
intramuscular (n=91), (B) iTDT with an oral GC tapering scheme (n=93), and (C) initial 
methotrexate monotherapy (iMM) with GCs similar to B (n=97). Data on QALYs, 
measured with Dutch EuroQol and Short Form 6D,  direct and indirect cost were used. 
Direct costs are costs of treatment and medical consumption, whereas indirect costs are 
costs due to loss of productivity. 
 
Results: 
Average QALYs for A, B and C were respectively 0.75, 0.75 and 0.73 for Dutch EuroQol; 
and 0.77, 0.76 and 0.75 for Short Form 6D. Highest total costs per QALY (standard 
deviation) were respectively €12748 (€18767), €10380 (€15608) and €17408 (€21828) for 
strategy A, B and C (p=0.012, B versus C). Direct as well as indirect costs were higher 
with iMM (strategy C) compared with iTDT (strategy B).  Higher direct costs were due to 
~40% more biological usage over time. Higher indirect costs on the other hand were 
caused by more long-term sickness and reduction in contract hours.  
 
Conclusion:  
iTDT had lower costs per QALY compared with iMM. Furthermore iTDT had better 
worker productivity.  
 
 
Key words   
• Cost-utility; Rheumatoid Arthritis; Early Arthritis; QALY; Worker productivity; 
Direct and Indirect costs  
 INTRODUCTION  
 
In last two decades major paradigm changes in the management of rheumatoid 
arthritis (RA) have occurred. These changes are: (1) early detection of the disease, hence 
development of 2010 criteria for RA 1, (2) early initiation of intensive therapy, and (3) a 
treat-to-target approach, leading to current EULAR recommendations.2 Complying with 
these recommendations result in better functional and radiological outcomes.3-4 
Although the management of RA has underwent major changes, some 
important debate points still exist. A prominent discussion is about specifying most 
appropriate initial treatment strategy, where the emphasis is on DMARD combination 
therapy versus monotherapy. 2, 5 Therefore, in the treatment in the Rotterdam Early 
Arthritis Cohort (tREACH) trial we compared the 1-year clinical efficacy of initial triple 
DMARD therapy (iTDT) versus initial methotrexate (MTX) monotherapy (iMM).6 We 
showed that treatment goals were attained faster and maintained with less expensive 
drugs with iTDT as opposed to iMM, without more serious adverse events.  Considering  
the decreased burden of the disease over time with iTDT, we were curious whether 
costs differed between initial treatment regimens, especially since 20-50% of the total 
costs are medication costs. 7  
Furthermore, to manage the exponentially increasing health care costs health 
insurance companies and governments will judge the compensation of  prescribed 
drugs by evidence based data on cost-effectiveness . Therefore, sufficient data on 
efficient use of expensive drugs, especially biologic agents, are needed to be able to 
continue optimal rheumatic care in the future. 8  
Previous cost analyses showed that a strategic approach with rapid treatment 
intensification to biological agents is cost-effective. 9-10 However, it is still unclear which 
initial treatment regimen has the best cost-effectiveness ratio. Furthermore, all previous 
cost-effectiveness analysis were performed in patients fulfilling 1987 classification 
criteria for RA.11 Until now no data on cost-effectiveness in patients fulfilling 2010 
criteria for RA are available.1 Trials in the early phase of RA, like our tREACH trial, are 
needed to evaluate if aforementioned approach is also cost-effective in very early RA. 
Therefore, our aim is to investigate (1) which initial treatment strategy has the 
lowest costs per Quality Adjusted Life Years (QALYs), with the emphasis on the 
comparison between iTDT and iMM and both glucocorticoid (GC) bridging therapies, 
and (2) whether the initial treatment regimens of the tREACH trial are cost-effective.  
 
 
PATIENTS AND METHODS 
 
Patients 
For this study data were used of the tREACH trial (ISRCTN26791028). tREACH, a 
multicenter, stratified single-blinded trial, is performed in eight rheumatology centres in 
the Netherlands. Medical ethics committees at each participating centre approved the 
study protocol, and all patients gave written informed consent before inclusion.  
 An extended description of the tREACH had already been published.6 Inclusion 
criteria for tREACH are: Age ≥18 years, arthritis in ≥1 joint, and symptom duration <1 
year.  Exclusion criteria are given in online supplement 1, table 1. 
Eligible patients were stratified into three groups according to their likelihood of 
progressing to persistent arthritis based of the Visser prediction model.12 The three 
strata (low, intermediate, and high) correspond with probability tertiles of developing 
persistent arthritis. For this analysis we included the high probability stratum.  
 
Design 
Patients were randomised, by an independent call centre,  into one of following initial 
treatment strategies: 
A. iTDT (MTX, sulfasalazine, and hydroxychloroquine) with GCs intramuscular  
B. iTDT with an oral GC tapering scheme 
C. iMM with oral GCs similar to B  
Concurrent therapy with NSAIDs, and intra-articular GCs injections (maximum of two 
per three months) was allowed during the study.  
DMARD dosages were: MTX 25 mg/week orally (dosage reached after three 
weeks), sulfasalazine 2 grams/day and hydroxychloroquine 400 mg/day, reduced to 
200mg/day after 3 months. GCs were either given intramuscular (methylprednisolone 
120mg or triamcinolone 80mg) or in an oral tapering scheme (weeks 1-4: 15 mg/day, 
weeks 5-6: 10 mg/day, weeks 7-8: 5 mg/day, and weeks 9-10: 2.5 mg/day). All patients 
received folic acid (10 mg/week) during MTX prescription. Osteoporosis prophylaxis 
(risedronate 35 mg/week and calcium/vitamin D combination 500/400 mg/IU/day) is 
given to patients in treatment arms B and C, during first 3 months.  
Trained research nurses, blinded for allocated treatment arm throughout the 
study, examined patients and calculated the disease activity score (DAS). 13 A treat-to-
target approach was used, aiming for a DAS<2.4.13 If DAS≥2.4 medication is intensified. 
Intensification steps were subsequent (1) MTX + etanercept (50mg/week, 
subcutaneous) (2)  MTX + adalimunab (40mg/ 2 weeks, subcutaneous), and (3) MTX + 
abatacept (500 – 1000 mg/ 4 weeks, intravenous, depending on weight). Treatment 
intensifications were the same for each treatment arm.  
If DAS<1.6 at two consecutive visits medication was tapered. Hierarchically 
ordered tapering steps are: (1) biological, (2) sulfasalazine, (3) MTX, and (4) 
hydroxychloroquine. Biological(s), MTX and sulfasalazine were gradually discontinued, 
whereas hydroxychloroquine was stopped immediately. A flare during tapering, defined 
as DAS≥2.4, results in restarting full therapy, according to the protocol. 
 
 Quality Adjusted Life Years (QALYs) 
QALYs express the influence of disease burden on patient’s health over time. Living in 
perfect health for 1 year corresponds with a QALY of 1, on the other hand a QALY of 0 
reflects death. 14 Patient’s health was described with following questionnaires: (1) the 
EuroQol (EQ-5D) and (2) Short Form 36. 15-16 From these questionnaires we respectively 
derived the Dutch EQ-5D and Short Form 6D (SF-6D). 17-19 The EQ-5D and SF-6D were 
assessed every 3 months and QALYs were calculated as the area under the curve (AUC). 
Costs per QALY are calculated, because since 2005 coverage of prescribed drugs by 
Dutch health insurance companies depend on this outcome. 20 In the Netherlands a 
treatment (approach) with an overall expenditure  ≤€ 20.000 per QALY is considered to 
be cost-effective.20 
Direct and indirect costs 
We analyzed direct and indirect costs during the first year of follow-up from a societal 
perspective.  Direct costs are the costs of treatment and medical consumption, whereas 
indirect costs are costs due to loss of productivity (i.e. sick leave and unemployment). 21 
Costs of (study) medication were calculated from the dose reported in the 
patients’ case records, valued according to the college of health insurances (see online 
supplement 2, table 1). 22 Reported medication costs also included costs for start-up 
dosages, used supplements and if necessary day-care admissions. Medication costs 
were calculated using following assumptions: (1) compliance was 100%, (2) treatment 
changes commenced immediately and (3) if patients were lost to follow-up (study) 
medication was stopped. 
Medical consumption was recorded every 6 months by questionnaires. Duration 
of hospitalisations and admission diagnosis were recorded every 3 months. We used the 
Dutch average length of stay by diagnosis if the duration of hospitalisation was 
unknown. Medical consumption, including hospital admissions, was valued at Dutch 
standard prices, except for costs of complementary and alternative medicine, which 
were based upon American data (see online supplement 2, table 2). 23-24 
Indirect costs included sick leave and reduction in work time. Patients filled out 
questionnaires, every 3 months, about loss of productivity. Complementary to this, half-
yearly questionnaires regarding work time and unemployment were filled out. The 
friction cost method was used to calculate the indirect costs. 25 The basic assumption of 
this method is that every employee is replaceable in time. The friction cost period is the 
time between occurrence of a job vacancy, due to long-term sick leave, and filling it. 
Costs due to loss of productivity are solely counted during this period, which 
encompasses 23 weeks (160 days) in the Netherlands. 23 Productivity costs were valued 
at age- and sex-dependent standard hourly costs, ranging from €9 to €39 per hour (see 
online supplement 2, table 3). 23  Indirect costs were calculated using following 
assumption: work time at baseline and after 6 months were respectively used for the 
calculation of the friction costs during the first and second half year. 
 
 Statistical Analysis 
Outcomes were calculated in an intention-to-treat analysis, using all available data. 
Statistical comparison of the baseline characteristics and outcomes (after 12 months) 
between iTDT and iMM (arm B versus C) and both GC bridging therapies (arm A versus 
B)  were made by student t test, χ2 test,  or Wilcoxon rank-sum test, when appropriate. 
Besides a drop-out ratio of 12%, respectively 9%, 4% and 4% of the patients 
incompletely or didn’t filled out the QALY, medical consumption and/or loss of 
productivity questionnaires. These missing data were equally distributed between 
treatment arms. Because total missing data exceeded 5% we used multiple imputations 
by chained equations, with 40 imputations, to deal with aforementioned missing data 
to overcome possible bias.26 An imputation regression model was constructed with EQ-
5D, SF-6D, medical consumption or loss of productivity as dependent variables and age, 
gender, treatment arm, and corresponding measures at all other time-points as the 
independent variables.  
In addition to the comparison of average costs per QALY between treatment 
arms, we also calculated the incremental cost-effectiveness ratios (ICERs) and its 
corresponding 95% confidence intervals with the Fieller method.27 An ICER is the ratio of 
the difference in costs to incremental benefits between treatment arms. 
All analyses were performed for patients in the high probability stratum and two 
subgroups consisting of patients with RA according to 1987 and 2010 criteria. 1, 11 All 
statistical analyses were carried out using STATA version 12.0. A p value <0.05 was 
considered statistically significant.   
 
 
RESULTS 
 
Patients 
In the high probability stratum 281 patients were randomly assigned to treatment arm 
A (n=91), B (n=93), or C (n=97). Of the 281 randomized tREACH patients 33 (12%) 
dropped-out within the first year of follow-up (see online supplement 1, figure 1). 
Patients were mostly females (68%) with an average symptom duration of 166 days 
(156-177 days, 95% confidence interval) (table 1). RF and/or ACPA positivity was present 
in 239 (85%) patients; of those, 176 (74%) were both RF and ACPA positive. At baseline, 
48 (17%) patients had ≥1 erosion typical for RA. The employment-population ratio is 
163/221 (74%). 
 Table 1: Baseline characteristics of patients with a high probability to develop a 
persistent arthritis, stratified for induction therapy. 
 A. MTX + SASP + HCQ 
+ im GCs (n=91) 
B. MTX + SASP + HCQ 
+ oral GCs (n=93) 
C. MTX + oral GCs 
(n=97)   
Demographic    
Age (yrs), mean (sd) 53 (15) 54 (14) 54 (14) 
Sex, female, no(%) 55 (60) 67 (72) 68 (72) 
Paid work, no(%) 53 (78) 53 (71) 57 (73) 
Working hours per week, median(IQR)* 36 (21 – 40) 24 (16 – 40) 32 (24 – 40) 
Retired, no(%) 23 (25) 18 (19) 19 (20) 
    
Disease characteristics    
Symptom duration (days), mean (sd)† 162 (97) 184 (92) 154 (83) 
RF pos., no(%) 55 (60) 51 (55) 51 (53) 
ACPA pos., no(%) 59 (65) 50 (54) 56 (58) 
Fullfillment RA criteria, no(%)    
1987‡ 69 (76) 57 (61) 63 (65) 
2010 83 (91) 80 (86) 83 (86) 
DAS, mean (sd) 3.28 (1.06) 3.40 (1.07) 3.38 (0.97) 
SJC44, median (IQR) 8 (5 -12) 7 (4 - 12) 7 (4 - 12) 
Erosion, no(%)§ 24 (26) 12 (13) 12 (12) 
    
Questionnaires¹    
EQ-5D, mean (sd) 0.60 (0.25) (n=86) 0.65 (0.22) (n=84) 0.61 (0.28) (n=88) 
SF-6D, mean (sd) 0.69 (0.13) (n=84) 0.69 (0.14) (n=88) 0.68 (0.15) (n=92) 
HAQ, mean (sd) 0.98 (0.67) (n=84) 0.96 (0.64) (n=84) 1.06 (0.68) (n=92) 
1Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
*p=0.027 for A vs. B  ‡p=0.034 for A vs B. 
†p=0.018 for B vs C.  §p=0.021 for A vs B. 
Abbreviations:  ACPA, anti-citrullinated protein/peptide antibodies; DAS, Disease Activity Score; EQ-5D, Dutch 
EuroQol; GCs, glucocorticoids; HAQ,Health Assessment Questionnaire; HCQ, hydroxychloroquine; im, 
intramuscular; IQR, interquartile range; MTX, methotrexate; RF, rheumatoid factor; SASP,sulfasalazine; sd, 
standard deviation; SF-6D, Short Form 6 Dimensions; SJC44, swollen joint count (44 joints). 
 
Clinical outcomes and QALYs 
Figure 1 shows the disease activity, functional ability and QALYs over time. Utilities, 
measured with EQ-5D and SF-6D did not differ at baseline (table 1) and over time  
(figure 1) between treatment arms. Both utility measures showed a similar pattern with 
the strongest improvement during the first 6 months. Average QALYs, measured with 
AUC, for treatment arm A, B and C were respectively 0.75, 0.75 and 0.73 for EQ-5D; and 
0.77, 0.76 and 0.75 for SF-6D. 
 
  
Figure 1: Disease activity, functional ability and QALYs over time.  
Error bars indicate 95% confidence intervals. Abbreviations: DAS, Disease Activity Score; EQ-5D, Dutch EuroQol; GCs, glucocorticoids; HAQ,Health Assessment 
Questionnaire; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate; QALYs, Quality Adjusted Life Years; SASP,sulfasalazine; SF-6D, Short Form 6 Dimensions 
 Direct and indirect costs 
Average direct costs (standard deviation) were respectively €3246 (4377), €3396 (4414) 
and €4919 (4996) for treatment arm A, B and C (p=0.027 for B versus C). Respectively 
75% and 25% of the average direct costs are medication and health care utilization 
costs. The difference in average direct costs between iTDT (arm B) and iMM (arm C) was 
due to difference in the usage of expensive drugs, because no differences were found in 
medical consumption (table 2). After 3 months less treatment failure occurred in the 
iTDT group, resulting in the prescription of ~40% fewer biologicals. This difference 
remained over time (figure 2). Direct costs did not differ between both GC bridging 
therapies (arm A versus B). 
Average indirect costs (standard deviation) were respectively €8913 (10593), 
€6207 (8130) and €10523 (10774) for treatment arm A, B and C (p=0.020 for B versus C). 
The sustained worker productivity in the iTDT group (arm B) caused the difference in 
indirect costs compared with the iMM group (arm C). After 12 months a small decrease 
in unemployment was seen in both iTDT groups compared to an increase in 
unemployment in the iMM group (table 3). Furthermore, less long term sickness, 
defined as sick leave >160 days, was seen with iTDT (table 3). Indirect costs did not differ 
between both GC bridging therapies (arm A versus B). 
Total costs per QALY are given in table 4. Patients with iTDT (arm B) have lower 
costs per QALY compared with iMM (arm C). Total costs did not differ between both GC 
bridging therapies (arm A versus B). Medication, health care utilization and loss of 
productivity respectively determined 28-38%, 9-12% and 50-62% of the total costs.  
 
 
Figure 2: Biological usage over time, stratified for induction therapy. 
 Table 2: Health care utilization and costs after 1 year of follow-up 
 A. MTX + SASP + HCQ + im GCs (n=91) B. MTX + SASP + HCQ + oral GCs (n=93) C. MTX + oral GCs (n=97) 
 Utilization Quantity1 Costs2 Utilization Quantity1 Costs2 Utilization Quantity1 Costs2 
Medication          
• DMARDs 91 (100) - € 195 (122) 93 (100) - € 267 (234)* 97 (100) - € 108 (161) 
• Glucocorticoids 89 (98) - € 7 (3) 92 (99) - € 5 (2)§ 97 (100) - € 7 (6) 
• Biological  23 (25) - € 2201 (4168) 26 (28) - € 2221 (4110)† 41 (42)‡ - € 3609 (4660) 
• Analgesia  26 (29) - € 15 (29) 23 (25) - € 24 (63) 29 (30) - € 15 (27) 
• Other 91 (100) - € 4 (5) 92 (99) - € 16 (3)** 97 (100) - € 18 (8) 
          
Medical consumption          
Hospitalisation 4 (4) 4.5 (8) € 86 (516) 6 (6) 2.5 (8 ) € 122 (539) 8 (8) 4 (33) € 298 (1974) 
          
Standard health care          
• Primary care physician 34 (38) 3 (11) € 40 (70) 38 (41) 2.5 (12) € 41 (74) 38 (39) 3 (12) € 44 (77) 
• Specialist 91 (100) 7 (14) € 514 (266) 93 (100) 7 (13) € 536 (248) 97 (100) 8 (20) € 566 (271) 
• Nurse practitioner/physician assistant 62 (68) 3 (9) € 68 (66) 65 (70) 3 (28) € 73 (117) 66 (68) 3 ( 64) € 75 (199) 
• Paramedical care          
o Physical therapy  24 (26) 9 (35) € 110 (264) 20 (22) 8 (48) € 91 (262) 21 (22) 11 (90) € 161 (472) 
o Podology 3 (3) 3 (3) € 5 (30) 1 (1) 1 (1) € 1 (6) 1 (1) 4 (4) € 2 (23) 
o Occupational therapy 0 (0) - € 0 (0) 0 (0) - € 0 (0) 2 (2) 4.5 (5) € 2 (14) 
          
Complementary medicine          
• Alternative medical systems 1 (1) 2 (2) € 1 (7) 1 (1) 1 (1) € 0 (3) 2 (2) 4 (5) € 3 (18) 
Results shown are respectively number (%) for utilization, median (maximum) for quantity and mean (standard deviation) for costs. 
1Quantity reflects respectively the median(maximum) length of stay (in days) of the patients who are hospitalized and number of visits/sessions of the patients who utilize 
standard health care and/or complementary medicine. 
2Reporterd costs are the average costs for all patients in corresponding treatment arm 
*p=0,01 and p<0.0001 for respectively A vs. B and B vs. C.  §p=0.002 and p=0.009 for respectively A vs. B and B vs. C. 
†p=0.031 for B vs. C.      ‡p=0.039 for B vs. C.       
**p<0,0001 and p<0.002 for respectively A vs. B and B vs. C. 
Abbreviations:  GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate and SASP,sulfasalazine.  
 Table 3: Loss of productivity and costs, stratified for induction therapy. 
 A. MTX + SASP + HCQ 
+ im GCs (n=91) 
B. MTX + SASP + HCQ 
+ oral GCs (n=93) 
C. MTX + oral GCs 
(n=97)   
Employment after 12 months    
Paid work 54 (79) 57 (76) 51 (65) 
Unemployment* -1 (-2) -4 (-8) +6 (+11) 
Working hours per week, median(IQR) 32 (4 – 40) 24 (12 – 40) 25 (4 – 36) 
    Loss of productivity    
Sick leave    
• Occurrence 47 (89) 43 (81) 46 (81) 
• Long term sickness1† 10 (19) 5 (9) 17 (30) 
• Days absent, median(IQR) 3 (1 – 8) 5 (2 – 11) 4 (1 – 8) 
Contract hours    
• Reduction    
o Occurrence 17 (32) 20 (38) 22 (39) 
o Decrease, median(IQR)‡ 18 (4 – 37) 5 (1 – 11) 29 (10 – 36) 
• Increase    
o Occurrence 8 (15) 7 (13) 9 (16) 
o Increase, median(IQR) 8 (4 – 11) 10 (2 – 17) 10 (4 – 20) 
Total productivity loss in days, median(IQR) 17 (3 – 100) 14 (4 - 51) 28 (4 - 179) 
    Indirect costs, mean(sd)§ € 8913 (10593) € 6207 (8130) € 10523 (10774) 
Results shown are number (%) unless stated otherwise. 
1Long term sickness is defined as absence from work longer than 160 days (Dutch friction period) 
*p=0.015 for B vs. C. ‡p=0.0007 for B vs. C. †p=0.0076  for B vs. C. §p=0.020 for B vs. C. 
 
Table 4: QALYs and (specified) average cost per QALY after 1 year of follow-up 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ C. MTX + oral GCs 
  + im GCs (n=91) + oral GCs (n=93) (n=97) 
QALYs (AUC)    
EQ-5D  0.75 (0.12) 0.75 (0.10) 0.73 (0.13) 
SF-6D 0.77 (0.08) 0.76 (0.09) 0.75 (0.10) 
    Costs per QALY using EQ-5D    
Total direct costs* € 4855 (7245) € 5105 (7154) € 7991 (10350) 
● Medication € 3686 (6774) € 3876 (6496) € 6177 (9650) 
● Medical consumption € 1025 (693) € 1014 (625) € 1302 (1265) 
● Hospitalization € 144 (884) € 215 (1002) € 512 (3446) 
Total indirect costs‡ € 7893 (15371) € 5276 (11624) € 9416 (15140) 
Total costs§ € 12748 (18767) € 10380 (15608) € 17408 (21828) 
    Costs per QALY using SF-6D    
Total direct costs* € 4409 (6102) € 4809 (6465) € 6983 (7478) 
● Medication € 3309 (5748) € 3632 (5953) € 5373 (7018) 
● Medical consumption € 970 (625) € 997 (621) € 1208 (1090) 
● Hospitalization € 131 (792) € 180 (812) € 401 (2541) 
Total indirect costs‡ € 7250 (13230) € 4847 (9682) € 8807 (14022) 
Total costs§ € 11659 (15366) € 9656 (12695) € 15790 (17870) 
Results shown are mean(sd). 
EQ-5D:  *p=0.027 for B vs C. ‡p=0.036 for B vs C. §p=0.012 for B vs C. 
SF-6D:  *p=0.034 for B vs C. ‡p=0.025 for B vs C. §p=0.007 for B vs C. 
Abbreviations: AUC, area under the curve; EQ-5D, Dutch EuroQol; GCs, glucocorticoids; HCQ, 
hydroxychloroquine; im, intramuscular; MTX, methotrexate; QALYs, Quality Adjusted Life Years; 
SASP,sulfasalazine; sd, standard deviation; SF-6D, Short Form 6 Dimensions. 
 The ICERs (95% confidence interval) between  iTDT and iMM (arm B vs. C), using 
both EQ-5D and SF-6D, are respectively -€157232 (-€310061 to -€4404) and  -€587547   
(-€1740584 to €565491). Between both GC bridging therapies (arm A vs. B) the ICERs are 
-€188280 (-€771164 to €394604) and €152304 (-€235583 to €540190) making 
respectively use of the EQ-5D and SF-6D.  
All above-mentioned analyses, in the results section, were also performed in 
both subgroups, namely RA according to 1987 and 2010 criteria, which produced 
similar results (see online supplement 3 and 4). 
 
 
DISCUSSION 
 
In this study, we showed that iTDT had lower costs per QALY compared with iMM. Direct 
as well as indirect costs were lower in the iTDT group compared with the iMM group. 
The difference in direct costs was due to ~40% more biological usage over time in the 
iMM group. Less unemployment, long-term sickness and reduction in contract hours on 
the other hand caused the difference in indirect costs, favouring iTDT. Besides lower 
costs, patients with iTDT had better worker productivity. No differences in direct, 
indirect and total costs between both GC bridging therapies were seen. Noticeable is 
the fact that the total costs of all treatment arms are less than €20.000 per QALY, which 
is the limit for cost-effectiveness, according to Dutch policy makers. 
This study was designed to compare initial intensive treatment strategies in early 
RA. At the time of writing the protocol the 2010 criteria for RA still had to be developed. 
Therefore, we based our design on the Visser model, which predicts the likelihood of 
progressing to persistent arthritis.12 Interestingly, the Visser algorithm and 2010 criteria 
for RA have similar discriminative ability to identify patients at risk of persistent arthritis 
at 1 year.28 The tREACH trial is, therefore, one of the first studies conducted in RA 
patients fulfilling 2010 criteria. 
Because treatment is initiated in a very early phase of the disease the influence of 
disease burden on patient’s health over time, expressed by QALYs, is less in comparison 
with previous trials (0.75 vs. 0.69, first year QALYs, measured with EQ-5D, of respectively 
the tREACH trial, arm B and BeSt trial, group 3). 10, 29-30 An explanation for this difference 
might be that, first, due to diagnosing RA in an earlier phase patients have less severe 
disease characteristics without irreversible joint destruction. For example, our baseline 
DAS was lower compared with the BeSt trial (3.4 vs. 4.5) and less erosive disease was 
seen (respectively 15% vs. 70%). 6, 31 Second, the intensive treatment strategy 
contributed to aforementioned difference, which is reflected by the higher proportion 
of patients reaching the predefined treatment goal (i.e. low disease activity 82% in 
tREACH, arm B versus 65% in BeSt, group 3 after 1 year). Important differences in iTDT 
between tREACH and BeSt were MTX dosage (respectively 25 versus 7.5 mg/week), and 
addition of hydroxychloroquine. This underlines the importance of initiating intensive 
DMARD therapy in an earlier phase of RA.  
 Less burden of the disease not only led to higher QALYs over time, but also less 
health care utilisation and loss of productivity, leading to lower costs, in comparison 
with previous cost-effectiveness analyses. 10, 29-30 Within our trial the difference in disease 
burden between iTDT and iMM also led to difference in medication usage and worker 
productivity. Especially, the difference in worker productivity is remarkable. This 
difference was caused by a higher job retainment rate with iTDT, which reinforces the 
importance of choosing the right initial treatment strategy.  
Our study had certain limitations. Foremost, baseline imbalances occurred, 
despite randomisation, which were in favour of iMM, because of less severe disease 
characteristics. Thus, differences in cost per QALY between treatment arms may even be 
higher if the groups were more homogeneous.  
Furthermore, the time-frame in our cost-utility analysis was the 1st year of follow-up. 
During this 1st  year, however, not all patients had attained or maintained the predefined 
treatment goals. Additionally, medication is tapered in patients with sustained remission. 
Hence, medication usage and indirectly medical consumption were still fluctuating, which 
might influence the longterm results of economic evaluations. However, the longterm 
economic conclusions will, in our case, possibly favour iTDT, because of better 
maintenance of predefined treatment goals and more frequent tapering of medication.   
Also, a recall bias could not be ruled out, because patients with a more active 
disease might have recollect the amount of sick leave better. Since patients with iTDT 
have less disease burden compared with iMM, they possibly underreport the amount of 
sick leave, which might have led to an underestimation of the indirect costs. On the 
other hand, we did not include reduced productivity due to the act of attending work 
while sick (presenteeism) in our indirect cost analysis. Indirect costs would be higher if 
presenteeism was taken into account, whereby the raise in indirect cost would probably 
be less in patients with iTDT compared with iMM, because of less burden of the disease.  
At last, generalizability of these data could be cumbersome, because of 
differences in legislation and regulations between countries. In the Netherlands 
discharging employees is relatively difficult due to legislation. Therefore, the Dutch 
labor market is characterized by low job mobility and high average duration of 
unemployment for older jobseekers.32 On the other hand working part-time is more 
common in the Netherlands in comparison with other countries. 33 This reduces the 
workload allowing people to retain their work productivity longer. Likewise, 
accessibility, affordability, efficiency and quality of health care differs between 
countries. 34 Despite aforementioned differences between countries, the fact that iTDT 
had lower cost per QALY than iMM is generalizable. 
In conclusion, iTDT had lower costs per QALY compared with iMM. Costs did not 
differ between both GC bridging therapies. Interestingly, all initial treatment regimens 
of the tREACH trial are cost-effective, according to the definition of Dutch policy makers. 
Besides lower costs, patients treated with iTDT also had better worker productivity 
compared with iMM. In line with the clinical effectiveness, aforementioned results 
underline again why iTDT instead of iMM, is preferred as first choice in very early RA. 
 Supplement 1: Study design and flow tREACH 
 
Table 1: Exclusion criteria tREACH trial 
Exclusion criteria are: 
1. Following diagnoses:  
• a crystal arthropathy 
• (post-)infectious arthritis 
• autoimmune disorder other than RA; 
2. Receiving DMARD therapy or glucocorticoids prior to randomisation 
3. Presence of contra-indications for  initial study medication, namely:  
• chronic liver disease 
• excessive alcohol and drug use 
• pregnancy (wish) 
• leucopenia < 3.0 × 109/l 
• thrombocytopenia < 150 × 109/l 
• aspartate aminotransferase/ alanine aminotransferase more than two 
times the upper normal value  
• creatinine level > 150 μmol/l.  
 
  
Figure 1: Trial profile.  
Other reasons for dropping out were incorrect randomisation and problems with communication. 
Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate; 
SASP, sulfasalazine.
 Supplement 2: Reference prices for cost-utility analyses tREACH 
 
Table 1: Medication costs in the Netherlands.   
Generic name Calculation base Costs 
DMARDs   
Methotrexate    
• Oral 2.5mg tablet € 0.13 
• Subcutaneous   
o 2.5 tot 10mg per piece € 16.30 
o 12.5 tot 20 mg per piece € 17.78 
o 22.5 tot 25mg per piece € 20.74 
Sulphasalazine (oral) 500mg tablet € 0.07 
Hydroxychloroquine (oral) 200mg tablet € 0.13 
Leflunomide (oral)   
• 20mg tablet per piece € 1.32 
• 10mg tablet per piece € 1.16 
   
Glucocorticoids   
Prednisone (oral)    
• Oral 5mg tablet € 0.05 
• Total tapering scheme  € 4.94 
Triamcinolone (i.m.) 80mg € 10.88** 
Methylprednisolone (i.m.) 120mg € 6.12** 
   
Biologicals   
Etanercept (s.c.)   
• 25mg per piece € 138.03 
• 50mg per piece € 283.26 
Adalimunab (40mg s.c.) per piece € 571.91 
Infliximab (i.v.) 100mg flask € 646.77 
Abatacept (i.v.) 250mg flask € 382.44 
Rituximab (i.v.) 500mg flask € 1536.15 
   
Analgesia   
Paracetamol 500mg tablet € 0.02 
NSAIDs (average) per month € 7.99 
COX-2 inhibitor (average) per month € 27.08 
   
Other   
Folic acid (oral) 5mg tablet € 0.03 
Risedronate (oral) 35mg tablet € 0.16 
Calcium carbonate/colecalciferol (oral) 500mg/400IE tablet € 0.12 
Proton-pump inhibitors (average) per month € 23.45 
* Total cost of prednisone’s gradual discontinuation scheme. 
** Costs for 1 intramuscular administration of methylprednisolone 
 Table 2: Reference prices for direct costs within the standard and complementary 
healthcare sector. 
 Reference price 
Standard healthcare  
Inpatient day  
• General hospital (day) € 435 
• University hospital (day) € 575 
Intensive care unit (day) € 2183 
Daycare treatment (day) € 251 
Outpatient visit  
• Specialist  
o General hospital  € 64 
o University hospital € 129 
• Nurse practitioner/physician assistent € 30 
Emergency room visit € 151 
Primary care physician  € 28 
Paramedical care  
• Physical therapy  € 36 
• Podology  € 56 
• Exercise therapy   € 35 
• Speech therapy  € 33 
• Occupational therapy (hour) € 22 
• Dietary advice (hour) € 27 
Mental healthcare  
• Social worker  € 65 
• Independent psychiatrist  € 103 
• Independent psychotherapist  € 77 
  
Complementary medicine  
Alternative medical systems € 31 
• Acupuncture   € 37 
• Homeopathic treatment € 25 
• Naturopathy € 49 
• Traditional healers € 15 
Manipulative and body-based therapies € 23 
• Chiropractic or osteopathic manipulation € 17 
• Massage € 36 
• Movement therapies € 4 
Energy-healing therapy € 22 
Results are shown as costs per session unless stated otherwise 
 
Table 3: Average productivity costs per hour, stratified for sex and age 
Age (years) Total Men Women 
15 to 19 € 9.27 € 9.65 € 8.76 
20 to 24 € 17.51 € 17.75 € 17.18 
25 to 29 € 23.93 € 24.19 € 23.62 
30 to 35 € 28.80 € 29.65 € 27.54 
35 to 40 € 32.25 € 34.03 € 29.25 
40 to 45 € 33.92 € 36.67 € 29.06 
45 to 50 € 34.87 € 38.32 € 28.91 
50 to 55 € 35.61 € 39.06 € 29.25 
55 to 60 € 36.37 € 39.38 € 29.50 
60 to 65 € 36.41 € 39.13 € 28.67 
Average € 30.02 € 32.49 € 25.94 
 Supplement 3: Subgroup analyses for patients with RA according to 
2010 ACR/EULAR criteria 
 
 
Table 1: Number of participants, with RA according to 2010 ACR/EULAR criteria,  at 
each time-point, stratified for induction therapy 
 T0 T3 T6 T9 T12 
A. MTX + SASP + HCQ + im GCs 87 82 78 77 74 
B. MTX + SASP + HCQ + oral GCs 88 84 81 81 80 
C. MTX + oral GCs 95 88 86 84 85 
 
 
 
Table 2: Baseline characteristics of patients with RA according to 2010 ACR/EULAR 
criteria, stratified for induction therapy. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ  C. MTX + oral GCs 
   + im GCs (n=87) + oral GCs (n=88) (n=95) 
Demographic    
Age (yrs), mean (sd) 53 (15) 54 (14) 54 (14) 
Sex, female, no(%) 52 (60) 63 (72) 67 (71) 
Paid work, no(%) 50 (77) 49 (70) 55 (72) 
Working hours / week, median(IQR)* 36 (20 – 40) 24 (13 – 40) 32 (20 – 40) 
Retired, no(%) 22 (25) 18 (20) 19 (20) 
    
Disease characteristics    
Symptom duration (days), mean (sd)† 160 (95) 183 (93) 151 (81) 
RF pos., no(%) 68 (78) 64 (72) 65 (68) 
ACPA pos., no(%) 72 (83) 66 (75) 75 (79) 
DAS, mean (sd) 3.34 (0.78) 3.44 (1.08) 3.40 (0.98) 
SJC44, median (IQR) 8 (5 - 12) 8 (4 – 12) 7 (4 – 12) 
Erosion, no(%) 24 (28) 12 (14) 12 (13) 
    
Questionnaires¹    
EQ-5D, mean (sd) 0.59 (0.26) (n=82) 0.64 (0.22) (n=81) 0.61 (0.28) (n=86) 
SF-6D, mean (sd) 0.69 (0.13) (n=80) 0.69 (0.14) (n=84) 0.68 (0.15) (n=90) 
HAQ, mean (sd) 0.98 (0.69) (n=80) 0.99 (0.63) (n=82) 1.06 (0.68) (n=90) 
1Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
*p=0.044 for A vs. B. 
†p=0.016 for B vs C. 
‡p=0.023 for A vs B . 
Abbreviations:  ACPA, anti-citrullinated protein/peptide antibodies; DAS, Disease Activity Score; EQ-5D, 
Dutch EuroQol; GCs, glucocorticoids; HAQ,Health Assessment Questionnaire; HCQ, hydroxychloroquine; 
im, intramuscular; IQR, interquartile range; MTX, methotrexate; RF, rheumatoid factor; SASP,sulfasalazine; 
sd, standard deviation; SF-6D, Short Form 6 Dimensions; SJC44, swollen joint count (44 joints)
 Table 3: Health care utilization and costs in patients with RA according to 2010 criteria, stratified for induction therapy. 
 A. MTX + SASP + HCQ + im GCs (n=87) B. MTX + SASP + HCQ + oral GCs (n=88) C. MTX + oral GCs  (n=95) 
 Utilization Quantity1 Costs2 Utilization Quantity1 Costs2 Utilization Quantity1 Costs2 
Medication          
• DMARDs 87 (100) - € 197 (124) 88 (100) - € 272 (240)* 95 (100) - € 109 (162) 
• Glucocorticoids 85 (98) - € 7 (3) 87 (99) - € 5 (2)† 95 (100) - € 7 (6) 
• Biological usage 23 (26) - € 2303 (4236) 25 (28) - € 2269 (4170) 40 (42)§ - € 3540 (4575) 
• Analgesia usage 24 (28) - € 16 (30) 22 (25) - € 25 (65) 28 (29) - € 15 (28) 
• Other 87 (100) - € 4 (5) 87 (99) - € 16 (3)‡ 95 (100) - € 18 (8) 
          
Medical consumption          
Hospitalisation 4 (5) 4.5 (8) € 90 (527) 5 (6) 1 (8) € 109 (525) 8 (8) 4 (33) € 304 (1994) 
          
Standard health care          
• Primary care physician 31 (36) 3 (11) € 37 (68) 36 (41) 2 (12) € 40 (74) 38 (40) 3 (12) € 45 (78) 
• Specialist 87 (100) 7 (14) € 508 (266) 88 (100) 7 (13) € 529 (248) 95 (100) 8 (20) € 569 (273) 
• Nurse practitioner/physician assistant 60 (69) 3 (9) € 69 (67) 61 (69) 3 (28) € 73 (120) 65 (68) 3 (64) € 87 (201) 
• Paramedical care          
o Physical therapy  22 (25) 9 (35) € 104 (261) 19 (22) 8 (48) € 96 (269) 20 (21) 14 (90) € 160 (476) 
o Podology 3 (3) 3 (3) € 6 (31) 1 (1) 1 (1) € 1 (6) 1 (1) 4 (4) € 2 (23) 
o Occupational therapy 0 (0) - € 0 (0) 0 (0) - € 0 (0) 2 (2) 4.5 (5) € 2 (14) 
          
Complementary medicine          
• Alternative medical systems 1 (1) 2 (2) € 1 (7) 1 (1) 1 (1) € 0 (3) 2 (2) 4 (5) € 3 (18) 
Results shown are respectively number (%) for utilization, median (maximum) for quantity and mean (standard deviation) for costs. 
1Quantity reflects respectively the median(maximum) length of stay (in days) of the patients who are hospitalized and number of visits/sessions of the patients who utilize 
standard health care and/or complementary medicine. 
2Reporterd costs are the average costs for all patients in corresponding treatment arm 
*p=0,01 and p<0.0001 for respectively A vs. B and B vs. C.  
†p=0.003 and p=0.011 for respectively A vs. B and B vs. C.    
‡p<0,0001; and p<0.002 for respectively A vs. B and B vs. C. 
Abbreviations:  GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate and SASP,sulfasalazine. 
 Table 4: Loss of productivity and costs in patients with RA according to 2010 
ACR/EULAR criteria, stratified for induction therapy. 
 A. MTX + SASP + HCQ 
 + im GCs (n=87) 
B. MTX + SASP + HCQ 
+ oral GCs (n=88) 
C. MTX + oral GCs 
(n=95)   
Employment after 12 months    
Paid work 51 (78) 53 (76) 49 (64) 
Unemployment* -1 (-2) -4 (-8) +6 (+11) 
Working hours per week, median(IQR) 30 (4 – 40) 24 (10 – 40) 25 (4 – 36) 
    Loss of productivity    
Sick leave    
• Occurrence 44 (88) 39 (80) 44 (80) 
• Long term sickness1† 9 (18) 5 (10) 17 (31) 
• Days absent, median(IQR) 3 (1 – 8) 4 (1 – 9) 4 (1 – 9) 
Contract hours    
• Reduction    
o Occurrence 17 (34) 20 (41) 22 (40) 
o Decrease, median(IQR)‡ 18 (4 – 37) 5 (1 – 11) 29 (10 – 36) 
• Increase    
o Occurrence 8 (16) 6 (12) 8 (15) 
o Increase, median(IQR) 8 (4 – 11) 7 (2 – 17) 11 (3 – 24) 
Total productivity loss in days, median(IQR) 21 (3 – 100) 14 (4 – 51) 32 (3 – 182) 
    Indirect costs, mean(sd)§ € 8724 (10183) € 6157 (8372) € 10787 (10869) 
Results shown are number (%) unless stated otherwise. 
1Long term sickness is defined as absence from work longer than 160 days (Dutch friction period) 
*p=0.009 for B vs. C. †p=0.010 for B vs C. ‡p=0.0007 for B vs. C.  §p=0.018 for B vs. C. 
 
Table 5: QALYs and (specified) average cost per QALY after 1 year of follow-up for 
patients with RA according to 2010 ACR/EULAR criteria. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ  C. MTX + oral GCs 
   + im GCs (n=87) + oral GCs (n=88) (n=95) 
QALYs (AUC)    
EQ-5D  0.75 (0.12) 0.75 (0.11) 0.73 (0.13) 
SF-6D 0.77 (0.08) 0.76 (0.09) 0.75 (0.10) 
    Costs per QALY using EQ-5D    
Total direct costs* € 5001 (7377) € 5176 (7236) € 7821 (10148) 
• Medication € 3844 (6887) € 3965 (6595) € 5992 (9420) 
• Medical consumption € 1006 (689) € 1014 (635) € 1306 (1276) 
• Hospitalization € 151 (904) € 197 (996) € 523 (3481) 
Total indirect costs† € 7573 (14757) € 5186 (11870) € 9475 (15274) 
Total costs‡ € 12574 (18420) € 10362 (15994) € 17296 (21835) 
    Costs per QALY using SF-6D    
Total direct costs € 4538 (6211) € 4892 (6559) € 6903 (7394) 
• Medication € 3450 (5841) € 3729 (6055) € 5278 (6914) 
• Medical consumption € 951 (622) € 997 (631) € 1216 (1099) 
• Hospitalization € 137 (810) € 166 (807) € 410 (2567) 
Total indirect costs* € 6987 (12704) € 4708 (9819) € 8896 (14148) 
Total costs† € 11526 (15019) € 9599 (12982) € 15799 (17952) 
Results shown are mean (standard deviation). 
EQ-5D   *p=0.045 for B vs. C. †p=0.036 for  B vs. C ‡p=0.016 for B vs. C.   
SF-6D  *p=0.022 for B vs. C. †p=0.009 for B vs. C. 
 
 Table 6: ICERs between treatment arms for patients with RA according to 2010 
ACR/EULAR criteria. 
 EQ-5D SF-6D 
ICERs between   
• iTDT and iMM (arm B and C) -€ 192077 (101689) -€ 851341 (1420466) 
• Both GC bridging therapies (arm A and B) -€ 243319 (442781) € 123778 (155164) 
Results shown are mean (sd). 
Abbreviations: EQ-5D, Dutch EuroQol; GCs, glucocorticoids; ICER, incremental cost-effectiveness ratio; 
iMM, initial Methotrexate monotherapy; iTDT, initial triple DMARD therapy; SF-6D, Short Form 6 
Dimensions. 
 
 
 
Figure 1: Biological usage over time in patients with RA according to 2010 
ACR/EULAR criteria, stratified for induction therapy. 
Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate;  
SASP, sulfasalazine. 
  
Figure 2: Disease activity, functional ability and QALYs over time for patients with RA according to 2010 ACR/EULAR criteria. 
Error bars indicate 95% confidence intervals. Abbreviations: DAS, Disease Activity Score; EQ-5D, Dutch EuroQol; GCs, glucocorticoids; HAQ,Health Assessment 
Questionnaire; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate; QALYs, Quality Adjusted Life Years; SASP,sulfasalazine; SF-6D, Short Form 6 Dimensions 
 Supplement 4: Subgroup analyses for patients with RA according to 
1987 ACR criteria 
 
 
Table 1: Number of participants, with RA according to 1987 ACR criteria,  at each 
time-point, stratified for induction therapy. 
 T0 T3 T6 T9 T12 
A. MTX + SASP + HCQ + im GCs 69 65 63 60 58 
B. MTX + SASP + HCQ + oral GCs 57 55 52 53 52 
C. MTX + oral GCs 63 59 57 55 56 
 
 
Table 2: Baseline characteristics of patients with RA according to 1987 ACR 
criteria, stratified for induction therapy. 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ  C. MTX + oral GCs 
   + im GCs (n=69) + oral GCs (n=57) (n=63) 
Demographic    
Age (yrs), mean (sd) 54 (16) 55 (14) 55 (14) 
Sex, female, no(%) 41 (59) 39 (68) 43 (68) 
Paid work, no(%) 35 (73) 26 (59) 34 (71) 
Working hours/week, median(IQR)* 36 (20 – 40) 24 (15.5 – 36) 32 (24 – 40) 
Retired, no(%) 21 (30) 13 (23) 15 (24) 
   
Disease characteristics    
Symptom duration (days), mean (sd) 160 (94) 174 (87) 146 (73) 
RF pos., no(%) 55 (80) 47 (82) 45 (71) 
ACPA pos., no(%) 56 (81) 40 (70) 49 (78) 
DAS, mean (sd) 3.43 (0.76) 3.56 (1.06) 3.57 (0.99) 
SJC44, median (IQR) 9 (6 - 12) 11 (6 – 12) 9 (6 – 11) 
Erosion, no(%) 23 (33) 11 (19) 9 (14) 
    
Questionnaires¹    
EQ-5D, mean (sd) 0.57 (0.26) (n=65) 0.63 (0.23) (n=54) 0.57 (0.29) (n=57) 
SF-6D, mean (sd) 0.68 (0.13) (n=64) 0.68 (0.15) (n=55) 0.68 (0.16) (n=60) 
HAQ, mean (sd) 1.05 (0.67) (n=64) 0.99 (0.64) (n=53) 1.10 (0.68) (n=60) 
1Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI. 
*p=0.034 for A vs. B 
Abbreviations:  ACPA, anti-citrullinated protein/peptide antibodies; DAS, Disease Activity Score; EQ-5D, 
Dutch EuroQol; GCs, glucocorticoids; HAQ,Health Assessment Questionnaire; HCQ, hydroxychloroquine; 
im, intramuscular; IQR, interquartile range; MTX, methotrexate; RF, rheumatoid factor; SASP,sulfasalazine; 
sd, standard deviation; SF-6D, Short Form 6 Dimensions; SJC44, swollen joint count (44 joints).
 Table 3: Health care utilization and costs in patients with RA according to 1987 ACR criteria, stratified for induction therapy. 
 A. MTX + SASP + HCQ + im GCs (n=69) B. MTX + SASP + HCQ + oral GCs (n=57) C. MTX + oral GCs (n=63) 
 Utilization Quantity1 Costs2 Utilization Quantity1 Costs2 Utilization Quantity1 Costs2 
Medication          
• DMARDs 69 (100) - € 184 (102) 57 (100) - € 273 (243)* 63 (100) - € 100 (144) 
• Glucocorticoids 68 (99) - € 7 (3) 56 (98) - € 6 (2)† 63 (100) - € 8 (7) 
• Biological usage 18 (26) - € 2231 (4149) 14 (25) - € 1986 (4053) 24 (38) - € 3552 (4864) 
• Analgesia usage 18 (26) - € 18 (33) 12 (21) - € 29 (73) 18 (29) - € 14 (27) 
• Other 69 (100) - € 4 (6) 56 (98) - € 15 (3)‡ 63 (100) - € 19 (9) 
          
Medical consumption          
Hospitalisation 4 (6) 4.5 (8) € 113 (591) 3 (5) 1 (1) € 62 (325) 7 (11) 3 (33) € 404 (2411) 
          
Standard health care          
• Primary care physician 26 (38) 3 (10) € 38 (66) 22 (39) 2 (12) € 39 (76) 25 (40) 3 (10) € 38 (67) 
• Specialist 69 (100) 7 (14) € 504 (243) 57 (100) 7 (12) € 509 (222) 63 (100) 8 (14) € 538 (257) 
• Nurse practitioner/physician assistant 51 (74) 4 (9) € 78 (69) 40 (70) 3 (28) € 73 (117) 42 (67) 3 (64) € 97 (243) 
• Paramedical care          
o Physical therapy  17 (25) 10 (28) € 96 (233) 10 (18) 6 (48) € 69 (259) 10 (16) 14 (60) € 111 (361) 
o Podology 3 (4) 3 (3) € 7 (35) 1 (2) 1 (1) € 1 (7) 1 (2) 4 (4) € 4 (28) 
o Occupational therapy 0 (0) - € 0 (0) 0 (0) - € 0 (0) 1 (2) 4 (4) € 1 (11) 
          
Complementary medicine          
• Alternative medical systems 0 (0) - € 0 (0) 1 (2) 1 (1) € 1 (4) 0 (0) - € 0 (0) 
Results shown are respectively number (%) for utilization, median (maximum) for quantity and mean (standard deviation) for costs. 
1Quantity reflects respectively the median(maximum) length of stay (in days) of the patients who are hospitalized and number of visits/sessions of the patients who utilize 
standard health care and/or complementary medicine. 
2Reporterd costs are the average costs for all patients in corresponding treatment arm 
*p=0,007 and p<0.0001 for respectively A vs. B and B vs. C. 
†p=0.016 and p=0.019 for respectively A vs. B and B vs. C.    
‡p<0,0001 and p<0.002 for respectively A vs. B and B vs. C. 
Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate and SASP,sulfasalazine.
 Table 4: Loss of productivity and costs in patients with RA according to 1987 ACR 
criteria, stratified for induction therapy. 
 A. MTX + SASP + HCQ 
 + im GCs (n=69) 
B. MTX + SASP + HCQ  
+ oral GCs (n=57) 
C. MTX + oral GCs 
(n=63)   
Employment after 12 months    
Paid work 35 (73) 31 (70) 30 (63) 
Unemployment* 0 (0) -5 (19) +4 (12) 
Working hours per week, median(IQR) 28 (4 – 40) 24 (10 – 38) 24 (3 – 32) 
    Loss of productivity    
Sick leave    
• Occurrence 33 (94) 22 (85) 27 (79) 
• Long term sickness1 8 (23) 3 (12) 11 (32) 
• Days absent, median(IQR) 3 (1 – 7) 4 (1 – 6) 3 (1 – 8) 
Contract hours    
• Reduction    
o Occurrence 13 (37) 11 (42) 17 (50) 
o Decrease, median(IQR)† 19 (4 – 37) 6 (0 – 12) 27 (4 – 36) 
• Increase    
o Occurrence 6 (17) 4 (15) 4 (12) 
o Increase, median(IQR) 8 (2 – 12) 7 (3 – 38) 17 (9 – 28) 
Total productivity loss in days, median(IQR) 26 ( 3 – 117) 10 (3 – 51) 34 (4 – 182) 
    Indirect costs, mean(sd)‡ € 10390 (11260) € 5201 (6478) € 10332 (9960) 
Results shown are number (%) unless stated otherwise. 
1Long term sickness is defined as absence from work longer than 160 days (Dutch friction period) 
*p=0.014 and p=0.035 for respectively A vs B and B vs C. †p=0.027 for B vs C. ‡p=0.026 for B vs C
     
 
Table 5: QALYs and (specified) average cost per QALY after 1 year of follow-up for 
patients with RA according to 1987 ACR criteria 
 A. MTX + SASP + HCQ B. MTX + SASP + HCQ  C. MTX + oral GCs 
   + im GCs (n=69) + oral GCs (n=57) (n=63) 
QALYs (AUC)    
EQ-5D  0.74 (0.12) 0.76 (0.11) 0.74 (0.13) 
SF-6D 0.77 (0.08) 0.76 (0.09) 0.76 (0.10) 
    Costs per QALY using EQ-5D    
Total direct costs* € 4949 (7437) € 4524 (6397) € 8202 (11618) 
• Medication € 3745 (6913) € 3432 (5798) € 6299 (10758) 
• Medical consumption € 1014 (669) € 940 (555) € 1192 (1129) 
• Hospitalization € 190 (1013) € 152 (929) € 711 (4230) 
Total indirect costs† € 8118 (16114) € 3582 (8113) € 8663 (14639) 
Total costs‡ € 13067 (20010) € 8106 (11404) € 16865 (23286) 
    Costs per QALY using SF-6D    
Total direct costs* € 4464 (6129) € 4351 (6184) € 6994 (8066) 
• Medication € 3334 (5748) € 3320 (5782) € 5367 (7518) 
• Medical consumption € 958 (594) € 933 (588) € 1085 (850) 
• Hospitalization € 173 (907) € 97 (532) € 542 (3096) 
Total indirect costs† € 7415 (13776) € 3261 (7023) € 7857 (12801) 
Total costs‡ € 11880 (16134) € 7612 (9717) € 14851 (17655) 
Results shown are mean (standard deviation). 
EQ-5D  *p=0.036 for  B vs. C. †p=0.022 for B vs. C. ‡p=0.011 for B vs. C.  
SF-6D  *p=0.048 for B vs. C. †p=0.018 for B vs. C. ‡p=0.007 for B vs. C. 
 Table 6: ICERs between treatment arms for patients with RA according to 1987 ACR 
criteria. 
 EQ-5D SF-6D 
ICERs between   
• iTDT and iMM (arm B and C) -€ 249749 (237858) € 2243771 (6410625) 
• Both GC bridging therapies (arm A and B) -€ 196360 (216701) € 709911 (1350450) 
Results shown are mean (sd). 
Abbreviations: EQ-5D, Dutch EuroQol; GCs, glucocorticoids; ICER, incremental cost-effectiveness ratio; 
iMM, initial Methotrexate monotherapy; iTDT, initial triple DMARD therapy; SF-6D, Short Form 6 
Dimensions. 
 
 
 
Figure 1: Biological usage over time in patients with RA according to 1987 ACR 
criteria, stratified for induction therapy. 
Abbreviations: GCs, glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate; 
SASP, sulfasalazine. 
 
  
Figure 2: Disease activity, functional ability and QALYs over time for patients with RA according to 1987 ACR criteria.  
Error bars indicate 95% confidence intervals.Abbreviations: DAS, Disease Activity Score; EQ-5D, Dutch EuroQol; GCs, glucocorticoids; HAQ,Health Assessment 
Questionnaire; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate; QALYs, Quality Adjusted Life Years; SASP,sulfasalazine; SF-6D, Short Form 6 Dimensions 
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 Objective 
To evaluate the therapeutic and economic consequences of various disease activity 
indices (DAIs) in rheumatoid arthritis (RA ) according to 1987 and 2010 criteria.  
 
Methods 
Data on disease activity states from all sustained visits were assessed from all patients 
who participated in the treatment in the Rotterdam Early Arthritis Cohort (tREACH) 
study, a stratified randomized trial to evaluate different treatment strategies in patients 
with a symptom duration of <1 year. Frequencies of treatment adaptations, based upon 
exclusive thresholds of various DAIs, were visualized in reclassification tables. The 
Stuart-Maxwell test was applied to analyze any significant differences between 
treatment decisions according to the different DAIs. Simulated annual median 
medication costs were estimated using the tREACH medication protocol with standard 
national costs.  
 
Results 
DAIs perform similar in RA according to 1987 and 2010 criteria. A total of 1104 disease 
activity scores per DAI were available from 296 patients. DAIs differ significantly, 
compared with the original disease activity score (DAS), in classifying a patient’s disease 
state. Consequently, treatment intensifications occur more frequently with simplified 
disease activity index (SDAI), clinical disease activity index (CDAI) and DAS28 usage, 
compared with DAS. Tapering treatment occurs less frequently with SDAI and CDAI and 
more frequently with DAS28. Simulated annual median medication costs are 
significantly higher with DAS28, SDAI and CDAI usage compared with DAS usage.  
 
Conclusion 
Usage of various DAIs in a single patient leads to inconsistent disease state 
categorizations. Consequently, these inconsistencies significantly influence therapeutic 
decisions and accompanying costs. As DAI usage is imperative to uphold current 
European League Against Rheumatology (EULAR) treatment recommendations, 
rheumatologists should consider these therapeutic and economic consequences before 
choosing a particular DAI.  
 
Key message 
• Usage of various DAIs in early RA leads to inconsistent disease state categorizations. 
• Inconsistencies between DAIs significantly influence therapeutic decisions and 
accompanying costs in early RA.  
• In early RA, therapeutic and economic consequences should also be considered 
for DAI selection. 
 
Key words   
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 INTRODUCTION 
 
In order to obtain better functional and radiological outcomes, in rheumatoid arthritis 
(RA), the recently published European League Against Rheumatology (EULAR) 
treatment guideline recommends treatment strategies that are targeted to achieve 
remission, or at least low disease activity.1-3 To achieve this goal within 3 months, and 
definitely within 6 months, patients should be monitored strictly (‘tight control’) with a 
disease activity index (DAI) and abide by intensifying medication.4 Consequently, 
intensifying treatment will be more expensive since most international guidelines 
recommend starting expensive biologicals after failing on two conventional DMARDs in 
an optimal dosage for 3 months.3, 5 Tight controlled intensive treatment also has an 
increased remission rate compared with routine care.6 Therefore, in the near future, DAI 
usage might expand to giving guidance in tapering treatment in case of sustained 
remission.2-3  
 There are various DAIs available: Disease Activity Score (DAS), DAS with 
substituting a constant for the patient’s global health (DAS (3var)), DAS with C-reactive 
protein (CRP) instead of erythrocyte sedimentation rate (ESR) (DAS-CRP), DAS with both 
previous mentioned modifications (DAS (CRP/3var)), same combinations for DAS with 
28 joints (DAS28), Simplified Disease Activity Index (SDAI) and Clinical Disease Activity 
Index (CDAI).7-10 A DAI is a pooled index that involves the incorporation of various 
parameters into a formula to obtain a numerical indicator of disease activity. The 
following core set parameters were identified: tender and swollen joint counts, acute-
phase reactants, general health, physician’s and patient’s global assessment of disease 
activity (EGA and PGA, respectively).11 All DAIs have their own thresholds for remission, 
low, moderate and high disease activity.10 There is no DAI recommended by the 
guideline developers, apart from that it should include a swollen and tender joint 
count.2-3 
 Previous studies showed good correlation (range 0.85-0.99) between various 
DAIs.12-15 A good correlation between DAIs implies that disease activity values have 
similar trends, but it gives no information on similarity of the state of the disease (i.e 
remission, low and moderate-to-high disease activity) of the various DAIs. Therefore, 
even with a good correlation of two DAIs, depending on the DAIs thresholds, patients 
could be classified into different disease activity states. Unfortunately, no data are 
presented on the discordance of disease state categorizations between DAIs. Since 
treatment adjustments are based on these thresholds, differences in disease state 
categorizations might have both therapeutic and economic consequences.  
 The current EULAR treatment guideline for RA2-3 is adopted for patients who 
fulfill the 2010 classification criteria for RA.16 The introduction of the 2010 classification 
criteria for RA leads to another challenge in the valid interpretation of DAIs. 
Interestingly, although all DAIs have been developed in cohorts comprising patients 
with RA according to the 1987 criteria17, DAIs already have been used in 
undifferentiated arthritis18-20, since validation is lacking in this early population.  
   
Therefore, our objectives were: (1) to estimate differences in treatment decisions 
based upon thresholds of various DAIs, using the original DAS as a reference standard; 
(2) to estimate annual median medication costs of various DAIs; and (3) to describe the 
characteristics of DAIs. All three objectives were accomplished in RA according to the 
2010 classification criteria and a subgroup, consisting of patients with RA according to 
the 1987 criteria. 
 
 
PATIENTS AND METHODS 
 
Patients 
For this study, data of a currently ongoing clinical trial (ISRCTN26791028), namely the 
treatment in the Rotterdam Early Arthritis Cohort (tREACH) were used.21 The tREACH 
study, a multicenter, stratified single-blinded trial to evaluate different treatment 
strategies in early RA, is performed in eight rheumatology centers in the southwestern 
part of The Netherlands. The study was approved by the Ethics Committee of the 
Erasmus Medical Center and CCMO (Dutch abbreviation for Central Committee on 
Research Involving Human Subjects). In all participating centres, the local ethics 
committee judged the protocol for local workability. The local ethics committees who 
judged the study protocol were the ethics committee of the Maasstad Hospital, Sint 
Franciscus Gasthuis, Vlietland Hospital, Albert Schweitzer Hospital, Admiraal de Ruyter 
Hospital and Zorgsaam Zeeuws-Vlaanderen. All patients gave written informed consent, 
according to the declaration of Helsinki, before inclusion.  
 Inclusion criteria for the tREACH study are age ≥18 years, arthritis ≥1 joint, 
symptom duration <1 year, no overexertion or trauma. Patients are excluded if their 
arthritis was due to (post-) infectious arthritis, crystal arthropathy or another 
autoimmune rheumatic disorder.  
 Eligible patients were stratified into three groups according to their likelihood of 
progressing to persistent arthritis based of the prediction model of Visser et al.22 The 
three strata (low, intermediate and high) correspond with probability tertiles of 
developing persistent arthritis according to the Visser model. For the present analysis 
we selected those patients who had a randomization date before 1 December 2010 and 
fulfilled the classification criteria for RA according to the 2010 ACR/EULAR criteria.16 
 In each probability stratum, patients are randomly assigned to three treatment 
strategies.  Allocated treatment strategies in the high probability stratum are: (A) 
Combination therapy (methotrexate (MTX), sulfasalazine (SSZ) and 
hydroxychloroquine(HCQ)) with glucocorticoids (GCs) intramuscular, (B) Combination 
therapy with an oral GC tapering scheme and (C) MTX with an oral GC tapering scheme. 
Treatment strategies in the intermediate group comprise: (A) MTX, (B)  an oral GC 
tapering scheme (C) HCQ. The low probability group has following induction therapies: 
(A) NSAID, (B) GCs intramuscular and (C) HCQ. DMARD dosages were MTX 25 mg/week 
 oral or subcutaneous, SSZ 2 g/day and HCQ 400 mg/day. GCs were either given 
intramuscular (methylprednisolone 120mg or triamcinolone 80mg) or in an oral 
tapering scheme (weeks 1-4: 15 mg/day, weeks 5-6: 10 mg/day, weeks 7-8: 5 mg/day, 
and weeks 9-10: 2.5 mg/day). All patients received folic acid (10 mg/week) during MTX 
prescription. Osteoporosis prophylaxis (risedronate 35 mg/week and calcium/vitamin D 
combination 500/400 mg/IU per day) is given to patients allocated to treatment arms 
with combination therapy and oral GCs (High B and C).  
 Treatment strategies are tightly controlled, with patients being examined every 
3 months and treatment decisions are based upon the original DAS thresholds.21 In case 
of treatment failure, defined as DAS≥2.4, medication is intensified according to the 
protocol. The intensifications steps in the protocol are: (1) Combination therapy, (2) MTX 
+ etanercept, (3) MTX + adalimunab and (4) MTX + abatacept.  
 In case of sustained remission, defined as DAS<1.6 at two consecutive visits, 
medication is tapered, which depends on the given therapy. The hierarchical ordered 
tapering steps are: (1) biological(s), (2) SSZ, (3) MTX, (4) HCQ. Anti-TNF agents, MTX, SSZ 
and oral GCs are gradually discontinued and all other medications were stopped 
immediately. A flare during tapering, defined as DAS≥2.4, results in restarting full 
therapy, according to the stage in the protocol.  
 
Methods 
Demographic and clinical characteristics of each patient were recorded at baseline. At 
each 3-monthly visit the following disease activity core set variables were assessed: a 
44-joint count for swelling, a graded 53-joint count for tenderness23, general health 
(GH), PGA and acute phase reactants (ESR and CRP). Since we did not collect the EGA24, 
we used the value of the PGA for the EGA. Using the value of the PGA for the EGA is a 
good estimation, because the ratio of the mean EGA and PGA is ~1; data adapted from 
Smolen et al.25 However,  we also used more conservative estimated values of 
respectively 0.5 and 0.75 of the PGA for the EGA in our analysis.  
 The following DAIs are calculated: DAS, DAS (3var), DAS-CRP, DAS (CRP/3var), 
same combinations for DAS28, SDAI and CDAI.7-10 Thresholds for remission and 
moderate to high disease activity for DAS (modifications), DAS28 (modifications), SDAI 
and CDAI are respectively <1.6 and ≥2.4, <2.6 and ≥3.2, ≤3.30 and >11, and ≤2.80 and 
>10.7-10 Appendix 1 shows the mathematical formulas and thresholds for given DAIs.  
 Median medication costs per year for each DAI were estimated by simulating 
treatment decisions in the tREACH medication protocol using the various DAIs with 
their exclusive thresholds for remission and moderate disease activity. For this 
simulation we used 124 patients, using data of their first year of follow-up, of whom 
frequencies of 3-monthly treatment switches and evolved medication costs were 
analyzed.  So at each visit (four in total) treatment could be continued, intensified or 
tapered. The amount of treatment intensifications and taperings for each patient were 
analyzed. Thereafter the medication costs simulation was performed, which had 
 following assumptions: (1) there were no protocol violations, (2) compliance was 100% 
and no side-effects occurred, and (3) treatment changes commenced immediately.  
As patients are their own controls in this post hoc analysis only the medication and not 
the other costs will differ. Appendix 2 gives an overview of the monthly medication 
costs in the Netherlands for used drugs at a maximum dosage.   
 
Statistical analyses  
To measure agreement between DAIs in disease state categorizations, the quadratic 
weighted kappa statistic26-27 was applied. Rule of thumb for the strength of agreement 
is: κ >0.8 ‘almost perfect’,0.61-0.8 ‘substantial’, 0.41–0.6 ‘moderate’, 0.21–0.4 ‘, ‘fair’  and 
<0.2 ‘slight’ agreement.28 The Stuart-Maxwell test was used to assess agreement 
between disease state categorizations. A statistically significant Stuart-Maxwell test 
indicates a large disagreement in disease activity states classification between two 
DAIs.29 Spearman rank correlations, using all available data, were also calculated. 
Discordance between indices was graphically represented with scatter plots.  
 Reclassification tables give insight in the possible difference in the frequency of 
treatment intensifications and taperings between DAS usage and other DAIs. Over- and 
underrating were defined as intensifying or tapering treatment more and less 
frequently, respectively, than the DAS.  Proportions of discordance with DAS usage were 
given and the Stuart-Maxwell test was applied to assess the strength of discordance. To 
demonstrate a difference in estimated median annual medication costs between DAS 
and all other DAIs a Wilcoxon rank-sum test was applied.  
All analyses were performed for patients fulfilling the 2010 classification criteria 
for RA16 and a subgroup, consisting of patients with RA according to ACR 1987 criteria.17 
All statistical analyses were carried out using STATA version 11.1. A p<0.05 was 
considered statistically significant.   
 
 
RESULTS 
 
Baseline characteristics 
Table 1 shows the baseline characteristics of the 296 tREACH patients who fulfilled the 
2010 ACR/EULAR classification criteria for RA. Patients were mostly females (68%) with 
an average symptom duration of 156 days (146 – 166 days, 95% confidence interval 
(CI)). Rheumatoid factor (RF) and/or Anti-citrullinated protein antibodies (ACPA) 
positivity was present in 199 patients (67%); of those, 142 (71%) were both RF and ACPA 
positive. At baseline, 47 patients (16%) had erosions. Active disease was found in  
96 - 126 patients (32% - 43%), depending on the DAI used. Combination DMARD 
therapy was provided to 68% of the patients, while, respectively, 21% and 11% of the 
patients used a single DMARD and steroids as initial protocolised treatment. The 
subgroup description of those patients fulfilling the ACR 1987 RA criteria showed higher 
DAI scores, more swollen joints and were more often RF and ACPA positive  
(resp. 79% and 70%) compared with the total population.  
 Table 1: Baseline characteristics of RA patients according to the 2010 and/or 1987 
classification criteria.    
 
Total population 
(n=296) 
Fullfillment of 1987 
criteria for RA(n=168) 
Fullfillment of 2010, but not
1987 criteria for RA (n=128) 
Age (yrs), mean (95% CI) 54 (52 - 55) 55 (53 - 57) 52 (49 - 54) 
Sex, female, no(%) 200 (68) 110 (65) 90 (70) 
Symptom duration (days),mean (95%CI) 156 (146 - 166) 152 (140 - 165) 161 (143 - 178) 
Initial treatment, no(%)    
• Combination therapy 116 (68) 145 (86) 57 (45) 
• Single DMARD 61 (21) 13 (8) 48 (37) 
• Steroids 33 (11) 10 (6) 23 (18) 
RF pos., no(%) 171 (58) 133 (79) 38 (30) 
ACPA pos., no(%) 170 (57) 118 (70) 52 (41) 
Erosion, no(%) 47 (16) 38 (23) 9 (7) 
Morning stiffness >1hr., no(%) 242 (82) 145 (86) 97 (76) 
Tender joints, median (IQR)    
• 44 joints 10 (5 - 15.5) 10 (5 - 16) 11 (5 - 15) 
• 28 joints 6 (3 - 10) 6 (3 - 10) 6 (2.5 - 10) 
Ritchi Articular Index (RAI), median(IQR) 7 (4 - 11) 7 (4 - 10.5) 8 (4.5 - 11) 
Swollen joints, median (IQR)    
• 44 joints 8 (4 - 12) 10 (6.5 - 13) 4 (2 - 11) 
• 28 joints 6 (3 - 10) 7 (5 - 11.5) 3 (1 - 8.5) 
General Health, median (IQR) 53 (30 - 68) 54 (30 - 70) 51 (32 - 65.5) 
PGA, median (IQR) 6 (4 - 8) 7 (4 - 8) 4 (6 - 10) 
ESR (mm/hr), median (IQR) 22 (12 - 39) 25 (15 - 44) 16 (9 - 35) 
CRP (mg/dl), median (IQR) 7 (4 - 19) 10 (5 - 24.5) 5 (3 - 12) 
DAS, mean (95% CI) 3.41 (3.30 - 3.52) 3.54 (3.40 - 3.68) 3.23 (3.06 - 3.40) 
DAS (3var), mean (95% CI) 3.27 (3.17 - 3.37) 3.39 (3.27 - 3.52) 3.10 (2.94 - 3.26) 
DAS (CRP), mean (95% CI) 3.26 (3.15 - 3.36) 3.36 (3.22 - 3.50) 3.12 (2.95 - 3.28) 
DAS (CRP/3var), mean (95% CI) 3.09 (3.00 - 3.19) 3.19 (3.07 - 3.31) 2.96 (2.81 - 3.11) 
DAS28, mean (95% CI) 4.85 (4.71 - 4.99) 5.11 (4.93 - 5.28) 4.51 (4.29 - 4.73) 
DAS28 (3var), mean (95% CI) 4.64 (4.50 - 4.77) 4.90 (4.74 - 5.06) 4.29 (4.06 - 4.51) 
DAS28 (CRP), mean (95% CI) 4.53 (4.41 - 4.66) 4.73 (4.57 - 4.89) 4.27 (4.09 - 4.45) 
DAS28 (CRP/3var), mean (95% CI) 4.31 (4.19 - 4.42) 4.51 (4.36 - 4.66) 4.03 (3.85 - 4.22) 
SDAI, mean (95% CI) 27.74 (26.30 - 29.19) 29.67 (27.78 - 31.55) 25.18 (22.98 - 27.38) 
CDAI, mean (95% CI) 26.06 (24.70 - 27.41) 27.67 (25.92 - 29.42) 23.90 (21.80 - 26.01) 
Abbreviations: ACP, Anti-citrullinated protein/peptide antibodies; CDAI, Clinical Disease Activity Index; CI, 
Confidence Interval; CRP, C-reactive protein; DAS, Disease Activity Score; DAS(3var), DAS without GH; DAS(CRP), 
DAS with CRP instead of ESR; DAS(CRP/3var), DAS with CRP and without GH; DAS28, DAS using a 28 joint count; 
EGA, Evaluator’s Global Assessment; ESR, Erythrocyte Sedimentation Rate; GH, general health; IQR, Interquartile 
range; PGA, Patient’s Global Assessment; RF,Rheumatoid Factor; sd, standard deviation and SDAI, Simplified 
Disease Activity Index.  
 
Disease state(s) agreement measures 
In total 1104 disease activity scores per DAI were available from 296 patients. 
Correlation between the DAIs (table 2), using all available data, ranged from 0.76 for 
CDAI with DAS28(3var) to 0.99 comparing DAS with DAS(3var) and SDAI with CDAI. The 
lowest weighted quadratic kappa statistic was 0.57 for DAS28(3var) versus SDAI or CDAI 
(table 2). Intercorrelations of DAI scores within patients declined as the time period 
between assessments were longer. Intercorrelations of DAIs ranged from ±0.65 for 
assessments with a 3-month interval to ±0.25 between visits with a time window of 1 
year. All correlation coefficients and kappa statistics had p<0.0001. Similar results were 
found in patients who fulfilled 1987 classification criteria for RA (data not presented).  
 Table 2: Quadratic weighted kappa statistics and correlation coefficients in RA according to 2010 classification criteria. 
 DAS DAS (CRP) DAS (3var) DAS (CRP/3var) DAS28 DAS28 (CRP) DAS28 (3var) DAS28 (CRP/3var) SDAI CDAI 
DAS  0.91 (87) 0.96 (94) 0.89 (84) 0.83 (82) 0.83 (78) 0.80 (75) 0.81 (76) 0.65 (65) 0.65 (65) 
DAS (CRP) 0.97  0.90 (86) 0.95 (93) 0.75 (74) 0.86 (80) 0.72 (68) 0.84 (79) 0.68 (66) 0.68 (66) 
DAS (3var) 0.99 0.95  0.90 (86) 0.81 (79) 0.81 (75) 0.81 (75) 0.82 (77) 0.63 (64) 0.63 (64) 
DAS (CRP/3var) 0.96 0.99 0.96  0.73 (71) 0.83 (77) 0.73 (67) 0.85 (78) 0.65 (64) 0.65 (63) 
DAS28 0.93 0.86 0.92 0.85  0.82 (81) 0.92 (90) 0.79 (79) 0.63 (41) 0.63 (67) 
DAS28 (CRP) 0.91 0.95 0.89 0.92 0.91  0.76 (74) 0.91 (87) 0.71 (71) 0.70 (69) 
DAS28 (3var) 0.90 0.81 0.91 0.82 0.98 0.87  0.80 (75) 0.57 (62) 0.57 (61) 
DAS28 (CRP/3var) 0.87 0.90 0.88 0.92 0.89 0.97 0.88  0.66 (67) 0.65 (66) 
SDAI 0.83 0.86 0.81 0.84 0.82 0.89 0.77 0.86  0.99 (97) 
CDAI 0.83 0.86 0.81 0.83 0.81 0.87 0.76 0.84 0.99  
Above the diagonal the quadratic weighted kappa statistics (percentage agreement within parentheses) are given. Below the diagonal the Spearman’s correlation 
coefficients are shown. All correlation coefficients and kappa statistics have p-values <0.0001. 
Abbreviations: CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS , Disease Activity Score; DAS(3var), DAS without GH; DAS(CRP), DAS with CRP instead 
of ESR; DAS(CRP/3var), DAS with CRP and without GH; DAS28, DAS using a 28 joint count; ESR, erythrocyte sedimentation rate; GH, general health and SDAI, 
Simplified Disease Activity Index. 
 
Table 3: DMARD and biologic usage in the tREACH trial for each time-point in patients with RA,  
according to the 2010 criteria, and 1 year follow-up (n=124). 
 Baseline 3 months 6 months 9 months 12 months 
MTX 40 (32) 18 (15) 14 (11) 13 (10) 13 (10) 
Combination therapy* 53 (43) 64 (52) 56 (45) 49 (40) 45 (36) 
MTX + Etanercept 0 (0) 26 (21) 26 (21) 25 (20) 25 (20) 
MTX + Adalimunab 0 (0) 0 (0) 16 (13) 17 (14) 13 (10) 
MTX + Abatacept 0 (0) 0 (0) 0 (0) 9 (7) 18 (15) 
Other medication† 31 (25) 16 (13) 12 (10) 11 (9) 10 (8) 
Results shown are a number (%) 
*Combination therapy comprises methotrexate, sulfasalazine and hydroxychloroquine. 
†Other medication comprises hydroxychloroquine, glucocorticoids and/or NSAIDs 
Abbreviations: MTX,  methotrexate (oral).  
 
 
  
The percentages of agreement on classifying patients into a particular disease state, 
however, varied widely (range 41%-97%). Discordance and concordance between disease 
activity states are graphically represented by scatter plots (figure 1). Scatter plots for DAS 
versus DAS(3var), DAS28, SDAI and CDAI, respectively, are shown (figure 1A, 1B, 1C, 1D 
respectively). All DAIs were significantly discordant with the original DAS regarding disease 
state classification. Patients were more often classified into a higher disease state (figure 1) if 
the DAS28, DAS28(CRP), DAS28 (3var), SDAI and CDAI were applied compared with DAS. 
Fewer patients were regarded as having active disease if the DAS(CRP), DAS(3var), 
DAS(CRP/3var) and DAS28(CRP/3var) were used. Similar results were found in patients who 
fulfilled 1987 classification criteria for RA (data not presented). 
 
Therapeutic and economic consequences 
In 124 patients with a follow-up ≥1 year, frequencies of 3-monthly treatment switches and 
evolved medication costs were analyzed using data of the first year of follow-up. Figure 2 
shows the reclassification tables for DAS versus DAS28, CDAI and SDAI over 1 year of 
treatment. On the diagonal the number of patients who receive a similar number of 
treatment intensifications and taperings, independently on the DAI used, are presented. 
Under the diagonal are patients who switched treatment more frequently, whereas 
patients above the diagonal switched less often when compared with the DAS.  
Proportions of over- and underrating for treatment intensifications and taperings 
compared with the DAS are shown in figure 2. At least 35% of the patients had more 
frequent treatment intensifications with DAS28, SDAI and CDAI usage compared with the 
DAS. Remission was less often achieved with SDAI and CDAI usage, leading to fewer 
treatment taperings. However, remission is achieved 2.3 times more frequently if the 
DAS28 is used, leading to more frequent treatment taperings compared with DAS usage. In 
the subgroup, RA according to 1987 criteria, similar results were found. (data not shown) 
Median medication costs per year for each DAI were estimated by simulating 
treatment decisions in the tREACH medication protocol using the various DAIs with their 
exclusive thresholds for remission and moderate disease activity. Table 3 gives an overview 
of biological and DMARD usage in the tREACH trial. For all other DAIs biologic and DMARD 
usage was simulated for each time-point. Combining this information with standard 
national costs and following assumptions: (1) there were no protocol violations, (2) 
compliance was 100% and no side-effects occurred, and (3) treatment changes 
commenced immediately, we performed the medication cost simulation and estimated 
annual median medication costs. Resulting in €318 (interquartiel range: €189 - €7733) as 
annual median medication costs per patient for the DAS. Simulated medication costs for all 
other DAIs ranged between €298 and €7658 for respectively, the DAS(CRP) and the SDAI 
(table 4). Compared with the DAS the estimated median cost increase for the DAS28 were 
€4958, for SDAI €7340 and for CDAI €6732. These differences were even larger when the 
simulation was applied to ACR 1987 RA patients only (data not presented). 
 
  
  
Figure 1: Concordance between DAIs in RA, according to 2010 classification criteria. 
Scatter plots for DAS vs DAS(3var), DAS-28, SDAI and CDAI are given (respectively, A, B, C and D). DAIs are concordant and discordant in the light grey and dark grey 
surfaces, respectively. The vertical and horizontal lines represent thresholds for corresponding DAIs on the x and y-axis, respectively. These threshold lines divide the 
graph into nine rectangles. (E) A schematic diagram of a graph divided into nine rectangles, in which each rectangle is identifiable by a letter. (F) The number of patients 
(percentage) for each rectangle per DAI vs the DAS. Rectangles A +B+D and F +H+ I give the number or percentage of patients who are classified into a more and less 
active disease state, respectively, by a particular DAI compared with the DAS. 
Abbreviations: CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS , Disease Activity Score; DAS(3var), DAS without GH; DAS(CRP), DAS with CRP instead of 
ESR; DAS(CRP/3var), DAS with CRP and without GH; DAS28, DAS using a 28 joint count; ESR, erythrocyte sedimentation rate; GH, general health and SDAI, Simplified 
Disease Activity Index. 
  
Figure 2: Simulated treatment reclassifications, using patients with RA, according 
to the 2010 criteria, and 1 year follow-up. 
Reclassification tables for DAS vs DAS28, SDAI and CDAI, respectively, are given. DAIs are concordant in 
the white areas. Patients are overrated (dark grey areas) and underrated (light grey areas) if treatment 
intensification or taperings, respectively, would have occured more and less frequently than when the 
DAS was used. The total number of patients (percentage) who are in agreement, overrated and 
underrated for treatment intensifications and taperings for each fictive use of DAI vs the DAS are shown 
in the table. The Stuart-Maxwell test (intensifications and taperings investigated seperately): p<0.05 
compared with the DAS (indicated by an asterisk). 
 Table 4: Simulation of annual medication costs per DAI in patients with RA, 
according to the 2010 criteria, and 1 year follow-up. 
DAI Median Interquartile range 
DAS € 318.24 € 188.78 - € 7732.97 
DAS (CRP) € 298.49 € 188.66 - € 7702.16 
DAS (3var) € 318.24 € 188.78 - € 7759.66 
DAS (CRP/3var)1 € 298.49 € 188.66 - € 7709.72 
DAS283  € 5267.65 € 214.35 - € 8953.94 
DAS28 (CRP)2 € 2740.06 € 207.72 - € 8828.27 
DAS28 (3var)1 € 2784.82 € 192.74 - € 8853.37 
DAS28 (CRP/3var) € 349.144 € 188.66 - € 7767.27 
SDAI3 € 7657.85 € 298.88 - € 10233.20 
CDAI3 € 7050.65 € 298.49 - € 10214.00 
Abbreviations: CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAI, Disease Activity Index; 
DAS , Disease Activity Score; DAS(3var), DAS without GH; DAS(CRP), DAS with CRP instead of ESR; 
DAS(CRP/3var), DAS with CRP and without GH; DAS28, DAS using a 28 joint count; ESR, erythrocyte 
sedimentation rate; GH, general health and SDAI, Simplified Disease Activity Index. 
1P<0.05  2P<0.01  3P<0.0001 
 
DISCUSSION 
 
In this study we compared the characteristics of DAIs in RA according to the 2010 and 
1987 classification criteria.16-17 The performance of the disease activity measures in 
patients fulfilling the new RA 2010 classification criteria was comparable to those with 
RA according to 1987 criteria, although lower levels of disease activity were seen for 
patients that only fulfilled the 2010 criteria. We found that DAS28, SDAI and CDAI 
overrate disease activity and classify patients into higher disease activity states 
compared with the DAS, potentially leading to more treatment intensifications  and 
associated medication costs. However, the consequence of using different DAIs on 
functional impairment and joint damage over time is not known and has still to be 
investigated.  
 The 2010 classification criteria are aimed at identifying RA earlier in the disease 
course than the 1987 criteria.30  This may explain the lower levels of disease activity 
shown in our study. A previous study by Fransen et al31 showed good performance of 
the DAS in undifferentiated arthritis, suggesting that DAIs could be used in the new 
patient group fulfilling the 2010 RA criteria. This is helpful, as DAIs are imperative to 
uphold current EULAR recommendations for treating RA.2-3 
 In daily practice usage of the original DAS takes too much time and 
rheumatologists would probably prefer a DAI that is faster and easy-to-do. Although we 
and others found strong correlation coefficients, the overall agreement measures were 
just acceptable between the DAS and the other measures of disease activity.12-15 This 
discrepancy is due to the fact that the correlation reflects the direction of a linear 
relationship between DAIs, but not the slope of that relationship (figure 1). Therefore, 
more important is the classification of patients into the disease states ‘remission’, ‘low’ 
or ‘moderate to severe’, which showed substantial variation. Considerable 
 reclassification was shown for the 28 joint DAIs (DAS28, SDAI and CDAI) compared with 
the DAS. One explanation for this might be that of all DAI formulas, the DAS and its 
modifications are less influenced by swollen joint counts (alterations). Due to the 
reclassification patients would have received more treatment intensifications, resulting 
in a substantial increase of medication cost. However, it is unclear if the various DAIs 
under- or overestimate the disease activity, which will lead to different patient 
outcomes as there are no head-to-head comparisons available.  
In our simulation study we compared the disease state distribution at 1 year for 2 
groups of patients: (1) Patients who were congruent in disease state on the DAIs at 3 
months and (2) patients who had a DAS-defined disease state at 3 months that differed 
from any other DAI. At 1 year there were no differences in the disease state 
distributions. Although the treatment decisions, in reality, were based on the DAS, these 
data suggest we did not undertreated those patients who were incongruent at 3 
months. Therefore, for the selection of a DAI, besides that it is easy to use, therapeutic 
and economic consequences should also be considered.  
 The choice of a DAI for usage in daily practice is cumbersome, because head-to-
head comparisons between DAIs are lacking. However, if a particular DAI is chosen to 
assess disease activity in a patient with RA, that same DAI should be used during the 
entire follow-up of that patient. Our DAI preference for daily practice is the DAS28, 
because, first, it is easy to use and, secondly, its ability to detect active disease, which 
results in treatment intensifications and higher medication costs, is in between the 
other DAIs. The DAS28 is more conservative compared with the SDAI and CDAI and 
more liberal compared with the DAS in detecting active disease. Remission rates, 
however, are much higher with DAS28 compared with other DAIs. We advise that the 
decision to taper treatment should not only depend on measuring sustained remission 
with DAS28, but also on the absence of forefeet arthritis and radiographic progression. 
 Our study had certain limititations. First, we did not assess the EGA.24 To be able 
to use the SDAI/CDAI we substituted the value of the EGA with the value of the PGA, 
based on the SDAI development cohort25, wherein the mean EGA and PGA are similar. 
However, Sokka et al32 have reported a ratio of 0.5 between the median values of EGA 
and PGA. Estimating the EGA with making use of the PGA has biased our results. 
Therefore, we conducted a sensitivity analyses with different EGA estimations to 
evaluate how much these different estimations would influence our results.  We 
performed our sensitivity analysis with imputed values of the EGA, which were 0.5 and 
0.75 times the PGA. This resulted in similar high correlations and substantial 
reclassification (Appendix 3). The weakness of our sensitivity analysis is the unknown 
relationship between EGA and PGA, which may be influenced by other components of 
the DAI and the physician’s perspective. Therefore, the real differences in disease state 
categorizations and annual median medication cost between SDAI/CDAI and DAS are 
probably within the extreme limits of our EGA estimations (respectively 0.5 and 1 times 
the PGA). 
  Second, for the cost analysis we had to simulate the consequences of the various 
DAIs, as our trial was tightly controlled by the DAS. A wrongful accumulation of 
treatment adaptations may have occured, as explained in the following example: If the 
DAS measured a low disease activity state and the SDAI measured a moderate to high 
disease activity state at a particular time-point, the DAS was followed and thus 
treatment was not adjusted. Consequently, at a following time point the effect of what 
would have happened if the SDAI was followed could not be measured. As patients 
were their own controls, only medication costs were used for our simulation. Other 
direct and indirect costs, like sick leave and medical consumption, could not be 
analysed in our simulation. To solve this problem in future research the outcome of 
treatment strategies using different DAIs could be compared. 
 In conclusion, DAIs perform similar in RA according to 2010 and 1987 criteria. 
Knowing that DAIs are essential in guiding treatment decisions, choosing a particular 
DAI could be cumbersome, because usage of various DAIs in a single patient leads to 
inconsistent disease state categorizations. Consequently, these inconsistencies 
significantly influence therapeutic decisions and accompanying costs. Therefore, for the 
selection of a DAI, the therapeutic and economic consequences should be considered.  
  
 
 APPENDIX 1: Formulas and thresholds for disease activity indices (DAIs). 
DAI Formula Thresholds 
DAS 0.53938√(RAI) + 0.06465(SJC44) + 0.33ln(ESR) + 0.00722(GH)   <1.6/<2.4/<3.7 
DAS (3var) 0.53938√(RAI) + 0.06465(SJC44) + 0.33ln(ESR) + 0.224    
DAS (CRP) 0.53938√(RAI) + 0.06465(SJC44) + 0.17ln(CRP+1) + 0.00722(GH) + 0.45   
DAS (CRP/3var) 0.53938√(RAI) + 0.06465(SJC44) + 0.17ln(CRP+1) + 0.65    
DAS28 0.56√(TJC28) + 0.28√(SJC28) + 0.70ln (ESR) + 0.014(GH) <2.6/<3.2/<5.1 
DAS28 (3var) (0.56√(TJC28) + 0.28√(SJC28) + 0.70ln (ESR))1.08 + 0.16  
DAS28 (CRP) 0.56√(TJC28) + 0.28√(SJC28) + 0.36ln (CRP+1) + 0.014(GH) + 0.96  
DAS28 (CRP/3var) (0.56√(TJC28) + 0.28√(SJC28) + 0.36ln (CRP+1))*1.10 + 1.15  
SDAI SJC28 + TJC28 + PGA + EGA + CRP ≤3.3/≤11/≤26 
CDAI SJC28 + TJC28 + PGA + EGA ≤2.8/≤10/≤22 
Abbreviations: CDAI, Clinical Disease Activity Index; CRP, C-reactive protein (DAS mg/l & SDAI  mg/dl); 
DAS , Disease Activity Score; DAS(3var), DAS without GH; DAS(CRP), DAS with CRP instead of ESR; 
DAS(CRP/3var), DAS with CRP and without GH; DAS28, DAS using a 28 joint count; EGA= Evaluator Global 
Assessment of disease activity (VAS of 10cm); ESR, Erythrocyte Sedimentation Rate (mm/hr); GH, General 
Health (Visual Analogue Scale (VAS) of 100mm); PGA, Patient Global Assessment of disease activity (VAS 
of 10cm); RAI, Ritchie Articular Index (53 joints in 26 units, graded for tenderness); SDAI, Simplified Disease 
Activity Index; SJC, Swollen Joint Count and  TJC, Tender Joint Count. 
 
 
APPENDIX 2: Monthly medication cost, in the Netherlands, for used drugs at a 
maximum dosage.   
Generic name Calculation base Monthly costs 
Methotrexate (oral) 25mg/week € 7.30 
Sulfasalazine (oral) 2000mg/day € 8.83 
Hydroxychloroquine (oral) 400mg/day € 7.28 
Prednisone (oral)  10mg/day € 4.94* 
Methylprednisolone (im) 120mg € 6.12** 
Etanercept (sc) 50mg/week € 1,044.06 
Adalimunab (sc) 40mg/2 weeks € 1,064.87 
Abatacept (iv) 750mg/4 weeks € 1,132.82 
Naproxen (oral)  1000mg/day € 4.32 
Folic acid (oral) 10mg/week € 1.50 
Risedronate (oral) 35mg/week € 26.03 
Calcium carbonate/colecalciferol (oral) 500mg/400IE/day € 7.81 
Abbreviations: im, intramuscular; iv, intravenous and sc,subcutaneous. 
* Total cost of prednisone’s gradual discontinuation scheme. 
** Costs for 1 intramuscular administration of methylprednisolone 
  
 
 
C Median Interquartile range 
SDAI† € 5242.69 € 264.15 - € 10193.07 
CDAI† € 5226.24 € 268.87 - € 10193.07 
 
 
Appendix 3: Simulated treatment reclassifications and annual medication costs for 
SDAI and CDAI with an EGA=0.5xPGA in RA, according to 2010 criteria. 
Reclassification tables for DAS versus respectively SDAI and CDAI are given (fig. 3A). DAIs are concordant 
in the white areas. Patients are over- (dark-grey areas) and underrated (light-grey areas) if treatment 
intensification or taperings respectively would have occured more and less frequent than when the DAS 
was used. The total number of patients (%) who are respectively in agreement, overrated and underrated 
for treatment intensifications and taperings for each fictive use of SDAI and CDAI versus the use of the 
DAS are shown in table 3B. Table 3C showns the annual median medication costs for SDAI and CDAI. 
*Stuart-Maxwell test (intensifications and taperings investigated seperately): p<0.05 compared with DAS.  
† SDAI and CDAI differed significantly compared with the DAS (p values <0.0001). 
Abbreviations: CDAI, Clinical Disease Activity Index; DAS , Disease Activity Score and SDAI, Simplified 
Disease Activity Index. 
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 Objective 
To investigate if a glucocorticoid (GC) response at 2 weeks, defined with EULAR 
response criteria, can predict active disease (Disease Activity Index (DAS)≥2.4) at 3 
months. 
 
Methods 
For this study data of the treatment in the Rotterdam Ealy Arthritis Cohort study 
(tREACH), an ongoing clinical trial that evaluates different induction therapies in early 
rheumatoid arthritis, were used. We selected the patients who had a high probability of 
progressing to persistent arthritis (>70% based on the prediction model of Visser). All 
patients within the high probability stratum, who had a baseline DAS>2.2 and a DAS 
assessment at 2 weeks after randomisation, were included (n=120). Besides GC 
response at 2 weeks, we investigated which other factors were associated with having 
active disease (DAS≥2.4) after 3 months of disease-modifying antirheumatic drug 
(DMARD) treatment. All variables with a p≤0.25 were assessed in our logistic regression 
model with backward selection. Variables were eliminated until all remaining variables 
had a significant association (p<0.05). 
 
Results 
Patients who did not respond to GC bridging therapy at 2 weeks had an overall OR of 
having active disease at 3 months of 10.29 (95% confidence interval (CI): 3.34 to 31.64; 
p<0.001) in comparison with responders. The corrected OR was 14.00 (95% CI: 3.31 to 
59.21; p<0.001). Our final model predicting response at 3 months included the 
following variables: gender, GC response, induction therapy arms and baseline DAS, 
which had an explained variance of 39%.  
 
Conclusion 
GC response at 2 weeks is a useful tool for recognising those patients who will probably 
have active disease (DAS≥2.4) after 3 months of DMARD treatment. 
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 INTRODUCTION 
The EULAR treatment guideline recommends that rheumatologists should strive, in 
patients with newly diagnosed rheumatoid arthritis (RA), for remission or at least low 
disease activity within 3 months in order to obtain better functional and radiological 
outcomes.1,2 Since the time span for the optimal effect of disease-modifying 
antirheumatic drugs (DMARDs) is at least 6-12 weeks,3 the right choice of the initial 
DMARD has an important role in obtaining recommended treatment goals. The 
guideline recommends methotrexate (MTX) as anchor drug, but studies show that only 
about 70% of patients will respond sufficiently to the initial therapy.4,5 Moreover, we 
recently showed that a combination of DMARDs shows better remission rates than MTX 
monotherapy in the early phase of RA.5 Therefore, it would be helpful to be able to 
predict treatment response to the initial DMARD treatment as early as possible, 
ultimately leading to a ‘tailor-made’ treatment approach.  
  The huge body of prognostic research till now has mainly focused on predicting 
long-term destructive and disabling disease in order to guide the initial choice of  
treatment.6 In contrast, studies evaluating prediction of treatment response are sparse. 
Aletaha et al7 demonstrated that high disease activity during the first 3 months of 
treatment are significantly related to high disease activity at 1 year, which subsequently 
leads to more destructive and disabling disease. Besides some possible 
pharmacogenetic markers (eg TYMS polymorphisms affect efficacy of MTX in RA), a 
clinical applicable predictor for treatment response to classical DMARDs in a very early 
stage, is unknown.8 
 In line with studies performed in polymyalgia rheumatica a clinical applicable 
predictor for treatment response in a very early stage might be the initial response to 
glucocorticoids (GCs).9 It is well known that GCs have a rapid anti-inflammatory effect, 
and, therefore, are often used as bridging therapy to treat active disease in the period 
between initiation of DMARD treatment and onset of their therapeutic effect.10  
However, in RA clinical responses to GCs differ between patients. Sliwinska-Stanczyk et 
al11 showed that steroid sensitivity of peripheral blood mononuclear cells of RA patients 
is related to their own observed clinical response to GCs. However, clinical data linking 
the early effect of GCs to DMARD response in RA are missing. Therefore, our objective 
was to investigate whether the GC response at 2 weeks, defined according to the EULAR 
response criteria,12 predicts DMARD response at 3 months.  
 
 
 PATIENTS AND METHODS 
 
Patients 
For this study data were used from a current clinical trial (ISRCTN26791028), treatment 
in the Rotterdam Early Arthritis Cohort (tREACH).13 The tREACH study, a multicenter, 
stratified single blinded trial to evaluate different induction treatment strategies in early 
RA, is being carried out in eight rheumatology centers in the Netherlands. The medical 
ethics committee at each participating center approved the study protocol, and all 
patients gave written informed consent before inclusion.  
An extended description of the material and methods section of the tREACH 
study has already been published.13 Inclusion criteria for the tREACH study are: age ≥18 
years, arthritis ≥1 joint and symptom duration <1 year.  Eligible patients were stratified 
into three groups according to their likelihood of progressing to persistent arthritis 
based on the prediction model of Visser.14 The three strata (low, intermediate and high) 
correspond to probability tertiles of developing persistent arthritis according to the 
Visser model. The Visser algorithm and 2010 criteria for RA have similar discriminative 
abilities to identify patients at risk of persistent arthritis at 1 year.15  
For our analysis we selected all patients who had a high probability of 
developing persistent arthritis and a Disease Activity Score (DAS) assessment at 2 weeks 
after randomisation. Not all patients in the high-probability stratum had a DAS 
assessment at 2 weeks, because this assessment was part of a substudy, primarily 
evaluating differences in GC sensitivity, embedded in the tREACH. Furthermore, patients 
with a DAS≤2.2 and/or DAS28≤3.3 were excluded, because the EULAR response criteria 
are only valid in patients having a baseline DAS>2.2 (DAS28>3.3).12 
 
Methods  
Patients were randomised, using variable block randomisation stratified for centre, into 
one of three initial treatment strategies (later referred to as ‘induction therapy arms’): 
A. Combination therapy (methotrexate (MTX), Sulfasalazine(SSZ) and 
hydroxychloroquine (HCQ)) with GCs intramuscularly) 
B. Combination therapy with an oral GC tapering scheme 
C. MTX with an oral GC tapering scheme  
DMARD dosages were: MTX 25 mg/week orally or subcutaneously (starting dose 
10mg/week, maximum dosage reached after 3 weeks), SSZ first week 1 g/day thereafter 
2 g/day and HCQ 400 mg/day. GCs were either given a single intramuscular dose at 
randomisation (methylprednisolone 120mg or triamcinolone 80mg) or prednisolone in 
an oral tapering scheme (weeks 1-4: 15 mg/day, weeks 5-6: 10 mg/day, weeks 7-8: 5 
mg/day and weeks 9-10: 2.5 mg/day).  
 We used a treat-to-target approach, with patients being examined every 3 
months. Treatment decisions were based, every 3 months, upon the DAS thresholds for 
low disease activity.16 When ‘treatment failure’ occurred, defined as DAS≥2.4, medication 
was intensified to MTX with etanercept (50mg/week). Treatment intensifications were 
the same in each stratum for each treatment arm. 
 Demographic and disease characteristics of each patient were recorded at 
baseline. After 2 weeks and 3 months the following variables were assessed: a 44-joint 
count for swelling, a graded 53-joint count for tenderness,17 general health and 
erythrocyte sedimentation rate, which we used to calculate the DAS and 28-joint count 
DAS (DAS28). At 2 weeks we also determined the EULAR response criteria.12 EULAR 
response criteria are based on attained level and change in DAS.   
 
Statistical analyses 
First, we investigated whether a GC response at 2 weeks, defined according to EULAR 
response criteria, was associated with DMARD response at 3 months of treatment. 
Active disease at 3 months was defined as DAS≥2.4. The discriminative ability of GC 
response at 2 weeks for identifying active disease at 3 months was expressed by 
sensitivity and specificity. To overcome confounding by medication we also carried out 
a stratified analysis for induction therapy arms. All analysis were also performed for the 
DAS28; active disease was defined as DAS28≥3.2.18 
Furthermore, we determined which other factors were associated with active 
disease at 3 months by comparing the baseline characteristics of patients with and 
without active disease after 3 months of DMARD induction therapy. Statistical 
comparison between baseline characteristics was made by the student t test, χ2 test, or 
the Wilcoxon rank-sum test, as appropriate. All variables with a p≤0.25 together with 
known prognostic factors (age, gender, disease duration, rheumatoid factor (RF), anti-
citrullinated peptide antibodies (ACPA) and baseline DAS) were analysed using 
univariate and multivariate logistic regression (with backward selection). In our 
backward selection procedure the variable with the highest p value was eliminated 
from the model, until all variables in the model had a significant association (p<0.05).  
 All statistical analyses were carried out using STATA V.11.1. A p<0.05 was 
considered statistically significant.   
 
 
 RESULTS 
 
Of the 281 tREACH patients within the high-probability stratum, 132 patients (47%) had 
a DAS assessment at 2 weeks after randomisation. Of those patients 12 (9%) were 
excluded because of a baseline DAS≤2.2. All those patients had a DAS<2.4 at 3 months 
of follow-up. Table 1 shows the baseline characteristics of the 120 patients. Patients 
were more often female (65%) and had a median symptom duration of 161 days (97 – 
210 days, interquartile range). RF and/or ACPA positivity was present in 92 patients 
(77%), of those 70 (76%) were both RF and ACPA positive. At baseline 20 patients (17%) 
had ≥1 erosion typical for RA. Active disease (DAS≥2.4) was found in 113 patients (94%).  
 
Table 1: Baseline characteristics for patients with a DAS>2.2 
 Total population (n=120) 
Age (yrs), median (IQR) 54 (44 – 63) 
Sex, female, no(%) 78 (65) 
Symptom duration (days), median (IQR) 161 (97 – 210) 
RF pos., no(%) 78 (65) 
ACPA pos., no(%) 84 (70) 
Morning stiffness >1hr., no(%) 93 (78) 
Erosion, no(%) 20 (17) 
Fulfillment RA criteria, no(%)  
• 1987 82 (68) 
• 2010 114 (95) 
DAS, mean (95% CI) 3.43 (3.28 – 3.57) 
TJC44, median (IQR) 10 (5 – 15) 
SJC44, median (IQR) 8 (4 – 12) 
ESR (mm/hr), median (IQR) 22 (13 – 39) 
General Health (0-100mm), median (IQR) 53 (37 – 66) 
Treatment, no (%)  
A. MTX+SSZ+HCQ+GCs im 43 (36) 
B. MTX+SSZ+HCQ+GCs oral 39 (33) 
C.  MTX+GCs oral 38 (32) 
Abbreviations: ACPA, anti-citrullinated peptide antibodies; CI, confidence interval; DAS, Disease Activity 
Score; ESR, erythrocyte sedimentation rate; GCs, glucocorticoids; HCQ, hydroxychloroquine;  
im, intramuscular; IQR, interquartile range; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid 
factor; SJC44, swollen joint count (44 joints); SSZ, sulfasalazine; TJC44, tender joint count (44 joints). 
 
The relation between GC response at 2 weeks, defined according to the EULAR 
response criteria, and having active disease after 3 months of induction DMARD 
treatment is shown in table 2A.  A total of 39 out of 78 patients with a DAS<2.4 after 3 
months of DMARD treatment (50%), were classified as good GC responders, whereas 
this was only the case for 6 out of 42 patients(14%) who still had active disease 
(DAS≥2.4). Vice versa, in patients with a DAS<2.4 only 12 of 78 patients (15%) did not 
respond initially to GC bridging therapy as distinct from 19 of 42 patients (45%) who 
had an active disease who were GC non-responders. Patients who do not respond to GC 
bridging therapy at 2 weeks had an overall odds ratio (OR) of having active disease at 3 
months of 10.29 (95% CI: 3.34 to 31.64;p<0.001) in comparison with responders. 
 Table 2B demonstrates the relationship between GC response and disease 
activity states stratified for induction therapy arms. The OR (95% CI) for active disease of 
being a non-GC responder relative to a good-GC responder for treatment arms (A), (B) 
and (C) is, respectively, 4.2 (0.75 to 23.18); 10.7 (0.98 to 115.7) and infinite. In treatment 
arm C, which is current recommended induction therapy, all GC none-responders have 
active disease at 3 months. The same analysis was performed for DAS28 instead of DAS, 
and showed similar results (see supplementary tables S1 and S2). 
 
Table 2: Overall relationship between active disease (DAS≥2.4) after 3 months of 
induction DMARD therapy and response to GCs at 2 weeks (A) and also stratified 
for induction therapy arms (B).  
A.  Active disease 
 Response to GCs at 2 weeks YES (n=42) NO (n=78) 
 • Good, no(%) 6 (13) 39 (87) 
 • Moderate, no(%) 17 (39) 27 (61) 
 • None, no(%) 19 (61) 12 (39) 
    
B.  Active disease 
 Response to GCs at 2 weeks YES (n=42) NO (n=78) 
 A. MTX+SSZ+HCQ+GCs im, no(%)   
 • Good  3 (17) 15 (83) 
 • Moderate 3 (21) 11 (79) 
 • None 5 (45) 6 (55) 
 B. MTX+SSZ+HCQ+GCs oral, no(%)   
 • Good  1 (6) 16 (94) 
 • Moderate 5 (42) 7 (58) 
 • None 4 (40) 6 (60) 
 C. MTX+GCs oral, no(%)   
 • Good  2 (20) 8 (80) 
 • Moderate 9 (50) 9 (50) 
 • None 10 (100) 0 (0) 
Abbreviations: DAS, Disease Activity Score; DMARDs, disease-modifying antirheumatic drugs; GCs, 
glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; MTX, methotrexate, SSZ, sulfasalazine. 
 
To determine the discriminative ability of GC response at 2 weeks for identifying 
active disease at 3 months, the following two cut-offs were used: (1) being a non-
responder to GC or not and (2) being a non-responder or moderate responder to GC or 
not. The sensitivity (95% CI) and specificity (95% CI) of GC response to identify active 
disease, using the first cut-off point, were ,respectively, 45% (30% to 61%) and 85% 
(75% to 92%). For the second cut-off point the calculated sensitivity (95% CI) and 
specificity (95% CI) were, respectively, 86% (72% to 95%) and 50% (39% to 62%). 
 Second, we investigated which other factors were associated with having active 
disease after 3 months of DMARD treatment (table 3). Besides known prognostic factors 
(age, gender, disease duration, RF, ACPA and baseline DAS), other possible variables 
associated with active disease after 3 months of DMARD treatment are type of induction 
therapy (treatment arm (A), (B) or (C)), presence of erosions and the components of the 
baseline DAS, except swollen joint count. Table 4 shows the univariate logistic 
regression (4A) and final multivariate model (4B), after backward selection, for the 
prediction of active disease after 3 months of DMARD induction therapy. The final 
model had an explained variance of 39%. The same analysis was performed for DAS28 
instead of DAS, which showed similar results (see supplementary table S3). 
 
Table 3: Comparing baseline characteristics of patients with and without active 
disease (DAS≥2.4) after 3 months of induction DMARD treatment.  
 Active disease p value 
  YES (n=42) NO (n=78)  
Age (yrs), median (IQR) 55 (45 – 63) 54 (43 – 64) 0.69 
Sex, female, no(%) 35 (83) 43 (55) 0.002 
Symptom duration (days), median (IQR) 139 (92 – 208) 164 (116 – 214) 0.30 
RF pos., no(%) 24 (57) 54 (69) 0.19 
ACPA pos., no(%) 27 (64) 57 (73) 0.31 
Morning stiffness >1hr., no(%) 33 (79) 60 (77) 0.84 
Erosion, no(%) 4 (10) 16 (21) 0.12 
Fulfillment RA criteria, no(%)    
• 1987 28 (67) 54 (69) 0.77 
• 2010 42 (100) 72 (92) 0.07 
DAS, mean (95% CI) 3.89 (3.65 – 4.14) 3.17 (3.02 – 3.34) <0.0001 
TJC44, median (IQR) 14 (10 – 21) 7 (3 – 14) <0.0001 
SJC44, median (IQR) 8.5 (4 – 12) 8 (4 – 12) 0.95 
ESR (mm/hr), median (IQR) 29 (17 – 45) 20 (12 – 34) 0.03 
General Health (0-100mm), median (IQR) 54 (50 – 70) 51.5 (30 – 65) 0.02 
Treatment, no (%)    
A. MTX+SSZ+HCQ+GCs im 11 (26) 32 (41) 0.11 
B. MTX+SSZ+HCQ+GCs oral 10 (24) 29 (37) 0.14 
C. MTX+GCs oral 21 (50) 17 (22) 0.002 
Abbreviations: ACPA, anti-citrullinated peptide antibodies; CI, confidence interval; DAS, Disease Activity 
Score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; GCs, 
glucocorticoids; HCQ, hydroxychloroquine; im, intramuscular; IQR, interquartile range; MTX, 
methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC44, swollen joint count (44 joints); SSZ, 
sulfasalazine; TJC44, tender joint count (44 joints). 
 Table 4: Predicting active disease (DAS≥2.4)  at 3 months with (prognostic) 
variable(s), using univariate logistic regression (A) and a logistic regression model 
with backward selection (B). 
A.  OR (95% CI) p value 
 Age (years) 1.01 (0.98 – 1.03) 0.72 
 Sex (1=female) 4.07 (1.61 – 10.27) 0.003 
 Symptom duration (days) 1.00 (0.99 – 1.00) 0.387 
 RF (1=positive) 0.59 (0.27 – 1.29) 0.187 
 ACPA (1=positive) 0.66 (0.30 – 1.48) 0.318 
 Erosion typical for RA (1=present) 0.41 (0.13 – 1.31) 0.132 
 Response to GCs at 2 weeks (ref. = good)   
 • Moderate 4.09 (1.43 – 11.72) 0.009 
 • None 10.29 (3.34 – 31.64) <0.001 
 Treatment (ref. =MTX+GCs oral)   
 • MTX+SSZ+HCQ+GCs im 0.28 (0.11 – 0.71) 0.007 
 • MTX+SSZ+HCQ+GCs oral 0.28 (0.11 – 0.73) 0.009 
 DAS 3.50 (1.95 – 6.30) <0.001 
 SJC44 1.01 (0.95 – 1.08) 0.704 
 TJC44 1.13 (1.06 – 1.19) <0.001 
 ESR (mm/hr) 1.01 (1.00 – 1.04) 0.062 
 General Health (0-100mm) 1.02 (1.00 – 1.04) 0.017 
    
B.  OR (95% CI) p value 
 Sex (1=female) 5.98 (1.67 – 21.40) 0.006 
 Response to GCs at 2 weeks (ref. = good)   
 • Moderate 1.67 (0.48 – 5.88) 0.424 
 • None 14.00 (3.31 – 59.21) <0.001 
 Treatment (ref. = MTX+GCs oral)   
 • MTX+SSZ+HCQ+GCs im 0.25 (0.07 – 0.90) 0.03 
 • MTX+SSZ+HCQ+GCs oral 0.18 (0.05 – 0.69) 0.01 
 DAS 5.54 (2.55 – 12.04) <0.001 
Abbreviations: ACPA, anti-citrullinated peptide antibodies; CI, confidence interval; DAS, Disease Activity 
Score; ESR, erythrocyte sedimentation rate; GCs, glucocorticoids; HCQ, hydroxychloroquine; im, 
intramuscular; MTX, methotrexate; OR, odds ratio; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC44, 
swollen joint count (44 joints); SSZ, sulfasalazine; TJC44, tender joint count (44 joints). 
 
DISCUSSION 
 
We investigated if a GC response at 2 weeks, defined by EULAR response criteria, can 
predict active disease after 3 months of DMARD induction therapy. Patients who do not 
respond to GC bridging therapy at 2 weeks have an overall OR of having active disease 
at 3 months of 10.29 (95% CI 3.34 to 31.64;p<0.001) in comparison with responders. If 
we stratify for induction therapy arms ORs (95% CI) were 4.2 (0.75 to 23.18); 10.7 (0.98 to 
115.7) and infinite for respectively treatment arms (A), (B) and (C). In treatment arm C, 
MTX with an oral GC tapering scheme, all GC none-responders have active disease after 
3 months of DMARD treatment.  Until now a clinical applicable predictor for treatment 
response of classical DMARDs in the very early stage was missing. However, we have 
shown that assessment of disease activity at 2 weeks, reflecting initial response to GCs, 
might be a predictor of active disease after 3 months of induction DMARD treatment. 
 Although our data do not necessarily indicate a direct causal association it is 
tempting to speculate about possible synergistic effects of GCs and DMARDs. GCs and 
DMARDs have mutual anti-inflammatory pathways. The anti-inflammatory actions of 
GCs are mediated via the GC receptor and include an transrepressive effect on the 
transcription factor nuclear factor kappa B (NF-κB).19 Other studies have shown that SSZ 
and MTX both suppress activation of NF-κB by inhibiting degradation of IκBα in vitro.20,21 
Another mutual pathway might be the effect of GCs and DMARDs on the intracellular 
levels of cyclic AMP (cAMP). GCs and DMARDs elicit a rise in intracellular cAMP levels, 
resulting in inhibition of proinflammatory cytokine production.22,23 Because of these 
mutual anti-inflammatory pathways it can be hypothesized that GC response reflects 
DMARD response, especially with MTX and/or SSZ usage. 
 Other non-modifiable baseline predictors associated with active disease after 3 
months of DMARD induction therapy are gender and baseline DAS. The only modifiable 
baseline predictor is the choice of induction therapy. First, the relationship between 
gender and active disease is probably found because women experience more pain, 
resulting in higher DAS values and more functional impairment than men.24,25 Second, 
the baseline disease activity is an important predictor of disease activity (states) during 
follow-up, which is reconfirmed in our study.26 Finally, the choice of induction therapy, 
which is the only modifiable predictor at presentation, determines the clinical response.  
The EULAR treatment guideline recommends a treat-to-target approach in which 
rheumatologists should strive for remission or low disease activity within 3 months, in 
patients with newly diagnosed RA with active disease.2 Until the desired target is 
reached, treatment should be altered every 1-3 months.2 Recommended induction 
therapy consists of MTX with or without GCs.1 However, some points in the mentioned 
recommendation can be discussed. 
 First, the choice of induction therapy wherein DMARD monotherapy is preferred 
over a combination of DMARDs. Current guidelines are based upon a systemic review27, 
which concluded that in DMARD-naïve patients the efficacy/toxicity ratio favours MTX 
monotherapy over combination therapy. However, in this review triple DMARD therapy 
versus MTX monotherapy in DMARD-naïve patients was not compared. Furthermore, 
trials favouring triple DMARD therapy (BeSt, FIN-RACo and COBRA trial) were excluded 
from this review.4,28,29  In a previous publication we have already shown that in patients 
with early RA a combination of DMARDs is better than MTX monotherapy in achieving 
low disease activity after 3 months5, which is supported by a recent systemic review by 
Graudal and Jürgens.30 
 Second, the time span for the optimal effect of DMARDs takes at least 6-12 
weeks3, and thus the right choice of induction DMARD treatment has an important role 
in obtaining recommended treatment goals. Furthermore, several studies have shown 
that only about 70% will respond sufficiently to the initial treatment.4,5 A tailor-made 
treatment approach might be preferable, however, no clinical applicable predictors for 
early treatment response are available. 
 Therefore, in daily practice we advise starting with a combination of DMARDs. 
However, if MTX monotherapy is preferred, either by the rheumatologist or patient, we 
recommend combining MTX with a GC bridging scheme and determining the response 
to GCs after 2 weeks. Patients who do not respond to GCs after 2 weeks have a higher 
risk of not reaching the treatment goals and, therefore, a higher risk of a poorer 
outcome. It seems sensible to intensify the initiated DMARD treatment, if patients do 
not respond to GC after 2 weeks. 
Our study had certain limitations. First, sample size calculations were not based 
upon our research question and therefore we had a small sample size, especially 
restricting the stratified analysis for induction therapy arms. Despite the small sample 
size we found significant ORs for active disease after 3 months of DMARD treatment of 
approximately 10 for non-responders relative to good responders. 
 Second, not all patients in the high-probability stratum had a DAS assessment at 
2 weeks, which possibly introduces a selection bias. The DAS assessment at 2 weeks was 
part of a substudy, primarily evaluating differences in GC sensitivity. Inclusion in the 
tREACH and the mentioned substudy started concurrently, with all randomised patients 
automatically enrolled in the substudy. The DAS assessment at 2 weeks was terminated, 
because the substudy had reached its predefined sample size. Therefore, we think that a 
significant selection bias did not arise.  
Third, the requirements for EULAR response criteria are a baseline DAS>2.2, as a 
result of which 12 patients (9%) were excluded from the analyses. Consequently, in daily 
practice we cannot use a GC response to predict DMARD response in patients with a low 
baseline DAS. In our study, however, we showed that none of the patients with a 
baseline DAS≤2.2 had active disease after 3 months of DMARD treatment. Therefore, if 
adequate DMARD treatment is initiated, we can assume that patients with a baseline 
DAS≤2.2 will respond to this treatment. Future research is necessary to validate our 
findings and to evaluate the clinical applicability of GC response as a prediction tool in 
daily practice. 
 In conclusion, determining GC response at 2 weeks is a useful tool for 
recognising those patients who will probably have active disease (DAS≥2.4) after 3 
months of DMARD treatment. 
 
 Supplement 1: Relationship between GC response at 2 weeks and 
active disease at 3 months using the DAS28, and patients with a 
baseline DAS28>3.3 (n=120) 
NOTE:  12 patients had a baseline DAS28≤3.3. All these patients had a DAS28<3.2 after 3 
months of DMARD treatment. 
 
Table 1: Baseline characteristics for patients with a DAS28 >3.3, also stratified for 
active disease (DAS28≥3.2) after 3 months of induction DMARD treatment. 
 Total population Active disease p value* 
  (n=120) YES (n=59) NO (n=61)  
Age (years), median (IQR) 55 (45 – 64) 55 (46 – 63) 54 (44 – 66) 0.62 
Sex, female, no(%) 79 (66) 45 (76) 34 (56) 0.02 
Symptom duration (days), median (IQR) 161 (96 – 201) 137 (88 – 197) 172 (133 – 214) 0.07 
RF pos., no(%) 78 (65) 37 (63) 41 (67) 0.61 
ACPA pos., no(%) 84 (70) 41 (69) 43 (70) 0.90 
Morning stiffness >1hr., no(%) 93 (78) 46 (78) 47 (77) 0.90 
Erosion, no(%) 20 (17) 8 (14) 12 (20) 0.37 
Fulfillment RA criteria, no(%)     
• 1987 83 (69) 42 (71) 41 (67) 0.64 
• 2010 114 (95) 58 (98) 56 (92) 0.10 
DAS28, mean (95% CI)) 4.96 (4.78 – 5.14) 5.30 (5.05 – 5.55) 4.63 (4.39 – 4.87) 0.0002 
TJC28, median (IQR) 6 (2 – 10) 4 (8 – 13) 4 (2 – 9) 0.001 
SJC28, median (IQR) 6 (4 – 10) 6 (4 – 10) 6 (3 – 10) 0.95 
ESR (mm/hr), median (IQR) 22.5 (13 – 39) 24 (16 – 44) 20 (13 – 34) 0.07 
General Health (0-100mm), median (IQR) 53 (37.5 – 67.5) 55 (49 – 71) 52 (29 – 62) 0.02 
Treatment, no (%)     
A. MTX+SSZ+HCQ+GCs im 42 (35) 18 (31) 24 (39) 0.31 
B. MTX+SSZ+HCQ+GCs oral 40 (33) 17 (29) 23 (38) 0.30 
C. MTX+GCs oral 38 (32) 24 (41) 14 (23) 0.04 
*p value= testing difference in baseline characteristics between patients with and without active disease 
after 3 months of induction DMARD treatment. 
Abbreviations: ACPA, Anti-citrullinated peptide antibodies; CI, Confidence Interval; DAS28, Disease 
Activity Score with an 28 joint count; ESR, Erythrocyte Sedimentation Rate; GCs, glucocorticoids; HCQ, 
hydroxychloroquine; im, intramuscular; IQR, Interquartile range; MTX, methotrexate; RF, Rheumatoid 
Factor; SSZ, sulfasalazine; SJC28, Swollen Joint Count (28 joints); TJC28, Tender Joint Count (28 joints). 
 
 
 Table 2: Overall relationship between active disease (DAS28≥3.2) after 3 months 
of induction DMARD treatment and response to GCs at 2 weeks (A) and also 
stratified for induction therapy (B).  
A.  Active disease 
 Response to GCs at 2 weeks YES NO 
 • Good, no(%) 11 (23) 36 (77) 
 • Moderate, no(%) 26 (53) 23 (47) 
 • None, no(%) 22 (92) 2 (8) 
    B.  Active disease 
 Response to GCs at 2 weeks YES NO 
 MTX+SSZ+HCQ+GCs im, no(%)   
 • Good  4 (25) 12 (75) 
 • Moderate 6 (35) 11 (65) 
 • None 8 (89) 1 (11) 
 MTX+SSZ+HCQ+GCs oral, no(%)   
 • Good  2 (11) 16 (89) 
 • Moderate 11 (65) 6 (35) 
 • None 4 (80) 1 (20) 
 MTX+GCs oral, no(%)   
 • Good  5 (38) 8 (62) 
 • Moderate 9 (60) 6 (40) 
 • None 10 (100) 0 (0) 
 
 
Table 3: Predicting active disease (DAS28≥3.2) at 3 months with (prognostic) 
variable(s), using univariate logistic regression (A) and a logistic regression model 
with backward selection (B). 
A.  OR (95% CI) p value 
 Age (years) 1.01 (0.98 – 1.03) 0.68 
 Sex (1=female) 2.55 (1.17 – 5.59) 0.02 
 Symptom duration (days) 1.00 (0.99 – 1.00) 0.14 
 RF (1=positive) 0.82 (0.39 – 1.74) 0.61 
 ACPA (1=positive) 0.95 (0.44 – 2.08) 0.91 
 Erosion typical for RA (1=present) 0.64 (0.24 – 1.70) 0.37 
 Response to GCs at 2 weeks (ref. = good)   
 • Moderate 3.70 (1.54 – 8.90) 0.003 
 • None 36 (7.29 – 177.82) <0.001 
 Treatment (ref. = MTX+GCs oral)   
 • MTX+SSZ+HCQ+GCs im 0.44 (0.18 – 1.07) 0.07 
 • MTX+SSZ+HCQ+GCs oral 0.43 (0.17 – 1.07) 0.07 
 DAS28 2.10 (1.39 – 3.18) <0.001 
 SJC28 0.99 (0.92 – 1.06) 0.77 
 TJC28 1.12 (1.04 – 1.21) 0.003 
 ESR (mm/hr) 1.02 (1.00 – 1.04) 0.05 
 General Health (0-100mm) 1.02 (1.00 – 1.04) 0.02 
    B.  OR (95% CI) p value 
 Response to GCs at 2 weeks (ref. = good)   
 • moderate 2.29 (0.87 – 6.00) 0.09 
 • none 30.35 (6.00 – 153.45) <0.001 
 DAS28 1.96 (1.20 – 3.18) 0.007 
Abbreviations: ACPA, anti-citrullinated peptide antibodies; CI, confidence interval; DAS28, Disease Activity 
Score with an 28 joint count; ESR, erythrocyte sedimentation rate; GCs, glucocorticoids; HCQ, 
hydroxychloroquine; im, intramuscular; MTX, methotrexate; OR, odds ratio; RA, rheumatoid arthritis; RF, 
rheumatoid factor; SJC28, swollen joint count (28 joints); SSZ, sulfasalazine; TJC28, tender joint count  
(28 joints). 
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 Objective  
To optimize use of the Disease Activity Score in 28 joints (DAS28) in early rheumatoid 
arthritis (RA) by adding the ‘squeeze test’ of forefeet. 
 
Methods 
The squeeze test is used to examine bilateral compression pain (BCP) across the 
metatarsophalangeal (MTP) joints. For this study, data for patients participating in the 
treatment in the Rotterdam Early Arthritis Cohort study, an ongoing clinical trial that 
evaluates different induction therapies in patients with early RA, were randomly divided 
into 2 subsets. In subset 1 (149 patients and 819 disease activity assessments), the 
mathematical function of the DAS28-squeeze was constructed using a linear regression 
model with the DAS as the dependent variable and the DAS28 and squeeze test as the 
independent variables. A DAS28-BCP disease state was also constructed, in which 
DAS28 disease state categorizations were upgraded one state if the result of the 
squeeze test was positive. In subset 2 (153 patients and 754 assessments), concordance 
in disease states between the DAS28, DAS28-squeeze, and DAS28-BCP disease states 
was compared, using both the DAS and Boolean-defined remission criteria as reference. 
 
Results 
Agreement between the DAS and the DAS28-squeeze (82%) was significantly higher 
than agreement between the DAS and the DAS28 (76%). When we assessed the group 
of patients who had arthritis of the forefeet only (22 patients and 46 assessments), 
overall agreement between the DAS and the DAS28 was 40%, while agreement 
between the DAS and the DAS28-squeeze was 59% and that between the DAS and the 
DAS28-BCP disease state was 65%. Furthermore, the specificities of the DAS28-squeeze 
and the DAS28-BCP (80% and 81%, respectively) were higher than that of the DAS28 
(76%), while the sensitivities of the DAS28, DAS28-squeeze, and DAS28-BCP to identify 
true remission according to the Boolean criteria were 88%, 87%, and 81%, respectively. 
 
Conclusion 
Adding the squeeze test of forefeet to the DAS28 has value for dependably classifying 
the disease state in patients with early RA.  
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 INTRODUCTION 
 
In the last 2 decades, significant progress was made in understanding the underlying 
pathophysiologic mechanism of and treatment modalities for rheumatoid arthritis (RA). 
This ultimately led to the unassailable need for early detection of the disease, early 
initiation of intensive therapy, and ‘tight control’ followup driven by regular 
measurements of disease activity.1  
 Tight-control monitoring of disease activity in clinical practice is commonly 
performed using the Disease Activity Score in 28 joints (DAS28)2, because it is easy to 
perform. The DAS28 comprises a 28-joint count excluding the feet. However, at the time 
of presentation, ~60% of patients with early RA had forefoot involvement; after 2 years, 
the prevalence decreased to 36% and then stabilized.3 Moreover, patients with disease 
in remission according to the DAS28 may have relatively large numbers of ‘residual joint 
counts,’ especially swollen joints.4 According to a recent report, ~40% of patients with 
disease in remission according to the DAS28 had forefoot involvement (pain and/or 
swelling in at least 1 metatarsophalangeal [MTP] joint. 5 
 In daily practice, however, assessment of MTP joint synovitis is cumbersome6; 
therefore, an alternative simple test to include foot involvement might be of added 
value to assess disease activity at an early stage, whereupon treatment decisions could 
be made. The squeeze test of forefeet, which examines bilateral compression pain (BCP) 
across the MTP joints (Figure 1), might be such a test. 
 Therefore, our objective was to analyze whether DAS28 disease state 
assessments in patients with a diagnosis of RA according to the 2010 American College 
of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria7,8 could 
be improved by adding the ‘squeeze test.’ 
 
 
PATIENTS AND METHODS 
 
Patients 
For this study, we used data from the ongoing treatment in the Rotterdam Early Arthritis 
Cohort (tREACH) study.9 The tREACH study, a multicenter, stratified, single-blind trial 
evaluating different induction treatment strategies in early RA, is performed in 8 
rheumatology centers in The Netherlands. Patients are examined every 3 months, and 
treatment decisions are based on the original DAS thresholds. 72,65 The medical ethics 
committee at each participating center approved the study protocol, and all patients 
gave written informed consent before inclusion. For the present analysis, we selected 
patients who had a randomisation date before December 1, 2010 and fulfilled the 2010 
ACR/EULAR criteria for RA.7,8   
 
  
Figure 1: The squeeze test of forefeet. The squeeze test is performed by placing the thumb just below the 
first metatarsophalangeal (MTP) joint (to prevent direct compression of this joint) and placing the index 
finger over the fifth MTP joint. The metatarsal joints are then compressed bilaterally, using a force equal 
to a handshake. 
Methods  
The clinical characteristics of each patient were recorded at baseline. At each 3-month 
visit, the following variables were assessed: a 44-joint count for swelling, a graded 53-
joint count for tenderness (Ritchie Articular Index [RAI])11,12, squeeze test of MTPs, 
general health, patient’s global assessment of disease activity (PGA), erythrocyte 
sedimentation rate, and C-reactive protein (CRP). The squeeze test was performed after 
completion of the joint examination. The squeeze test of MTP joints (Figure 1) is 
performed by placing the thumb and index finger, respectively, just below the first MTP 
joint and over the fifth MTP joint. The thumb is placed just below the first MTP joint to 
prevent direct compression of this joint. Thereafter, the metatarsal joints are bilaterally 
compressed, using a force equal to a handshake. The DAS and DAS28 thresholds for 
remission and moderate-to-high disease activity were <1.6 and ≥2.4 and <2.6 and ≥3.2, 
respectively. 
 Statistical analyses 
For this study, patients were randomly divided into 2 subsets. The first subset (n=149 
patients) was used to develop a new disease activity measure, the DAS28-squeeze. In 
the second subset (n=153 patients), the DAS28-squeeze was validated. Comparisons 
between the baseline characteristics of patients in each subset were performed using 
student’s t tests, chi-square tests, or Wilcoxon’s rank sum tests, when appropriate. 
 In subset 1 (development group), the mathematical function of the  
DAS28-squeeze was constructed with a linear regression model with the DAS as the 
dependent variable and the DAS28 and squeeze test as the independent variables. The 
constant was suppressed to preserve an uncomplicated model. To provide insight into 
the stability of the estimated model, we performed an additional bootstrap analysis13 
100 times, and the average weighted coefficients were added to the model. This model 
was then validated in subset 2 (validation group) by predicting the DAS based on the 
new formula.  
 In addition, we constructed a simpler model, the DAS28-BCP disease state, in 
which the disease state of patients is determined by the DAS28, and patients with a 
positive squeeze test result on either side are upgraded to a higher disease state (i.e., 
from remission to low disease activity). 
 Scatter plots were used to visualize the performance of the DAS28, DAS28-
squeeze, and DAS28-BCP disease states compared with the DAS, as reference for each 
disease state. The Stuart-Maxwell test was used to assess agreement between disease 
state categorizations.14 We also tested concordance in remission rates between the 
recently described Boolean-defined remission criteria109 and remission according to the 
DAS28, the DAS28-squeeze, and the DAS28-BCP disease states. The Boolean-defined 
remission criteria are as follows: at any time point, the patient must have a tender joint 
count (TJC) of ≤1, a swollen joint count (SJC) of ≤1, a CRP level of ≤1 mg/dl, and a PGA of 
≤1 on a 0–10 scale.15,16 Both a 28-joint count and a 44-joint count for tenderness and 
swelling were used for the Boolean remission criteria. The discriminative abilities of the 
DAS28, the DAS28-squeeze, and the DAS28-BCP disease states for identifying true 
remission (Boolean criteria) were expressed by sensitivity and specificity.  
 All statistical analyses were carried out using Stata version 11.1. P values less 
than 0.05 were considered significant. 
 
 
RESULTS 
 
Baseline characteristics 
Table 1 shows the baseline characteristics of the 2 subsets of patients used to develop 
(n=149) and validate (n=153) the DAS28-squeeze and DAS28-BCP disease states. 
Patients in both subsets represented a common population of patients with early RA. 
No difference between the subsets was observed except for morning stiffness duration 
of  >1 hour (p=0.03). 
   
Table 1. Baseline characteristics of the patients with rheumatoid arthritis in the 
subsets used to develop and validate the DAS28-squeeze* 
 
Development  group 
(n=149) 
Validation group 
(n=153) 
Age (years), mean (95% CI) 55 (53 - 57) 52 (50 - 55) 
Sex, female 99 (66) 106 (69) 
Symptom duration (days), mean (95% CI) 159 (144 - 174) 152 (139 - 166) 
RF pos. 84 (56) 88 (58) 
ACPA pos. 88 (59) 84 (55) 
Erosions 19 (13) 28 (18) 
Morning stiffness >1hour.† 115 (77) 133 (87) 
No. of tender joints, median (IQR)   
• 44 joints 11 (5 - 15) 10 (5 - 16) 
• 28 joints 6 (3 - 10) 6 (2 - 10) 
Ritchi Articular Index (RAI), median (IQR) 8 (5 - 11) 7 (4 - 10) 
No. of swollen joints, median (IQR)   
• 44 joints 8 (4 - 12) 8 (4 - 12) 
• 28 joints 6 (3 - 10) 6 (3 - 10) 
Forefoot involvement 122 (82) 118 (77) 
•  Swelling 76 (51) 76 (50) 
•  pain  108 (72) 106 (69) 
Squeeze test   
• Positive 1-sided test result 31 (21) 30 (20) 
• Positive 2-sided test result 64 (43) 59 (39) 
General Health (0–100mm), median (IQR) 54 (34 - 68) 50 (30 - 67) 
PGA (0 – 10), median (IQR) 6 (4 - 8) 6 (4 - 8) 
ESR (mm/hr), median (IQR) 22 (12 - 39) 21 (11 - 39) 
CRP (mg/dl), median (IQR) 7 (4 - 18) 7 (4 - 20) 
DAS, mean (95% CI) 3.43 (3.28 - 3.59) 3.37 (3.21 - 3.53) 
DAS28, mean (95% CI) 4.82 (4.62 - 5.02) 4.88 (4.66 - 5.09) 
* Except where indicated otherwise, values are the number (%).  
†p = 0.03 versus development group. 
Abbreviayions: ACPA, anti–citrullinated protein antibody;CI, confidence interval; CRP, C-reactive protein; 
DAS, disease activity score; DAS28, Disease activity score using an 28 joint count; DAS28-squeeze, Disease 
Activity Score in 28 joints with the addition of the squeeze test of forefeet; ESR, erythrocyte sedimentation 
rate; IQR, interquartile range; PGA, Physician’s global assessment and RF, Rheumatoid Factor. 
 
Development of DAS28-squeeze 
In the development subgroup (149 patients and 819 assessments) the DAS28-squeeze 
was constructed using linear regression and had the following mathematical formula: 
DAS28-squeeze =  0.64 x DAS28 + 0.23 x squeeze test. The squeeze test was coded as 
follows: 0 = test negative on both forefeet, 1 = test positive on 1 side, 2 = test positive 
on both forefeet. We set DAS28-squeeze thresholds for remission and moderate-to-high 
disease activity at  <1.6 and ≥2.4, respectively, in accordance with DAS (dependent 
variable) thresholds. The DAS28-squeeze model had an explained variance of 97.5%. We 
also created more complicated DAS28-squeeze models by using the quadratic term and 
natural logarithm of the squeeze test. However, these models had similar explained 
variances and were therefore not used. 
 Validation and agreement in disease state categorizations 
Overall data were available for 153 patients (754 assessments) in the validation 
subgroup. The correlations between the DAS and the DAS28 and between the DAS and 
the DAS28-squeeze were 93% and 94%, respectively. However, concordance of disease 
state categorizations between the DAS, DAS28, and DAS28-squeeze are more 
important, because treatment adjustments are based on these thresholds. Agreements 
in disease state classifications between the DAS and the DAS28 and between the DAS 
and the DAS28-squeeze are shown as scatter plots in Figures 2A and B. In both scatter 
plots, a strongly linear pattern was observed, especially for the state of remission 
measured by the DAS and the DAS28-squeeze. This linear pattern was attributable to 
the fact that the 44-joint SJC and the 28-joint SJC as well as the RAI and the 28-joint TJC, 
which are used for calculation of the DAS and DAS28- squeeze, respectively, were equal. 
 In the DAS28-BCP disease state model, all disease activity assessments with a 
positive squeeze test result at either forefoot (n=270 [36%]) were reclassified to a higher 
disease state. Among those assessments, 85% (n=230) showed forefoot involvement on 
physical examination (painful and/or swollen joints). In contrast, the squeeze test was 
negative in 156 (40%) of 386 assessments of patients with forefoot involvement. Figure 
2C shows the proportional agreement and disagreement in disease state classifications 
between the DAS and the DAS28, DAS28-squeeze, or DAS28-BCP disease state. The 
DAS28, DAS28-squeeze, and DAS28-BCP disease states had a significant overall 
disagreement with the DAS regarding disease state classification. However, overall 
agreement between the DAS and DAS28-squeeze was 82% (95% confidence interval 
[95% CI] 79–85%), which was significantly higher compared with the overall agreement 
between the DAS and the DAS28 (76% [95% CI 73–79%]; p<0.01). The overall percent 
agreement between DAS and DAS28-BCP disease state was 75% (95% CI 71–78%). 
To investigate the potential of the DAS28-squeeze and DAS28-BCP disease 
states, we selected patients who had forefoot arthritis without arthritis in any other joint 
on physical examination (22 patients and 46 assessments). The DAS28 and  
DAS28-squeeze but not the DAS28-BCP had a significant overall disagreement with the 
original DAS regarding disease state classification. However, overall agreement 
between the DAS and the DAS28 was 40% (95% CI 23–52%), which was significantly 
lower than the agreement between the DAS and the DAS28-squeeze (59% [95% CI 43–
73%]; p<0.05) or between the DAS and the DAS28-BCP (65% [95% CI 50–79%]; p<0.01).  
Subsequently, we compared true remission (Boolean criteria with a 44-joint 
count for swelling and tenderness) with remission according to the DAS28, the DAS28-
squeeze, or the DAS28-BCP disease state. True remission was not defined in 196 
assessments, because of missing data (no PGA and/or CRP). In 67 (13%) of 529 disease 
activity assessments, true remission was achieved. The DAS28, DAS28-squeeze, and 
DAS28-BCP disease states, respectively, met their own remission thresholds in 169 
(31%), 150 (28%), and 140 (26%) disease activity assessments. The sensitivities of the 
DAS28, DAS28-squeeze, and DAS28-BCP to identify true remission were 88% (95% CI 
78–95%), 87% (95% CI 76–94%), and 81% (95% CI 78–85%), respectively.  
  
  
Figure 2. Agreement in disease state categorization between the Disease Activity Score (DAS) and the 28-
joint DAS (DAS28)/DAS28-squeeze in rheumatoid arthritis, according to the 2010 American College of 
Rheumatology/European League Against Rheumatism classification criteria. A and B, Scatter plots for the 
DAS versus the DAS28 (A) and for the DAS versus the DAS28-squeeze (B). The vertical and horizontal lines 
represent the thresholds for corresponding disease activity scores on the x-axis and y-axis, respectively. 
The square symbols in A represent patients with a positive squeeze test result for either foot. C, 
Schematic diagram showing agreement (white rectangles) and disagreement (shaded rectangles) 
between the DAS and the DAS28, DAS28-squeeze, or DAS28 bilateral compression pain (BCP) disease 
state. In the DAS28-BCP disease state model, all patients represented by the square symbols in A were 
reclassified into a higher disease state and moved above the horizontal threshold lines. The bar charts 
represent the distribution of DAS28 (solid bars), DAS28-squeeze (shaded bars), and DAS28-BCP (open 
bars) disease states over the 9 rectangles.  
 
The specificities of the DAS28, DAS28-squeeze, and DAS28-BCP were 76% (95% CI 72–
80%), 80% (95% CI 76–84%), and 81% (95% CI 78–85%), respectively. Similar results for 
sensitivity and specificity were observed using the Boolean remission criteria with a 28-
joint count for swelling and tenderness (data not shown). 
 The DAS28-squeeze and DAS28-BCP disease states, respectively, correctly 
reclassified 18 (16%) and 24 (22%) of 110 DAS28 remission classifications that did not 
fulfill the Boolean remission criteria. However, the DAS28-squeeze and DAS28-BCP, 
respectively, failed to identify true remission in 1 (2%) and 5 (8%) of 59 assessments 
fulfilling Boolean criteria that were correctly identified by the DAS28. 
 
 
 DISCUSSION 
 
In this study, we showed that compared with DAS, the DAS28-squeeze improved 
disease state categorization in patients with RA according to 2010 criteria.7,8 Moreover, 
the addition of the squeeze test elicited correct reclassification of DAS28 remission 
assessments that were nonremission assessments according to the Boolean criteria.15,16  
The feet are frequently affected in both early and established RA, and foot 
impairment is an important cause of disability during the course of the disease.103 Visser 
et al17 demonstrated that forefoot involvement in patients with early arthritis is a strong 
prognostic indicator for the development of RA. Moreover, disease activity indices 
based on 28 joints underestimate the actual disease activity and expected joint damage 
in RA patients with predominantly forefoot involvement.18 A clinically simple solution 
may be implementation of the squeeze test of forefeet into disease activity scores such 
as the DAS28-BCP disease state and upgrading DAS28 disease state categorizations one 
state if the results of the squeeze test are positive.  
Our study had certain limitations. First, we used many assessments obtained in a 
relatively small number of patients. Dependency between assessments within patients 
will exist, but because disease activity indices were compared within each assessment, 
we believe that this within-patient dependency will not have much influence on the 
results. Furthermore, when we used only the second assessment and not the first 
because of the distribution of disease state categorizations, overall agreement between 
the DAS and the DAS28, DAS28-squeeze, or DAS28-BCP disease states increased, but 
similar differences in overall agreement remained (data not shown). 
 Second, we used the original DAS as the reference standard, because it is the 
only index that includes feet in calculation of disease activity. Furthermore, all treatment 
decisions within tREACH are based on the original DAS. However, because no head-to-
head comparisons between different disease activity indices are available, it remains 
unclear whether either the DAS or the DAS28 underestimates or overestimates disease 
activity, which would lead to different patient outcomes. 
 Third, the individual joint examination of feet and the squeeze test are 
performed consecutively. Because both examinations are related, the results of the 
individual joint examination of feet may influence the squeeze test, and an information 
bias could be introduced. However, at the time of the examination, the research nurses 
who performed the tests did not know our research question. 
 Finally, although both models perform better than the DAS28, both models 
sometimes detect active disease in patients in whom the Boolean remission criteria are 
met. This may be attributable to the presence of residual synovitis in the forefeet that 
was not detected during MTP joint assessment but was possibly identified with the 
squeeze test. This hypothesis could be validated using imaging techniques. 
 In conclusion, the squeeze test of the forefeet might add value to the disease 
state categorizations of the DAS28. An important role may be reserved for the  
DAS28-BCP disease state, because it is a simple and clinically applicable tool. 
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 CHAPTER 8 
 
General discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 Although the management of rheumatoid arthritis (RA) has underwent major paradigm 
changes, in the last two decades, a lot of unresolved questions remain and there is still 
room for improvement. The unresolved questions concerning the management of early 
RA and possible improvements are discussed in this chapter. We will address the 
following unresolved questions, which were mentioned in the general introduction: 
• Applicability of current guidelines in patients with early RA 
• Most appropriate initial treatment regimen: 
o Initial MTX monotherapy (iMM) versus initial triple DMARD therapy (iTDT) 
o GC bridging therapy: a single injection versus an oral tapering scheme 
• Cost-effectiveness of various initial treatment regimens with a treat-to-target 
approach in early RA. 
• How to monitor disease activity in early RA 
Thereafter, methodological considerations, followed by the applicability in daily 
practice are discussed. Finally, recommendations for future research are made. 
 
Early detection of the disease 
The ACR/EULAR 2010 classification criteria for RA are more and more incorporated in 
daily practice of rheumatologists.1 The 2010 EULAR recommendations for the 
management of RA, however, were formulated using data from studies in patients 
fulfilling 1987 criteria for RA.2-3 Thus trials in the early phase of RA are needed for 
validation of current recommendations. In our tREACH trial, we used the Visser model to 
stratify patients into probability tertiles according to their likelihood of progressing to 
persistent arthritis.4 The Visser algorithm and 2010 criteria for RA have similar 
discriminative abilities to identify patients at risk of persistent arthritis at 1 year.5 
Because of  these similar discriminative abilities all upcoming recommendations for 
daily practice could also be applied for patients fulfilling 2010 classification criteria for 
RA. 
Thanks to the introduction of the 2010 criteria of RA we are able to detect RA in 
an earlier phase of the disease. However, the time period in which the window of 
opportunity exist is very short, namely the first 12 weeks after symptom onset.6 Several 
studies showed that initiation of DMARDs in this period improved clinical outcome and 
delayed or even prevented radiographic damage.6-11 Therefore, identifying those 
patients who will develop a persistent arthritis within the first 12 weeks after symptom 
onset is crucial. However, in the tREACH only 20% of patients fulfilling the 2010 criteria 
for RA were assessed within the window of opportunity by a rheumatologist. 
Ultrasonography and Magnetic Resonance Imaging (MRI) detect joint inflammation 
better than clinical examination and can, therefore, enhance the diagnostic ability of 
the 2010 criteria for RA.12-13 Moreover, ultrasound and MRI are useful tools for predicting 
progression to RA from undifferentiated arthritis.12 Thus, implementation of mentioned 
imaging techniques in daily practice would probably result in detecting RA in an even 
earlier stage of the disease. Consequently, the proportion of patients with RA assessed 
by rheumatologists within the window of opportunity would increase.  
 However, I think that early referral is more important than improving the 
diagnostic ability of the 2010 criteria for RA to increase the proportion of RA patients, 
assessed within the window of opportunity by rheumatologists. Although referral may 
be obstructed by the long waiting lists of rheumatologists, the majority of delays are 
caused by general practioners (GPs).14 Interpretation of complaints, i.e. symptoms are 
not serious or will go away, and gradual onset of symptoms are associated with a 
prolonged delay in seeking help. On the other hand acute onset of symptoms, 
functional disability and/or loss of productivity resulted in instantly seeking medical 
help.15-16 When patients eventually visit their GP, the GP has the difficult task of 
distinguishing those patients who will develop RA, which has an annual incidence of 
approximately 50 per 100.000.17 Prescription of and acute response to NSAIDs may 
further delay diagnosis. Furthermore, GPs have insufficient knowledge to effectively 
detect and manage arthritis. Early referral guidelines for GPs are needed to reduce 
referral delay. However, not much research has been done yet in this field, but this will 
probably increase in upcoming years.  
 
Early initiation of ‘intensive’ therapy 
Early initiation of ‘intensive’ therapy is another major paradigm change in nowadays 
management of RA, because it improves clinical efficacy and may even prevent 
radiographic damage.8, 11, 18-19 However, still no consensus has been reached about what 
the most appropriate initial ‘intensive’ treatment regimen should be. 
I recommend iTDT over iMM as 1st choice in newly diagnosed RA patients, 
because treatment goals are attained faster and maintained with 40% fewer biologicals. 
No differences were seen in dosage adjustments due to adverse events (AEs), after 
stratification for drug. One single intramuscular GCs injection as well as an oral GC 
tapering scheme would suffice as bridging therapy. 
Furthermore, iTDT had lower costs per QALY compared with iMM. Interestingly,  
all initial treatment regimens of the tREACH are cost-effective, according to the definition 
of Dutch policy makers. Besides lower costs, patients treated with iTDT also had better 
worker productivity. In line with the clinical effectiveness, aforementioned results 
underline again why iTDT instead of iMM, is preferred as 1st choice in very early RA. 
However, some patients and/or rheumatologists may have some aversion for 
iTDT, mainly because of the large amount of drugs that have to be taken. Medication 
adherence in RA is strongly influenced by patient’s belief about the needfulness of the 
drugs.20 These beliefs are moulded by rheumatologists through the information given 
about the disease and treatment approach.20 Therefore, if iMM is still preferred, either by 
the rheumatologist or patient, I recommend combining MTX with a GC bridging scheme 
and determining the response to GCs after 2 weeks. As it happens determining GC 
response at 2 weeks is a useful tool for recognising those patients who will probably 
have active disease (DAS≥2.4) after 3 months of DMARD treatment. Subsequently, 
treatment should be intensified to triple DMARD therapy in GC non-responders. 
 However, future research is needed to evaluate the efficacy and efficiency of the above 
proposed approach. 
Although iTDT is superior to iMM in our trial, one could still contest if iTDT is the 
most appropriate initial intensive treatment regimen. In our trial, for example, we did 
not compare initial MTX plus a biological with iTDT. Studies comparing initial DMARD 
combination therapy with MTX plus a biological are sparse. However, the TEAR21 as well 
as the BeSt22 trial compared aforementioned treatment regimens and showed no 
difference in clinical effectiveness between both regimens. The 2012 ACR 
recommendations23 for the management of RA advocate iTDT or initial MTX plus a 
biological in newly diagnosed RA patients with active disease and ≥1  poor prognostic 
factor(s). Updated EULAR recommendations will probably not recommend biologicals 
as part of the initial treatment strategy, in the near future, because (1) biologicals are 
only restituted after failing on 2 conventional DMARDs in an optimal dosage for 3 
months, (2) striking evidence of superior efficacy over iTDT is lacking and (3) treatment 
is far more expensive than iTDT. 
Due to our treat-to-target design initial treatment could already be intensified to 
biologicals after three months, if the target was not reached. In the iMM group one 
could argue if triple DMARD therapy instead of biologicals should be the first step-up. 
Controversy about improved clinical efficacy of step-up therapy to biological over triple 
DMARD therapy after iMM failure still exists.21, 24 The 2010 EULAR guideline recommends 
treatment intensification to a biological, after failing on iMM, in patients with following 
prognostic factors: (1) auto-antibodies positivity, (2) high disease activity, and/or (3) 
erosive disease. In our trial 29/36 (81%) of iMM failures, after three months, had two or 
more aforementioned factors. Therefore, we think intensification to biologicals after 
failing on iMM was a valid choice. Nevertheless there are still doubts about cost-
effectiveness, especially in the long-term, which also supports the prefential for iTDT 
over iMM. 
GC bridging therapy is used to treat active disease in the period between 
induction of DMARD therapy and onset of their therapeutic effect.25 We find that 
intramuscular and oral GCs are equally effective as bridging therapy and can both be 
used, but one single dose of GCs intramuscular might be more feasible. However, the 
duration and dosage of our GC tapering scheme was short (10 weeks) and low (initial 
dosage 15mg) in comparison with, for example, the original COBRA regimen 
(respectively 28 weeks, initial dosage 60mg).18 Because GCs have disease-modifying 
traits with long-lasting benefits even after withdrawal, a different oral GC tapering 
scheme might be superior.25 For the 2010 EULAR recommendations Gorter et al26 
reviewed the literature, looking at the efficacy of GCs in RA. They concluded that future 
research is needed for optimizing GC bridging therapy with DMARDs, especially 
focusing on optimal dosage and tapering schemes, which is in line with our findings.26 
 Our results are based upon data from the first year of follow-up. During this first 
year, however, not all patients had attained and/or maintained the predefined 
treatment goals. Additionally, medication is tapered in patients with sustained 
 remission. Hence, the average burden of the disease is still fluctuating, which will 
probably reach a ‘steady state’ after a couple of years of follow-up. Several studies have 
demonstrated that early treatment response is associated with less active disease, 
functional impairment and indirectly less joint destruction and treatment changes 
needed to achieve the predefined treatment goals in the longterm.27-29 Furthermore, 
there is also a relationship between early treatment response and retainment of work 
productivity.30 However, in comparison with mentioned studies, which were performed 
in patients fulfilling 1987 criteria for RA, we included patients in an earlier phase of RA, 
representing a larger population. Therefore, the results of the long-term follow-up of 
the tREACH, including analyses of joint destruction and cost-effectiveness, should clarify 
if the benefits of iTDT remain in the longterm. Taking aforementioned considerations 
into account the longterm conclusions will, in our case, probably favour iTDT, because 
of faster attainment and better maintenance of predefined treatment goals and more 
frequent tapering of medication.   
 
A treat-to-target approach 
Although all disease activity indices (DAIs) have been developed in cohorts comprising 
patients with RA according to the 1987 criteria, DAIs already have been used in early RA 
to uphold recommended treatment goals. 3, 31-33 Therefore, in this thesis, we compared 
the characteristics of DAIs in RA according to the 2010 and 1987 classification criteria.1, 3 
The performance of the DAIs in patients fulfilling 2010 criteria for RA were comparable 
with those in RA according to 1987 criteria, although lower levels of disease activity 
were seen for patients who only fulfilled the 2010 criteria. Therefore, we think it is valid 
to use DAIs in a treat-to-target approach for patients who fulfill 2010 criteria for RA. 
To achieve the predefined treatment goals patients should be monitored strictly 
with a DAI.2, 34-35 There are various DAIs available for monitoring RA.36-39 There is no DAI 
recommended by the 2010 EULAR guideline developers, apart from that it should 
include a swollen and tender joint count. 2, 34 But, if a particular DAI is chosen to assess 
disease activity in a patient with RA, the same DAI should be used during the entire 
follow-up of that patient, because usage of various DAIs in a single patient leads to 
inconsistent disease state categorizations. Consequently, these inconsistencies 
significantly influence therapeutic decisions and accompanying costs. As DAI usage is 
imperative to uphold current EULAR treatment recommendations, physicians should 
consider these therapeutic and economic consequences before choosing a particular 
DAI. However, the consequence of using various DAIs on functional impairment and 
joint damage over time is not known and has still to be investigated.  
My DAI preference for daily practice is the DAS28, because (1) it is easy to use 
and (2) its ability to detect active disease is in between the other DAIs. The DAS28 is 
more conservative compared with the SDAI and CDAI and more liberal compared with 
the DAS in detecting active disease. Remission rates, however, are much higher with 
DAS28 usage compared with other DAIs. I advise that the decision to taper treatment 
 should not only depend on measuring sustained remission with DAS28, but also on the 
absence of forefeet arthritis and radiographic progression. 
Feet are frequently affected in the early stages of the disease, while in DAS28 
feet are excluded from the disease activity assessment.40 Moreover, DAS28 
underestimate the actual disease activity and expected joint damage in RA patients 
with predominantly forefoot involvement.37, 41-42  Therefore, DAS28 should be optimised 
for usage in early RA patients. A clinically simple solution may be implementation of the 
squeeze test of forefeet – examining bilateral compression pain (BCP) across the MTP 
joints - into the DAS28. For daily practice the DAS28-BCP disease state, in which DAS28 
disease state categorizations are upgraded one state if the results of the squeeze test is 
positive at either side, might be the solution. Because, adding the squeeze test of 
forefeet to the DAS28 has value for dependably classifying the disease state in patients 
with early RA. The DAS28-BCP disease state model, however, needs to be validated in 
another early RA cohort, before it can be implemented in daily practice. 
Ultrasound may also be a useful tool for monitoring disease activity in early RA, 
because of better detection of joint inflammation as opposed to clinical examination.12 
However, a validated and accepted (universal) ultrasound scoring system is still 
missing.43 Most important unresolved question herein is that of how many and which 
joints should be scanned for a reliable reflection of the actual disease activity.43 A major 
disadvantage of ultrasound is that it is time-consuming. Therefore, I think ultrasound 
will not be used for monitoring disease activity in early RA in the near future. 
Nevertheless, an exception might be verifying sustained remission before commencing 
tapering of treatment. Especially, since patients with disease in remission according to a 
certain DAI, particularly those using an 28 joint count, may have relatively large 
numbers of ‘residual joint counts’, including swollen joints, causing unexpected 
radiographic progression over time.44-45 
 
 
METHODOLOGICAL CONSIDERATIONS 
 
Study design 
The treatment in the Rotterdam Early Arthritis Cohort (tREACH) is a stratified single-
blinded randomized clinical trial (RCT), which is nested in the REACH. The REACH is a 
prospective, inception cohort, initiated in the greater Rotterdam area in July 2004, to 
study (etio)pathogenic, diagnostic and prognostic factors in a very early stage of RA. 
Recruitment of patients was done by GPs and/or rheumatologists of eight hospitals. 
Inclusion criteria for the REACH study were arthritis ≥1 joint or, in the absence of joint 
swelling, artralgy in ≥2 joints with 2 or more of following criteria: (1) morning stiffness 
≥1 hour, (2) joint pain in hands and/or feet, (3) difficulties wearing rings or shoes, (4) a 
family history of RA, (5) Symmetrical presentation of joint complaints, (6) pins and 
needles in the fingers and/or (7) unexplained fatigue <1 year. Due to this nested design 
of the tREACH within the REACH we were able to include patients within an earlier 
phase of the disease, because of less referral delay by GPs. 
 The strong advantages of a RCT are elimination of (1) confounding and selection 
bias by randomisation and (2) information bias by blinding. Confounding involves the 
possibility that an observed association is due, totally or in part, to the effects of 
differences between the study groups (other than the exposure under investigation). 
Although patients are randomised, sometimes confounding by randomisation occurs, 
especially in small groups, which is recognisable by baseline imbalances.46-47 This 
happened in our trial, which was probably due to the variable block randomisation 
stratified for centre. Because patients are randomised per centre, relatively small groups 
are randomised, which increases the chance of confounding by randomisation. 
However, these baseline imbalances were in favour of iMM; after correction differences 
between both groups increased favouring iTDT. 
Bias is a systemic error within the study. Systemic errors are caused by prejudice 
in selection of  patients, measuring outcomes, or analysing data, which will lead to 
results that are flawed. There are two important types of bias that may effect a study, 
namely selection and information bias.46-47 In our study selection bias is eliminated by 
randomisation. For our study, only research nurse were blinded for allocated treatment 
arm. This design was chosen, since we wanted to mimic daily practice as well as 
possible. Single blinding however could be a potential source of information bias, 
because not everyone is blinded and therefore measurements may be distorded. In our 
case possibly favouring iMM, because of the aversion for iTDT by the rheumatologist 
and/or patient. The same reasoning is also applicable for reporting (serious) adverse 
events, which was done by the attending rheumatologists. However, I think the tREACH 
has a good internal validity, because we tried to minimize the possible distorting effects 
of confounders and/or bias. 46-47 Therefore, our results are trustworthly and incorrupted. 
 The external validity on the other hand says something about the 
generalisability of the (main) findings to, for example, patients with newly diagnosed RA 
in daily practice of rheumatologists.46-47 When the protocol was written, the 2010 criteria 
for RA still had to be developed. Therefore, we based our design on the Visser model, 
which predicts the likelihood of progressing to persistent arthritis.4 Interestingly, the 
Visser algorithm and 2010 criteria for RA have similar discriminative abilities to identify 
patients at risk of persistent arthritis.5 Moreover, similar results were found in both 
subgroups consisting of RA patients according to 2010 and 1987 criteria.1, 3 Therefore, 
we think our results could be applied to all newly diagnosed RA patients fulfilling 1987 
as well as 2010 classification criteria for RA. Especially, since we mimicked daily practice 
as well as possible in our RCT. 
 
 Analyses 
Statistics are the mathematical science that deals with the organization, summarisation 
and interpretation of data acquired from the investigated population. Statistical 
analyses are especially useful for drawing conclusions, which enable us to  answer the 
predefined research questions.  This is also known as (null) hypothesis testing. The result 
of (null) hypothesis testing is never free of error. Two types of error are distinguished, 
namely type I and II error.46-47 
 Type I and II errors are intertwined with each other. If circumstances are 
unaltered, decreasing the probability of a type I error, will lead to an increase of a type II 
error. A type I error is the incorrect rejection of a correct/true (null) hypothesis. For 
example, sending an innocent person to jail is a type I error. The type I error rate is 
affected by the α level.  In general the α level is set at 5%, which means that 1 out of 20 
statistical analyses will reject a correct hypothesis by chance.40-41 
On contrary, with a type II error an incorrect/false (null) hypothesis is accepted by 
mistake. Setting a criminal free is an example of a type II error.  A type II error is not 
really an error, but there is not enough evidence to reject the hypothesis. The 
probability of a type II error is called β. The probability of correctly rejecting a false null 
hypothesis equals 1- β and is called power. The power is most often set at 80%. Power 
analyses are used to calculate the minimum sample size required to detect a predefined 
difference in effect size.40-41 In the tREACH, for example, sample-size calculation was 
based upon area the under the curve (AUC) of the HAQ, using data from the BeSt 
study22, where mean AUC HAQ of combination therapy and monotherapy respectively 
were 7.7 (SD 5.5) and 10.5 (SD 7.4). A target sample size of 270 patients per probability 
stratum was needed to detect mentioned difference with a power of 80% and two-
sided α=0.05. This size is sufficient to detect a difference of 6.1 AUC DAS and 20% 
difference in radiographic progression. 
Due to the economic recession and exponentially increasing health care cost, 
especially in rheumatology due to higher prescription rates of expensive biologicals, 
restitution of biologicals was altered by the government. Biologicals are not restituted 
by health insurance companies directly to individuals anymore, but hospitals are 
responsible for the provision of biologicals to patients.48 Therefore, efficient use of 
expensive drugs is needed to be able to continue optimal rheumatic care in the future.49 
That’s why we published the results of our interim analyses (chapter 2). 
  An interim analyses investigates wether there is a difference in the treatment 
groups before completion of the trial.50 Interim analyses are most often used to diminish 
unnecessarily risk of possible harmful effects or detect an enormonous beneficial effect 
of a certain treatment, whereby it’s unethetical to continue the trial.50 However, the 
disadvantage of interim analyses is the fact that repeated testing of the null hypothesis 
increases the likelihood of a type I error by giving more opportunities to reject the 
hypothesis. However, we only performed one interim and final analysis and therefore 
we think that the chance of a type I error was negligible. 
   Although the trial was designed and powered to compare the clinical efficicacy 
of iTDT with iMM, new research question emerged during the trial. These new 
hypothesis were tested in different post-hoc analyses. Post-hoc analyses encloses 
investigating and drawing conclusions from the data for hypothesis, which are not 
defined in the protocol.51 Major disadvantage of post-hoc analyses is misuse of this tool, 
leading to a fishing expedition for significant results. In this thesis, chapter 5, 6 and 7 are 
post-hoc analyses from the tREACH trial. However, in all these studies the research 
questions were defined before the analyses were performed. Furthermore, the 
investigated outcomes were not related to each other. Therefore, I am convinced  that 
we did not misuse the post-hoc analyses method. Still, the problem of underpowering 
exists, because the trial was not designed to answer these research questions. 
 
Specific limitations of research questions  
In preceding paragraphs I discussed the common methodological considerations 
associated with the design and (post-hoc and/or interim) analyses of a RCT. For specific 
limitations of research questions I would like to refer to corresponding chapters. 
 
 
CLINICAL IMPLICATIONS 
 
• Initial triple DMARD therapy is recommended over initial MTX monotherapy, as 
first choice in patients with newly diagnosed RA 
• However, if MTX monotherapy is preferred, we recommend combining MTX with 
a GC bridging scheme and determining the response to GCs after 2 weeks. 
Subsequently, treatment should be intensified to triple DMARD therapy in GC 
non-responders. 
• A single intramuscular GC injection as well as an oral tapering scheme can be 
used as bridging therapy 
• If a particular disease activity index (DAI) is chosen to assess disease activity in a 
patient with RA, the same DAI should be used during the entire follow-up of that 
patient. 
 
 FUTURE RESEARCH SUGGESTIONS 
 
Although several unresolved questions for daily practice are resolved in this thesis, 
management of early RA will still evolve in next couple of years. Future research is 
necessary to optimize the management of early RA. I will point-by-point touch upon 
most important research objectives: 
• A ‘tailor made’ versus a population based treatment approach.  
o For example comparing a treatment approach which makes use of our GC 
response model versus treating all patients with iTDT. 
o Or depending the intensity of the initial treatment regimen on the 
presence of prognostic markers (i.e. erosive disease, anti-citrullinated 
peptide antibodies or rheumatoid factor positivity) versus treating all 
patients with iTDT. 
• Comparing the clinical efficacy of a single GC injection intramuscular with a oral 
GC tapering with a higher initial dosage and/or longer duration than used in the 
tREACH. 
• Tapering DMARDs and biologicals in sustained remission. Most important 
questions are: 
o When to commence tapering? 
o How to taper DMARDs or biologicals: gradually versus immediate stop? 
o What is the optimal interval between taperings? 
• Comparing a treat-to-target approach that aims for remission with an approach 
that aims for low disease activity. Hereby, also taking cost-effectiveness into 
account. 
• Comparing the difference in clinical efficacy, radiographic progression and cost-
effectiveness between treat-to-target approaches, which use different DAIs for 
monitoring the disease. 
o Noteworthy is the fact that the DAS28-BCP disease state model may also 
be validated in such a trial. 
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 CHAPTER 9 
 
Summary 
 
 
 
 
 
 
 
 
 
 
 
 Major paradigm changes in the management of rheumatoid arthritis (RA) have occurred 
in the last two decades, due to evolvement of clinical trial methodology, emergement 
of new therapeutic options – in particular biologicals – and reevaluating treatment 
strategies. These major paradigm changes are: 
• Early detection of the disease; 
• Early initiation of ‘intensive’ therapy; 
• A treat-to-target approach 
Although the management of RA has underwent these major paradigm changes, a lot 
of unresolved questions remain and there is still room for improvement. Therefore the 
focus of this thesis is on the management of early RA. In this chapter the findings of the 
conducted studies are summarized. 
 For all upcoming studies, data of a currently ongoing clinical trial, namely the 
treatment in the Rotterdam Early Arthritis Cohort (tREACH) were used. The tREACH trial 
is a single-blinded randomized clinical trial in patients ≥18 years with recent-onset 
arthritis (symptom duration < 1 year). Main goal of the tREACH is to evaluate different 
initial treatment strategies in early RA. Patients, who had a high probability (> 70%) of 
progressing to persistent arthritis, based on the prediction model of Visser, were 
included. Noteworthy is the fact that the Visser algorithm and 2010 criteria for RA have 
similar discriminative abilities to identify patients at risk for persistent arthritis at 1 year. 
Patients were randomised into one of following initial treatment regimens: 
A. Triple Disease Modifying Anti-Rheumatic Drug (DMARD) therapy (methotrexate 
(MTX) + sulfasalazine + hydroxychloroquine) with a single glucocorticoid (GC) 
injection intramuscularly 
B. Triple DMARD therapy with an oral GC tapering scheme 
C. MTX with oral GCs similar to B.  
A treat-to-target approach was used, with patients being examined every 3 months, 
aiming for low disease activity, defined as DAS<2.4.  
Early detection of the disease is one of the major paradigm changes in the 
management of RA, which ultimately led to the development of the 2010 classification 
criteria for RA. These criteria for RA are more and more incorporated in daily practice of 
rheumatologists. All guidelines for the management of RA, however, are based upon 
data from studies in patients fulfilling 1987 criteria for RA. Thus trials in the early phase 
of RA are needed for validation of current guidelines. All upcoming studies are 
conducted in early RA patients and can, therefore, be used to validate current 
guidelines. 
Early initiation of ‘intensive’ therapy is another major paradigm change in 
nowadays management of RA, because it improves clinical efficacy and may even 
prevent radiographic damage. However, there is still debate on the most appropriate 
initial treatment regimen in patients with newly diagnosed RA. Most important 
discussion herein is that of initial MTX monotherapy (iMM) versus a combination of 
DMARDs. Hence, in chapter 2,  we compared the clinical efficacy of (1) initial triple 
DMARD therapy (iTDT) versus iMM, independent of GCs, and (2) of different GC bridging 
 therapies: oral tapering versus a single injection, using the 3 months data of the tREACH 
trial. iTDT reduced disease activity more rapidly after 3 months than iMM. Consequently, 
50% fewer biological were prescribed in the iTDT group. Although the proportion of 
patients with medication adjustments due to adverse events (AEs) differed significantly 
between treatment arms, no differences were seen after stratification for the drug. One 
single intramuscular GC injection or an oral GC tapering scheme can be used as 
bridging therapy, because they are equally effective. No difference in serious adverse 
events were seen between treatment arms. 
Several studies have demonstrated that the choice of the initial treatment 
regimen influences the initial clinical response, which indirectly influence the amount of 
joint destruction and treatment intensifications needed to maintain current treatment 
goals in the longterm. The longterm follow-up of the tREACH must clarify if this also 
applies for patients with early RA. Therefore, in chapter 3, the 1-year clinical efficacy of 
the different initial treatment strategies are studied. iTDT had a better clinical efficacy 
and efficiency than iMM in early RA. The burden of disease activity and functional 
impairment over time was less in the iTDT group compared with iMM. Furthermore, 
treatment goals were attained faster and maintained with less frequent treatment 
intensifications, which led to the prescription of ~40% fewer biologicals, after 3 months 
up to 1 year, in the iTDT group. Moreover, more patients with iMM failed on their first 
biological, reducing therapeutic options rather swiftly. Radiographic progression did 
not differ between groups. After stratification for drug no differences in dosage 
adjustments due to AEs were seen. Moreover, treatment could be tapered more often in 
the iTDT group, without increasing flare ratios. On contrary no differences were seen in 
both GC bridging therapies. The longterm data of the tREACH confirmed once more 
that iTDT is preferred over iMM, especially because of its efficiency due to attaining and 
maintaining treatment goals faster with less expensive drugs. 
The policy for covering prescribed drugs by health insurance companies and 
governments is more and more influenced by cost-effectiveness, because of 
exponentially increasing health care costs. Therefore, for health economic reasons 
efficient use of expensive drugs, especially biologicals, is needed to be able to continue 
optimal rheumatic care in the future. Therefore, we investigated, in chapter 4, which 
initial treatment regimen within the tREACH trial had the best cost-effectiveness ratio. 
iTDT had lower costs per Quality Adjusted Life-Years (QALY) compared with iMM. Total 
costs are the sum of the direct and indirect costs. Direct costs are the costs of treatment 
and medical consumption, whereas indirect costs are costs due to loss of productivity 
(i.e. sick leave and unemployment). Direct as well as indirect costs were significantly 
higher in the iMM group compared with the iTDT group. The difference in direct costs 
was due to ~40% more biological usage over time. Less unemployment, long-term 
sickness and reduction in contract hours on the other hand caused the difference in 
indirect costs. Interestingly, all initial treatment regimens within the tREACH trial are 
cost-effective, according to the definition of Dutch policy makers. Besides lower costs 
 iTDT had better worker productivity. This underlines again why iTDT instead of iMM is 
preferred as first choice in very early RA. 
A treat-to-target approach is advocated in order to obtain better functional and 
radiological outcomes in RA. To achieve the predefined treatment target patients 
should be monitored strictly with a disease activity index (DAI) and treatment should be 
adjusted until the target is reached. There are various DAIs available for monitoring RA. 
Interestingly, although all DAIs have been developed in cohorts comprising patients 
with RA according to the 1987 criteria, DAIs already have been used in early RA, 
although validation is lacking in this early population. Therefore, in chapter 5, we (1) 
described the performance of DAIs in RA according to 1987 and 2010 criteria and (2) 
investigated how inconsistencies between DAIs influenced therapeutic decisions and 
accompanying costs. DAIs performed similar in RA according to 2010 and 1987 criteria. 
Knowing that DAIs are essential in guiding treatment decisions, choosing a particular 
DAI could be cumbersome, because usage of various DAIs in a single patient leads to 
inconsistent disease state categorizations. Consequently, these inconsistencies 
significantly influence therapeutic decisions and accompanying costs. Therefore, for the 
selection of a DAI the therapeutic and economic consequences should be considered. 
Management of RA is still evolving, particularly in the areas of efficiency. Ideally a 
‘tailor made’ treatment approach is used to circumvent problems as over-treatment and 
accompanying (serious) adverse events. Since the time span for the optimal effect of 
DMARDs takes at least 6-12 weeks, the right choice of the initial DMARD therapy plays 
an important role in obtaining recommended treatment goals. About 60% will respond 
sufficiently to the initial treatment. Therefore, it would be helpful to be able to predict 
treatment response to the initial DMARD therapy as early as possible, ultimately leading 
to a ‘tailor made’ treatment approach. In chapter 6 we link the early effect of GCs to 
initial DMARD response. We investigated whether the GC response at 2 weeks, 
according to the EULAR response criteria, can predict active disease, defined as 
DAS≥2.4, after 3 months of initial DMARD treatment. Patients who do not respond to GC 
bridging therapy at 2 weeks have a 10-fold increased risk of having active disease after 3 
months of treatment compared with GC responders. Therefore, determining GC 
response at 2 weeks could be a useful tool for daily practice, resulting in a more ‘tailor 
made’ treatment approach. An approach could be combining MTX monotherapy with a 
GC bridging scheme and determining the response to GCs after 2 weeks. Subsequently, 
treatment should be intensified, to triple DMARD therapy, if patients do not respond to 
GCs. However, future research is needed to evaluate the efficacy and efficiency of above 
proposed approach. 
The unassailable need for early detection of the disease, eventually resulted in 
the development of the 2010 classification criteria for RA. The feet are frequently 
affected in the early stages of the disease. However, in daily practice rheumatologists 
often use DAIs for monitoring RA, which exclude the feet, because of their user-
friendliness. The most often used DAI is the DAS28. Therefore, in chapter 7, we tried to 
optimize DAS28 usage in early RA by adding the ‘squeeze test’ of forefeet. The squeeze 
 test examines bilateral compression pain (BCP) across the metatarsophalangeal (MTP) 
joints, which is a sensitive measure for the existence of arthritis in the forefoot. First, the 
mathematical function of the DAS28-squeeze was constructed using a linear regression 
model with the DAS as the dependent variable and the DAS28 and squeeze test as the 
independent variables. A DAS28-BCP disease state was also constructed, in which 
DAS28 disease state categorizations were upgraded one state if the result of the 
squeeze test was positive at either side. Thereafter, we investigated if adding the 
squeeze test to the DAS28 improved disease state categorization, using both DAS and 
Boolean remission criteria as reference. The squeeze test of forefeet adds value to the 
disease state categorizations of the DAS28. An important role may be reserved for the 
DAS28-BCP disease state, because it is a simple and clinically applicable tool. 
Finally, in chapter 8, I addressed the unresolved questions mentioned in the 
general introduction by making use of our main findings. Thereafter, methodological 
considerations, followed by the applicability in dialy practice are discussed. Finally, 
recommendations for future research are made. 
 
 
 CHAPTER 10 
 
Nederlandse samenvatting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 In de laatste 20 jaar hebben de vooruitgang in onderzoeksmethodologie, opkomst van 
nieuwe therapeutische opties – met name biologicals – en het verbeteren van 
behandelstrategiën geleid tot grote paradigmaveranderingen in de behandeling van 
reumatoïde artritis (RA). Deze grote paradigmaveranderingen zijn: 
• Vroege herkenning van de ziekte 
• Vroege ‘intensieve’ behandeling van de ziekte 
• Doelgerichte behandeling van de ziekte 
Ondanks dat de behandeling van RA dramatisch is veranderd, zijn er nog altijd veel 
onopgeloste vragen en is er genoeg ruimte voor verbetering. De nadruk van dit 
proefschrift ligt dan ook op de behandeling van vroege RA. In dit hoofdstuk worden de 
bevindingen van de uitgevoerde onderzoeken samengevat. 
Voor de komende onderzoeken is data van een nog lopend onderzoek, 
genaamd treatment in the Rotterdam Early Arthritis Cohort (tREACH), gebruikt. Het 
tREACH onderzoek is een enkelblind, gerandomiseerd onderzoek, die in meerdere 
ziekenhuizen word uitgevoerd. In dit onderzoek worden alle patiënten >18 jaar met een 
recent ontstane gewrichtsontsteking (klachtenduur <1 jaar) zo snel mogelijk gezien en 
behandeld. Het belangrijkste doel van de tREACH is het vergelijken van de effectiviteit 
van verschillende geinitieërde behandelstrategiën in vroege RA. Patiënten met een 
>70% kans op het ontwikkelen van persisterende artritis, op basis van het 
voorspelmodel van Visser, werden geïncludeerd. Noemenswaardig is het feit dat het 
Visser model en de 2010 classificatie criteria voor RA evengoed patiënten herkennen 
met een verhoogd risico op een chronische gewrichtsonsteking na 1 jaar. Patiënten 
werden gerandomiseerd naar één van de volgende initiële behandelstrategiën: 
A. Combinatietherapie, bestaande uit methotrexaat (MTX), sulfasalazine en 
hydroxychloroquine, en 1x een glucocorticoïd (GC) injectie intramusculair. 
B. Combinatietherapie met een orale GC afbouwschema. 
C. MTX met een gelijksoortige GC afbouwschema als B. 
Het doel van de behandeling is het bereiken van ‘lage’ ziekteactiviteit, wat gedefinieerd 
is als DAS<2.4 (Disease Activity Score). Patiënten worden elke 3 maanden beoordeelt, 
en zolang het behandeldoel niet is bereikt, wordt er krachtiger behandeld. 
 Vroege herkenning van de ziekte is één van de paradigmaveranderingen in de 
behandeling van RA, wat uiteindelijk tot de ontwikkeling van de 2010 classificatie 
critieria voor RA heeft geleid. Deze criteria worden steeds meer in de dagelijkse praktijk 
gebruikt. De huidige richtlijnen zijn echter gebaseerd op gegevens van onderzoeken bij 
patiënten die aan de 1987 classificatie criteria voor RA voldeden. Aldus zijn er 
onderzoeken in de vroege fase van RA nodig om de huidige richtlijnen te valideren. Alle 
onderzoeken in dit proefschrift werden uitgevoerd in patiënten met vroege RA en met 
deze gegevens kunnen de huidige richtlijnen worden gevalideerd.  
 Vroege ‘intensieve’ behandeling is een andere belangrijke paradigma-
verandering in de behandeling van RA. Dit vanwege een betere klinische effectiviteit, 
die mogelijk zelfs radiologische schade voorkomt. Er is echter nog steeds geen 
consensus bereikt over wat de beste initiële behandelstrategie is. Dit is één van de 
 belangrijkste onopgeloste vragen in de behandeling van RA. De belangrijkste discussie 
hierin is die van het starten met MTX monotherapie versus een combinatie van Disease 
Modifying Anti-Rheumatic Drugs (DMARDs). Vandaar dat we, in hoofdstuk 2,  de 
effectiviteit van (1) initiële combinatietherapie (iCT) vergelijken met initiële MTX 
monotherapie (iMM), onafhankelijk van GC, en (2) verschillende 
overbruggingstherapieën met GC - een orale afbouwschema versus een eenmalige 
injectie - hebben bestudeerd. Hierbij hebben we gebruik gemaakt van de 3 maands 
data van het tREACH onderzoek. iCT brengt een snellere daling in ziekte-activiteit 
teweeg in vergelijking met iMM. Hierdoor worden 40% minder biologicals, na 3 
maanden, voorgeschreven in de iCT groepen. Hoewel het percentage patiënten met 
medicatiedosis aanpassingen als gevolg van bijwerkingen significant verschilden tussen 
de behandelgroepen, werden deze verschillen teniet gedaan na stratificatie voor 
medicijngebruik. Daarom raden wij iCT, in plaats van iMM aan als eerste keus bij nieuw 
gediagnosticeerde RA patiënten. Zowel een eenmalige GC injectie als een orale GC 
afbouwschema kan als overbruggingstherapie worden gebruikt, aangezien beide even 
effectief zijn. Er werden geen verschillen gevonden in ernstige bijwerkingen tussen de 
behandelarmen  
 Diverse studies hebben aangetoond dat de keuze van de initiële 
behandelstrategie de initiële klinische respons en indirect de ernst van de 
gewrichtsschade en het aantal medicatie aanpassingen, welke nodig zijn om de 
voorafgestelde behandeldoelen te handhaven, op de lange termijn beïnvloedt. De 
lange termijn resultaten van het tREACH onderzoek moeten verduidelijken of 
bovenstaande ook geldt voor patiënten met vroege RA. Om deze reden werd, in 
hoofdstuk 3, de 1-jaars effectiviteit van de verschillende initiële behandelstrategieën 
vergeleken. Patiënten met iCT hadden over de gehele periode minder last van de 
ziekte-activiteit en functionele beperkingen, welke gepaard gaan met de ziekte, in 
vergelijking met patiënten met iMM. Na 3 maanden werden circa 40% minder 
biologicals, wat zeer dure geneesmiddelen zijn, voorgeschreven in de iCT groep in 
vergelijking met de iMM groep. Dit verschil veranderde niet meer over de tijd. Tevens 
faalde meer patiënten in de iMM groep op hun 1e biological, waardoor minder 
therapeutische opties overblijven. Er werden geen verschillen gevonden tussen de 
verschillende initiële behandelstrategieën in röntgenologische schade na 12 maanden 
behandeling. Hoewel het percentage patiënten met medicatiedosis aanpassingen, als 
gevolg van bijwerkingen, significant verschilden tussen de behandelgroepen, werden 
deze verschillen teniet gedaan na stratificatie voor medicijngebruik. Tevens konden 
medicijnen vaker worden afgebouwd  in de iCT groep,  zonder een procentuele 
toename van het aantal opvlammingen in ziekte-activiteit.  Er werden daarentegen 
geen verschillen gezien in beide GC overbruggingstherapiën. De lange termijn 
resultaten van de tREACH bevestigen nogmaals dat iCT de voorkeur geniet boven iMM, 
omwille van zijn klinische effectiviteit en efficiëntie, wat blijkt uit het sneller bereiken en 
handhaven van de voorafgestelde behandeldoelen met minder dure geneesmiddelen. 
  Doordat de kosten in de gezondheidszorg exponentieel groeien, gaat kosten-
effectiviteit steeds meer een belangrijkere rol spelen bij beleidsmakers - de 
zorgverzekeraars en overheid - die de vergoeding voor medicijnen bepalen. Om deze 
reden is het efficiënt gebruik van dure geneesmiddelen, met name biologicals, erg 
belangrijk, zodat  de excellente reumatologisch zorg ook voor de toekomst 
gewaarborgd is. Daarom onderzochten we, in hoofdstuk 4, welke van de drie 
behandelarmen in de tREACH studie de beste kosten-effectiviteits ratio had. Beide iCT 
hebben lagere kosten per per Quality Adjusted Life-Years (QALYs) in vergelijking met 
iMM. De totale kosten worden bepaald door de som van de directe en indirecte kosten. 
Directe kosten zijn de kosten van behandeling en medische dienstverlening, terwijl 
indirecte kosten kosten zijn als gevolg van verlies in productiviteit (bv. ziekteverzuim en 
werkloosheid). Zowel de directe als indirecte kosten waren hoger in de iMM groep in 
vergelijking met de iCT groepen. Het verschil in directe kosten werd veroorzaakt door 
het verschil in gebruik van biologicals (ca. 40% van 3 maanden tot 1 jaar). Een afname in 
werkloosheid, minder patiënten met langdurig ziekteverzuim en geringer afname in 
contracturen waren de oorzaken voor het verschil in indirecte kosten. Noemenswaardig 
is het feit dat alle behandelarmen binnen de tREACH kosteneffectief zijn volgens de 
Nederlandse definitie; opgesteld door het college voor zorgverzekeringen. Naast de 
lagere kosten hadden patiënten met iCT ook een beter arbeidsrendement. Dit 
onderstreept eens te meer waarom iCT de voorkeur geniet boven iMM. 
Doelgerichte behandeling in RA heeft er toe geleid dat er minder radiologische 
schade optreed met verbetering van de functionele capaciteit. Om de voorafgestelde 
behandeldoelen te bereiken worden patiënten nauwlettend in de gaten gehouden met 
een meetinstrument voor ziekte-activiteit. Er wordt steeds krachtiger behandeld, totdat 
het doel is bereikt. Verschillende meetinstrumenten voor ziekte-activteit zijn 
ontwikkeld. Interessant is het feit dat alle ziekte-activiteit meetinstrumenten (ZAM) 
ontwikkeld zijn in patiëntenpopulaties die aan de 1987 classificatie criteria voor RA 
voldeden. Toch worden deze ZAM gebruikt bij patiënten met vroege RA, ondanks dat 
ze niet gevalideerd zijn. Derhalve bestuderen wij, in hoofdstuk 5, (1) hoe ZAM in 
patienten met RA volgens de 1987 en 2010 classificatie criteria presteren en (2) wat de 
therapeutische en economische gevolgen zijn van inconsistenties tussen ZAM. Het 
gedrag van ZAM, in patiënten met RA volgens de 1987 en 2010 classificatie criteria, is 
vergelijkbaar. Het gebruik van verschillende ZAM  in één patiënt leidt tot inconsistente 
ziekte-activiteit categorisering, wat een significante weerslag heeft op de 
therapeutische beslissingen en de bijbehorende kosten. Wetende dat ZAM essentieel 
zijn in de behandeling van RA, zal bovenstaande de keuze voor een bepaalde ZAM 
zeker niet vergemakkelijken. Bij het kiezen van een ZAM dient men dus ook rekening te 
houden met de therapeutische en economische gevolgen. 
De behandeling van RA is nog in ontwikkeling, met name op het gebied van het 
efficiënt gebruik van DMARDs en biologicals is nog veel vooruitgang te boeken. 
Idealiter wordt behandeling op maat gegeven om problemen als overbehandeling met 
de bijbehorende (ernstige) bijwerkingen te omzeilen. Aangezien het minimaal 6-12 
 weken duurt voordat DMARDs hun optimale werking hebben, speelt de keuze van de 
initiële behandelstrategie een belangrijke rol in het behalen van de huidige 
behandeldoelen. Ongeveer 60% van de patiënten reageert afdoende op hun initiële 
behandeling. Als we de respons op de initiële behandeling in een zeer vroeg stadium 
kunnen voorspellen, wordt behandeling op maat meer en meer een feit. In hoofdstuk 6 
koppelen we de vroege behandeleffecten van GC aan de initiële DMARD respons. We 
hebben onderzocht of het behandeleffect van GC na 2 weken,  actieve ziekte - 
gedefinieerd als een DAS≥2.4 - na 3 maanden DMARD behandeling kan voorspellen. 
Patiënten die niet reageren op overbruggingstherapie met GC, na 2 weken, hebben een 
10-voudig verhoogd risico op actieve ziekte in vergelijking met patiënten die wel op GC 
reageren. Derhalve is het bepalen van het behandeleffect van GC na 2 weken een 
bruikbaar instrument voor de dagelijkse praktijk, aangezien het tot een meer op maat 
gesneden benadering van de behandeling van RA leidt. In de dagelijkse praktijk kan 
bijvoorbeeld in nieuw gediagnosticeerde RA patiënten worden gestart met iMM in 
combinatie met een GC overbruggingstherapie. Na 2 weken wordt het GC behandel-
effect bepaald. Indien onvoldoende respons op GC, wordt er krachtiger behandeld met 
bijvoorbeeld een combinatie van DMARDs. Echter, de effectiviteit en efficiëntie van de 
hierboven voorgestelde behandelaanpak moet nog worden onderzocht. 
De onbetwistbare noodzaak voor vroege detectie van de ziekte heeft uiteindelijk 
geleid tot de ontwikkeling van de 2010 classificatie criteria voor RA. Gewrichts-
ontstekingen aan de voeten komen vaak voor, met name in de vroege fase van de 
ziekte. Daarentegen worden in de dagelijkse praktijk vaak ZAM gebruikt die geen 
rekening houden met de betrokkenheid van de voetgewrichten, dit vanwege hun 
gebruiksgemak. De meest gebruikte ZAM is de DAS28. Derhalve hebben we, in 
hoofdstuk 7, geprobeerd om de accuratesse van de DAS28 in vroege RA  te verbeteren 
door het toevoegen van de voorvoet knijptest. Deze knijptest onderzoekt de 
aanwezigheid van tangentiële drukpijn (TDP) over de metatarsofalangeale (MTP) 
gewrichten, wat een gevoelige maat is voor het bestaan van artritis aan de voorvoet. 
Allereerst hebben we een regressiemodel gemaakt, waarin de DAS werd verklaard door 
de DAS28 en de knijptest. Tevens hebben we een DAS28-TDP model ontwikkeld, waarin 
de ziekte-activiteit categorisering van de DAS28 wordt opgewaardeerd in aanwezigheid 
van TDP in één of beide voorvoeten. Vervolgens hebben we onderzocht of het 
toevoegen van de knijptest de ziekte-activiteit categorisering van de DAS28 verbeterd, 
waarbij de DAS en de Boolean remissie criteria als referentie werden gebruikt. De 
knijptest heeft een additieve waarde voor de DAS28 in vroege RA, omdat toevoeging 
van deze test tot een betrouwbaarder ziekte-activiteit categorisering leidt. Hierbij is 
wellicht een belangrijke rol weggelegd voor het DAS28-TDP model bij het opvolgen van 
de ziekte in de dagelijkse praktijk, vanwege zijn eenvoud en gebruiksgemak.   
Tenslotte worden in hoofdstuk 8 de onopgeloste vragen uit de algemene 
inleiding bediscussieerd aan de hand van de bevindingen uit onze onderzoeken. 
Vervolgens worden de methodologische beperkingen en klinische implicaties 
besproken. En tot slot worden er aanbevelingen voor toekomstig onderzoek gedaan. 
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 DANKWOORD 
 
Zonder de hulp van velen was dit proefschrift nooit tot stand gekomen; allen BEDANKT 
hiervoor!!! Deze laatste pagina’s geven mij echter de mogelijkheid om enkele van jullie nog 
persoonlijk te bedanken.  
Als eerste mijn promotor, Prof.dr. J.M.W. Hazes. Beste Mieke, ondanks je overvolle 
agenda, maakte je altijd tijd voor mijn onaangekondige 5 minuten gesprekken, iets wat ik 
altijd zeer heb gewaardeerd. Daarnaast wil ik je bedanken voor je ‘blindelingse’ vertrouwen, 
waardoor je mij de ruimte gaf om te ontwikkelen als (logistiek) manager, organisator en 
wetenschapper. Het gebruik van jongleren als metafoor voor het coördineren van een 
studie, verschafte veel inzicht en zal me altijd bijblijven. Verder bedankt voor de goede 
begeleiding; met een kritische blik of bemoedigend woord waar nodig. 
  Vervolgens mijn co-promotor, Dr. A.E.A.M. Weel. Beste Angelique, wat is het  
geweldig om met jouw samen te werken. Je enthousiasme voor onderzoek en de reuma-
tologie werken erg aanstekelijk, mede hierdoor heb ik besloten om als specialisatie reuma- 
tologie te kiezen. Naast al je suggesties voor verbeteringen en tijd wil ik je vooral bedanken 
voor je luisterend oor, vooral ten tijde van mijn razernijen bij tegenvallende gebeurtenissen. 
  Verder wil ik alle patiënten binnen het tREACH onderzoek bedanken voor hun 
deelname en tijd. Een aantal van jullie heb ik ook op één van de poliklinieken mogen 
beoordelen. Wat opviel was de aversie voor corticosteroïden die velen van jullie hadden en 
de blijdschap enkele dagen later na afname van de klachten, dankzij het gebruik van 
diezelfde corticosteroïden, na enige uitleg/overtuiging. Dankzij jullie deelname hebben we 
nu handvaten op de behandeling van RA verder te optimaliseren. 
  Ook alle reumatologen (in opleiding) inclusief ondersteunend personeel, die aan 
de tREACH hebben deelgenomen, wil ik bedanken voor hun medewerking, enthousiasme, 
zorg en natuurlijk inclusies. Regelmatig heb ik jullie ziekenhuizen bezocht, voor o.a 
dataschoningsacties, het presenteren van studieresultaten en het onder de aandacht 
houden van de studie, waarbij ik altijd met open armen ben ontvangen, waarvoor veel 
dank. Zelfs tussen de spreekuren door maakte velen van jullie tijd voor mij vrij, en dankzij 
deze gesprekken zijn de ideeën voor een aantal hoofdstukken in dit proefschrift ontstaan.  
  Natuurlijk vergeet ik jullie niet, want sommige van jullie kende een zeer 
uitgebreide persoonlijke SOP, maar zonder ‘mijn’ onderzoeksverpleegkundigen had ik hier 
vandaag niet gestaan. Sjaan, Anke, Hetty, Conny, Tania, Gerda, Mireille, Corrie, Simone, 
Heleen en Bram bedankt voor het vele praktische werk dat jullie hebben verricht, maar ook 
jullie zorgvuldigheid, flexibiliteit en vooral gezelligheid. Een tweetal personen die hier ook 
zeker bijhoren zijn Anneke en Ron. Anneke als administratieve spil zorgde je er altijd voor 
dat de logistieke trein niet ontspoorde en dat alle patiënten hun vragenlijsten op tijd 
kregen, waarvoor veel dank. Ron bedankt voor het volledig digitaliseren van de tREACH, 
waardoor het verwerken en controleren van de data vele malen gemakkelijker werd. Voor 
mij was het toevoegen van het medicatieprotocol aan filemaker, waardoor alle 
reumatologen medicatieadvies kregen, met als gevolg een reductie in het aantal protocol 
violations, een absolute topprestatie, waarvoor nogmaals veel dank. 
 Nu we het toch hebben over de logistieke ondersteuning, wil ik ook het 
studententeam bedanken voor hun bijdrage. Jullie hebben onder andere meer dan 1000 
vragenlijsten ingescand, honderden aanmeld- en randomisatiepakketten klaargelegd en 
het archief bijgehouden. Zonder deze werkzaamheden had de tREACH nooit zo soepel 
gelopen, waarvoor dank. In het bijzonder wil ik Joyce, Myrthe en Dennis bedanken 
vanwege hun coördinerende taken binnen het studententeam. 
Eveneens wil ik alle (oud)promovendi bedanken voor hun bijdragen aan dit 
proefschrift en natuurlijk gezelligheid. De volgende personen wil ik nog persoonlijk 
bedanken. Celine bedankt voor het wegwijs maken in de studie, access en stata en je hulp 
bij het opzetten van de studie. Maurits bedankt voor het opzetten van de bloedlogistiek 
binnen de tREACH en samenwerking, wat tot enkele mooie (gezamelijke) publicaties heeft 
geleid. Rogier bedankt voor je brabantse gezelligheid en hulp bij het opzetten van de 
studie. Sjel, Marie-Louise, David en Martijn bedankt voor het scoren van alle röntgenfoto’s. 
Florentien bedankt voor je luisterend oor, die soms behoorlijk wat te verduren had. 
Bovendien kunnen alle (oud)collega’s bij de reumatologie - Radboud, Marijn, 
Edgar, Erna, Erik, Patricia, Marjolein, Yäel, Joyce en Jolanda - niet ontbreken in mijn 
dankwoord. Bedankt voor jullie steun en leerzame discussies. Radboud als graadmeter 
voor logistieke problemen in de kliniek, wist je altijd de vinger op de zere plek te leggen, 
mede hierdoor kon ik altijd snel genoeg ingrijpen om te voorkomen dat de logistieke trein 
ontspoorde, waarvoor veel dank. Marijn bedankt voor het opvragen en verwerken van alle 
hand- en voetfoto’s. Erik door jouw enthousiasme voor de basale wetenschap, heb je zelfs 
mij, als echte clinicus, weten te enthousiasmeren voor de basale wetenschap, wat 
uiteindelijk leidde tot een samenwerkingsverband, waarvoor veel dank. Jolanda bedankt 
voor alle puntjes op de i, waardoor mijn onderzoek net dat tikkeltje extra kreeg. 
Tot slot wil ik mijn familie en vrienden bedanken voor de belangrijke rol die zij in 
mijn leven spelen. Enkele van jullie wil ik echter nog persoonlijk bedanken. Allereerst mijn 
vrouw Marleen, als directe steun en toeverlaat sta jij altijd voor me klaar. Je laat me vrij, 
maar geeft me ook dat duwtje in de rug als ik deze nodig heb. Ik hou ontzettend veel van 
je. Bedankt voor wie je bent en voor alles wat je doet. Dan mijn kinderen, Samantha en 
Jasper, wat ben ik ongelooflijk trots op jullie. Beide te klein om te beseffen wat er vandaag 
gebeurd, maar alijd in mijn gedachten aanwezig. Jullie gaan beide een mooie toekomst 
tegemoet, waarin ik altijd voor jullie klaar zal staan. Ik dank jullie voor mijn veranderde kijk 
op het leven. Pa en Ma bedankt dat jullie er altijd voor mij waren, en dag in dag uit nog 
steeds zijn. Bedankt voor alle levenslessen, o.a. ‘Waar een wil is, is een weg’ en ‘let it be’. 
Patrick, ondanks dat we het nu allebei een stuk drukker hebben, zeker nu we volwassen 
zijn en een gezin hebben, stond en sta jij, als trotse broer, altijd aan mijn zijde bij elke 
belangrijke gebeurtenis in mijn leven. Het is dan ook een eer om je vandaag, letterlijk en 
figuurlijk, aan mijn zijde te hebben als paranimf. Ook je vrouw, Tamara en kinderen, Naomi 
en Anouk, wil ik bedanken voor al hun zoete invallen, die een prettige chaos veroorzaken, 
waardoor je alles even vergeet. Vanaf nu zullen we zeker weer vaker afspreken. Dit geld 
ook voor jou Arian. Jij was altijd mijn wingman tijdens het stappen, logischerwijs sta ook jij, 
als paranimf, aan mijn zijde tijdens mijn verdediging, waarvoor veel dank. 
